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ABSTRACT 
In the past decade, multi-resistant Escherichia coli with CTX-M enzymes have rapidly 
become the leading producers of extended-spectrum {3-lactamases (ESBLs) worldwide. E. coli with 
CTX-M-15 (3-lactamases are the most common, and are now endemic in many UK hospitals and in 
the community. Their epidemiology is complex, including five major epidemic clones as defined 
by pulsed-field gel electrophoresis, as well as many unrelated producers. This study sought to 
characterise, at a molecular level, E. coli isolates with CTX-M ESBLs and to investigate their 
nationwide dissemination, so as to identify the basis for the clinical success of these organisms. 
The molecular mechanisms responsible for the multi-drug resistance phenotype of representative 
isolates with CTX-M enzymes were explored and compared, as were their phylogenetic and 
virulence backgrounds. The genetic support and environment of the various blacrx-M genes were 
also investigated. 
The multi-drug resistance of E. coli with CTX-M enzymes was principally encoded by 
single plasmids, generally self-transferable. Among producers of CTX-M-15 enzyme, and 
regardless of their host strain's epidemic status, these plasmids were closely-related (IncFII) and 
encoded most often blaTEM-1o blaoxA-1 along blacrx-M-15, as well as aac(6')-Ib-cr, aac(3)-IIa and 
tet(A). The most prevalent UK clone (A) expressed a lower level ofCTX-M-15 enzyme than most 
other producers, probably owing to an IS26 element located downstream of the gene's normal 
promoter. Its CTX-M-15-encoding plasmid was not self-transferable in-vitro, but carried twelve 
genes effecting resistance to eight classes of antibiotics, as well as genes for virulence 
determinants. Most E. coli with CTX-M enzymes, including the major epidemic clones, belonged 
to the virulence-associated phylogenetic group B2 or D, but did not harbour more virulence 
determinants than B2 isolates with non-CTX-M ESBLs. Although related, three slightly distinct 
virulence profiles were apparent for clonal and non-clonal isolates with CTX-M-15 enzymes. 
In conclusion, CTX-M ESBLs have rapidly spread in the UK among virulent E. coli 
isolates, aided by horizontal transfer of multi-resistance plasmids, as well as by clonal spread of 
epidemic producer strains. Their dissemination worryingly undermines the success of antibiotic 
therapy, especially in community patients, where few oral options remain. 
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INTRODUCTION 
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The need to distinguish between pathogenic bacteria (causing disease) and commensal 
bacteria (living in symbiosis on or within an organism without causing injury) has led to the 
creation of a classification system known as taxonomy. Bacterial taxonomy is in constant flux as 
new species are discovered, and also as new technologies are developed and used. Precise 
identification of bacteria has become essential for the clinical microbiologist, not only for treatment 
issues, but also for epidemiological and surveillance studies. 
1. The Enterobacteriaceae 
Enterobacteriaceae are one of the commonest families of bacteria encountered in medical 
microbiology. Members ofthis family (e.g. Escherichia coli) share a number of morphological and 
biochemical properties, which include: 
Being short (4-5 microns) Gram-negative bacilli not forming spores (Figure 1) 
Possessing peritrichous flagella, if motile 
Being facultative anaerobes: growing both aerobically and, by fermentation of sugars, 
anaerobically (often associated with gas production) 
Generally displaying optimum growth at 37°C, although some species grow better at 25-30°C 
Being catalase-positive and cytochrome c oxidase-negative 
Being nitrate reductase-positive 
Members of the Enterobacteriaceae are closely related to each other and their genomes 
share a high degree of homology, with a guanosine + cytosine content between 39 and 59%. 
Depending on the species, Enterobacteriaceae are widely distributed in the environment (plants, 
soil and water), but are mostly found in the intestines of humans and animals. They are a major 
component of the normal intestinal flora of humans, and are relatively uncommon at other body 
sites. Some genera such as Salmonella and Shigella are inherently pathogenic, while others are 
known as opportunistic pathogens, and E. coli, according to the strain, may fall into either of these 
categories. 
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Figure 1. (A) Microscopic observation of Escherichia coli following Gram staining; (B) 
Scanning electron micrograph of Escherichia coli adhered to a cover slip 
Source: http: //biology.clc.uc.edulfankhauser/LabslMicrobiology/Gram_ Stain 
Source: http://en.wikipedia .org/wikilImage:EscherichiaColi_NIAID.jpg 
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Enterobacteriaceae are associated with a wide range of human infections including abscesses, 
pneumonia, meningitis, septicaemia, and infections of wounds, also infections of the urinary tract 
and of the intestines. Some species are important causes of nosocomial infections - e.g. Klebsiella 
pneumoniae is a major agent of nosocomial pneumonia and Escherichia coli is the major cause of 
nosocomial urinary tract infections [UTls, (Ronald, A., 2003)]. 
1.1. Identification of Enterobacteriaceae 
Many different approaches have been described in order to identify Enterobacteriaceae (Farmer, J. 
J., III et al., 1985). Most laboratories fIrstly isolate bacteria from clinical materials on to selective 
agars, which often include a unique carbohydrate as a fermentation substrate (e.g. lactose in 
MacConkey agar). Depending on the colonial appearance after 24 hr incubation, a series of further 
biochemical screening tests is performed, following confrrmation of the absence of cytochrome c 
oxidase. The most common biochemical pathways examined include the ability to produce acid and 
gas from various carbon sources such as glucose, lactose, maltose, mannitol, arabinose and citrate, 
but also the metabolism of urea, indole production and the degradation of various amino-acids (e.g. 
tyrosine, phenylalanine) as well as the production of hydrogen sulphide (H2S) gas. These tests 
generally allow identification to species level, although genera such as Salmonella or Shigella 
require additional serological testing, usually by agglutination tests. Table 1 summarises key 
biochemical properties of the genera belonging to those Enterobacteriaceae often isolated from 
human clinical specimens. Nowadays, clinical laboratories often use commercially available kits 
such as the API20E system from BioMerieux, which consists of a series of miniaturised and 
standardised biochemical tests. These time-saving kits usually correctly identify the most common 
species of Enterobacteriaceae, but may not be as accurate for the identification of new or minor 
specles. 
Serotyping and molecular methods are useful when identification to a more advanced level 
is required, i. e. to define strains in research and epidemiological studies. Molecular methods are not 
often available commercially and protocols may therefore vary between laboratories. Most are 
based on PCR technology, fragment length polymorphism (e.g. pulsed-field gel electrophoresis) or 
DNA sequencing, and are more typically used in reference or research laboratories. 
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Table 1. Main characteristics of Enterobacteriaceae genera frequently responsible for human 
infections 
Genera 
Citrobacter spp. 
Enterobacter spp. 
Escherichia spp. 
Hafnia spp. 
Klebsiella spp. 
Morganella spp. 
Proteus spp. 
Providencia spp. 
Salmonella spp. 
Serratia spp. 
Shigella spp. 
Yersinia spp. 
Morphological and biochemical properties 
Motile 
Citrate+; lysine" 
Motile 
Ferment glucose with production of acid and gas 
Variable biochemically: citrate+, Voges-Proskauer+ 
Motile 
Extremely variable biochemically; indole+ (see page 31) 
Motile 
More active biochemically at 25°C than 37°C 
Mucoid colonies, encapsulated cells, non-motile 
very active biochemically: ferment most sugars, lysine+ and vp+ 
Motile 
Very inactive biochemically: citrate", H2S", gelatinase", urease+ 
Motile, swarm on blood agar, pungent odour 
Urease+, H2S+, lipase+ and gelatinase+ 
Motile, no swarming 
H2S", ge1atinase", lipase" and urease" 
Motile except S. typhi and S. paratyphi 
Lactose", sucrose", H2S+ 
Motile 
Lipase+, DNase+ and gelatinase+ 
Non-motile 
Biochemically inactive: lysine", gas" 
Motile at 25°C (non-motile at 37°C) 
More active biochemically at 25°C, urease+ 
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1.2. Clinical significance 
Although they are a major component of the normal intestinal flora of humans, specIes of 
Enterobacteriaceae can cause a wide range of infections. Data from 1998 (COR weekly, 
Communicable Disease report vol. 8(20), 15 may 1998) suggest Enterobacteriaceae account for 
80% of clinically-significant Gram-negative bacilli and 50% of all clinically-significant bacteria 
examined in clinical microbiology laboratories. They cause up to 50% of septicaemia cases, 70% of 
urinary tract infections and a similar percentage of intestinal infections, according to the same 
source. Infections due to these organisms are usually divided into two groups: intestinal and extra-
intestinal infections. A limited range of species of Enterobacteriaceae are implicated in intestinal 
infections in humans and animals, predominantly members of the genera Escherichia, Salmonella, 
Shigella and Yersinia. On the other hand, many species of Enterobacteriaceae can cause extra-
intestinal infections though E. coli, K. pneumoniae, K. oxytoca, P. mirabilis, E. aerogenes, E. 
cloacae and S. marcescens are responsible for the vast majority of them. Urinary tract infections 
are the most common extra-intestinal infections, followed by respiratory, wound, bloodstream and 
central nervous system infections. Many of these, especially the life-threatening sepsis and 
meningitis, are hospital-acquired, but E. coli is the major agent of community UTls. 
1.3. Antibiotic susceptibility 
The antibiotic susceptibility of Enterobacteriaceae can be assessed by several methods, the most 
commonly-used being disc diffusion and, broth or agar dilution. The basic methodology of 
antibiotic susceptibility testing itself has hardly been altered since a standardized method was first 
described in the mid-1960s (Bauer, A. W. et al., 1966), though techniques have been automated to 
a degree. However, with the appearance of antibiotic resistance, frequently selected following the 
introduction of a new drug on to the market, interpretation guidelines are constantly being adjusted. 
Among Enterobacteriaceae, the frequent antibiotic resistances observed vary depending on 
the species, but also on its origin. Most species exhibit intrinsic resistance to certain antibiotics 
(e.g. Enterobacter aerogenes is resistant to cephalothin, Proteus mirabilis to polymyxins and 
tetracycline, Serratia marcescens to polymyxins). 
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This intrinsic resistance facilitates identification for the clinical microbiologist (e.g. a culture of 
Enterobacter spp. appearing susceptible to cephalothin requires checks for culture purity and repeat 
test for identification and antibiogram). Finally, in addition to providing the basis for treating 
patients with infections, antibiograms have also become a significant tool for epidemiological 
studies, being particularly useful laboratory markers for comparing strains. 
2. Escherichia coli 
The genus Escherichia is composed of motile bacteria that conform to the definition of the family 
Enterobacteriaceae. Although seven species are known (E. adecarboxylata, E. albertii, E. blattae, 
E. coli, E. fergusonii, E. hermannii and E. vulneris), E. coli is by far the most common, being one 
of the most-encountered bacteria in the clinical laboratory. Discovered in 1885 by German 
pediatrician and bacteriologist Theodore Escherich, Escherichia coli has also been used as a model 
organism for research in microbiology and genetics laboratories for decades. Sequencing of the 
entire genome of the benign laboratory strain E. coli K-12 (4,639,22l-bp) was completed in 1997 
(Blattner, F. R. et al., 1997), and is now publicly available (http://www.ncbLnlm.nih.gov). 
2.1. Natural habitats 
E. coli is most commonly isolated from the intestines of humans and animals, and is the most 
abundant facultatively anaerobic commensal inhabitant of the large intestines of healthy humans 
(up to 109 cells per gram of faeces) and of many other warm-blooded animals. It colonizes the 
intestines shortly after birth and remains there throughout life. In the large intestine, E. coli assists 
with waste processing, production of vitamin K, and food absorption. However, E. coli is not 
confined to the mammalian gut, and can be found also in the environment, where it often is an 
indicator of faecal contamination. As a result of its adaptation to the mammalian intestines, E. coli 
grows best at temperatures around 37°C, rather than the cooler temperatures found in soil and other 
environments. 
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2.2. Identification 
2.2.1. Biochemical characteristics 
Nowadays, most clinical laboratories identify E. coli with easy-to-use and time-saving commercial 
systems, e.g. the API20E test kit from BioMeneux (Figure 2). Those kits provide reliable 
identification in 18-24 hr. Identification to strain level is achieved by serotyping or, increasingly, 
molecular methods, as detailed below. 
2.2.2. Serotyping 
The serologic classification of E. coli is based on three types of antigen: 0 (somatic), H (flagellar) 
and K (capsular). These antigens are stable and reliable strain characteristics, and are usually 
identified by agglutination tests. Although complete serotyping of E. coli strains is labour-
intensive, with more than 170 0 antigens, 100 K antigens and 70 H antigens characterised, and 
over 700 serotypes recognised, it remains particularly useful for epidemiological purposes. 
2.2.3. Molecular typing 
Pulsed-field gel electrophoresis (PFGE) is used for strain typing of E. coli isolates, particularly in 
reference and research laboratories. Although serotyping and antibiotic susceptibility testing may 
be sufficient to distinguish between most E. coli strains, PFGE remains the gold standard for 
defining an outbreak strain, detecting fine differences between isolates. 
More recently, Multi-Locus Sequence Typing (MLST) has come to be used in order to 
subtype E. coli isolates. MLST entails sequencing internal fragments of a small number of 
housekeeping genes (usually seven), such as adk (adenylate kinase) and mdh (malate 
dehydrogenase) for E. coli. Like serotyping and unlike PFGE, MLST assigns definitive types; 
PFGE and other methods, such as AFLP and RAPD by contrast, are comparative, indicating only 
the relatedness between several isolates. 
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Figure 2. API20E strip inoculated with a saline suspension of a pure culture of E. coli after 
18-hr incubation at 37°C 
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Source: www. jI i ndgu iSLneUgenera Itn icro 
Test Biochemical property Result 
ONPG ,B-Galactosidase + 
2 ADH Arginine dehydratase 
3 LDC Lysine decarboxylase + 
4 ODC Ornithine decarboxylase + 
5 ClT Citrate use as sole carbon source 
6 1-I2S Hydrogen sulphide production 
7 URE Urea hydrolysis 
8 TDA Tryptophan deaminase 
9 IND Indole production + 
10 VP Acetoin production 
11 GEL Gelatine hydrolysis 
12 GLU Glucose fermentation + 
13 MAN Mannitol fermentation + 
14 INO Inositol fermentation 
15 SOR Sorbitol fermentation + 
16 RHA Rhamnose fermentation + 
17 SAC Sucrose fermentation + 
18 MEL Melibiose fermentation + 
19 AMY Amygda lin fermentation 
20 ARA Arabinose fermentation + 
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2.3. Molecular phylogeny and virulence of E. coli 
It is well known that E. coli can co-exist with its host peacefully (non-pathogenic, commensal 
variants), but it can also cause devastating illness (pathogenic variants). This paradox is due to the 
existence of different strains of E. coli with differing pathogenic potential. This variation is 
attributable to the presence or not of specific genes encoding virulence factors (VFs), as well as to 
the capacity of E. coli for genetic exchange (e.g. by recombination and conjugation ... ). 
Pathogenic E. coli strains are usually divided into two groups: those that cause gastro-
intestinal diseases and those that cause extra-intestinal infections, although some pathotypes may 
transcend these boundaries. The ability of a given pathogenic E. coli variant to cause disease 
largely depends on its VF gene repertoire (Siitonen, A., 1994). The most common VFs of E. coli 
include adhesins (promote adhesion), toxins (cause direct injuries to host cells and tissues), 
siderophores (sequester iron and promote colonisation), secretion systems (stimulate a noxious host 
inflammatory response), capsules and polysaccharide-coating proteins (help avoiding host defence 
mechanisms). These factors are generally absent from commensal strains, but are commonly found 
among both intestinal and extra-intestinal E. coli pathotypes (Eisenstein, B. I. and Jones, G. W., 
1988; Mobley, H. L. et al., 1994; Orskov, I. and Orskov, F., 1985; Siitonen, A., 1994). 
At least, seven major E. coli pathotypes are now recognised (Donnenberg, M. S., 2002), 
including: enteropathogenic E. coli (EPEC), enterohaemorrhagic or shiga toxin-producing E. coli 
(STEC or EHEC), enterotoxigenic E. coli (ETEC), enteroaggregative E. coli (EAEC), 
enteroinvasive E. coli (EIEC), uropathogenic E. coli (UPEC) and meningitis-associated E. coli 
(MAEC). Extra-intestinal pathogenic E. coli (ExPEC) strains include both UPEC and MAEC 
pathotypes. In addition, four main phylogenetic groups of E. coli are recognised, A. Bl, B2 and D, 
as defined by Multi-Locus Enzyme Electrophoresis (M LEE) and Multi-Locus Sequence Typing 
[MLST (Clermont, O. et al., 2000; Herzer, P. J. et al., 1990; Lecointre, G. et al., 1998)]. Virulent 
E. coli strains mostly belong to phylogenetic group B2, and to a lesser extent to group D. More 
specifically, intestinal pathotypes mostly belong to phylogenetic group D, but sometimes also A 
and Bl if these have acquired sufficient VFs to cause disease. 
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Extra-intestinal pathogenic E. coli are concentrated in group B2 (Johnson, J. R. et al., 2002; Picard, 
B. et al., 1993). Commensal and environmental strains mostly belong to phylogenetic groups A and 
Bl, respectively. 
2.3.1. Adhesive pili 
The initial step towards infection, whether intestinal or extra-intestinal, consists of recognising and 
adhering to the host tissues, and in the case of E. coli requires the presence of hair-like structures 
called pili, which extend from the surface of the bacterium. The best characterised pili of E. coli are 
the P (pyelonephritis) pilus and the type 1 pilus systems, encoded by the pap and jim genes 
clusters, respectively. These operon-like structures include genes that encode (i) a major rod 
subunit (papA and jimA), (ii) an adhesin (papG and jimH) and (iii) an adapter (papEFK and 
jimFG). The adhesin protein, which is located at the tip of the pilus, facilitates the binding of the 
invading bacterium to a receptor, usually a carbohydrate or a carbohydrate complex, on the host 
cell surface (Donnenberg, M. S., 2002). 
Type IV pili, also known as fimbriae, are another group of pili, involved in cell interactions 
and widely distributed among E. coli isolates. Their assembly is complex and requires a variety of 
proteins, which have to be assembled in a co-ordinated manner in order to allow pilin 
polymerisation, fibre stabilisation and surface translocation. Furthermore, since fimbriae represent 
a potential target for the host immune system, it is important that their expression remains confined 
to the first stage of the infection, where they are specifically required. 
2.3.2. Siderophores and iron uptake 
Human and animal tissues provide all the nutrients necessary for the survival of E. coli, but these 
are more or less available. Iron is an essential cofactor found in all organisms, but its availability 
for the colonising E. coli may easily become a growth-limiting factor, since most of it is 
sequestered and held within cells (e.g. as haemoglobin or ferritin) or is bound to iron-binding 
proteins such as transferrin and lactoferrin (Donnenberg, M. S., 2002). Like many potential 
pathogens, E. coli produce aerobactins, which are iron-chelating siderophores. These low-
molecular weight molecules remove the iron from the iron-binding proteins and transport it into the 
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bacterial cell. E. coli generally uses multiple iron-uptake systems and often will preferentially use 
the iron from haemoglobin. But, as haemoglobin is rarely present free in tissue fluids, it has been 
suggested that the toxin haemolysin (see section 2.3.3) may intervene in order to make the iron 
available (Boehm, D. F. et al., 1990a; Boehm, D. F. et al., 1990b). 
2.3.3. Secretion systems and toxins 
Toxins are responsible for causing lesions to the host tissues during infections, but may also induce 
an inflammatory response. Several E. coli toxins have been characterised, and different pathotypes 
produce different types of toxin: e.g. STEC produce a shiga-like toxin, most ETEC produce the 
heat-labile enterotoxin called holotoxin, and UPEC may produce the cytotoxic necrotising factor 1 
(Donnenberg, M. S., 2002). 
In addition, many Gram-negative pathogens, including Shigella, Yersinia, Salmonella, and 
also EPEC and EHEC isolates use secretion systems to inject virulence factors into the cytosol of 
the eukaryotic host cells in order to subvert cellular processes to the advantage of the bacterium. 
Five major secretion systems have been described to date (numbered I to V), with the best-known 
secretion substrate being the E. coli haemolysin (via the type I system). The type III secretion 
system also has been extensively characterised and is mostly used by EPEC and EHEC pathotypes. 
The secretion process, which is activated once the bacteria adhere to the surface of the host cells, 
allows the transport of VFs across three membranes: the inner and outer membranes of the 
bacterium, as well as the eUkaryotic cell membrane. 
The E. coli haemolysin, secreted by the type I secretory system, is an important VF 
involved in infections of the urinary tract and other extra-intestinal sites, and is also produced by 
the enterohaemorrhagic E. coli 0157. Haemolysin is a membrane-targeted protein with cytocidal 
activity, encoded by the hly operon. It attacks erythrocytes, releasing the iron bound to 
haemoglobin, as well as granulocytes, monocytes, endothelial cells and renal epithelial cells. It 
stimulates the production of cytokines, leading to an inflammatory response (Uhlen, P. et al., 
2000). 
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Other important toxins produced by E. coli pathotypes include a wide range of heat-labile 
and heat-stabile enterotoxins (mostly produced by ETEC), the shiga-like toxins (also known as 
vero-cytototoxins and secreted by EHEC), the cytolethal distending toxin, and the cytotoxic 
necrotising factor (CNF). 
2.3.4. Capsules and lipopolysaccharides 
The various features on the bacterial cell surface, such as flagella, fimbriae, capsules and 
lipopolysaccharides, are essential components for survival, since they mediate the contact of the 
bacterium with its direct environment. In addition to "assessing" the environment, these structures 
often participate in the pathogenesis of infectious diseases. Many pathogenic E. coli strains, but 
especially extra-intestinal pathotypes, have a polysaccharide layer or capsule outside their outer 
membrane, and/or a complete lipopolysaccharide (LPS) in the outer leaflet of their outer 
membrane. These traits partly dictate the pathogenic potential of E. coli. 
Although a capsule's primary function is to mediate the adherence of the bacterium to a 
given surface, it may also protect the bacterium from non-specific host defence mechanisms by 
interfering with complement and predatory phagocytes. Four groups of capsules (1-4) have been 
proposed for E. coli (Whitfield, C. and Roberts, I. S., 1999). If intestinal pathogenic E. coli isolates 
possess a capsule, it is usually a group 1 or 4 (e.g. K30 and K40), while group 2 and 3 capsules 
(such as Kt and KS) are mostly associated with extra-intestinal pathogenic E. coli (ExPEC) 
isolates. 
LPS is a unique glycolipid present in the outer membranes of Gram-negative bacteria and 
consists of lipid A inserted in the membrane core, a core oligosaccharide region, and a serotype-
specific O-antigen composed of repeating sugar subunits (Orskov, I. et al., 1977). Over 170 
antigenically distinct types have been described in E. coli so far. 
Both capsules and LPS are considered to be VFs that protect E. coli against various host 
defence factors. These structures however also behave as pathogen-associated molecular patterns, 
thus enhancing the innate immune response. 
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3. E.filcherichia coli-associated infections 
Pathogenic E. coli strains are responsible for both gastro-intestinal and extra-intestinal infections. 
Among the latter, E. coli is considered as the "number one" cause of human UTls, but has been 
linked also with diseases in virtually every other part of the human body, and also with diseases in 
a broad array of animal species such as pigs, cattle, birds and sheep (Chiu, N. C. et al., 1989; 
Farooqui, B. J. et al., 1989). The most common diseases resulting from E. coli infections in humans 
include cystitis and ascending disease that affects the kidneys (i.e. pyelonephritis), diarrhoea, 
dysentery, haemolytic-uremic syndrome, neonatal meningitis and septicaemia. 
3.1. Gastro-intestinal tract infections and food-poisoning 
Although E. coli are the predominant aerobic members of the normal gut flora of humans, ingested 
pathogenic strains are also responsible for most cases of gastro-intestinal infections. These 
infections can result in a vast array of diseases with different degree of severity, ranging from mild 
gastroenteritis to dysentery or enterocolitis, and can subsequently also cause damage at distant 
body sites. 
The five major E. coli pathotypes that cause gastro-intestinal infections (EPEC, EHEC, 
ETEC, EAEC and EIEC) each have specific pathogenic mechanisms. ETEC possess colonization 
factors that enable the bacteria to bind to corresponding receptors on the intestinal cell membrane, 
where they secrete powerful enterotoxins, resulting in increased fluid secretion. EHEC serotypes 
such as E. coli 0157, which usually are foodbome, attach to the intestinal mucosa and release a 
verotoxin, also resulting in diarrhoea. In addition, EHEC, which is often also referred to as 
verocytotoxin-producing E. coli, causes haemorrhagic colitis and haemolytic-uraemic syndrome. In 
contrast, EPEC and EAEC strains do not produce toxins: EPEC use a particular mechanism of 
adherence to enterocytes, resulting in the destruction of microvilli, whilst EAEC use a distinctive 
aggregative pattern. Both EPEC and EAEC pathotypes cause diarrhoea, but whereas EPEC is 
mostly associated with severe infantile gastroenteritis, EAEC generally only cause mild enteritis. 
Finally, EIEC serotypes attach specifically to the mucosa of the large intestine, invade peripheral 
cells by endocytosis and spread to adjacent cells, causing tissue destruction and inflammation. 
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3.2. Urinary tract infections 
Aside from its most peripheral sections, the urinary tract is normally a sterile environment. It is also 
one of the commonest sites of bacterial infections, especially in women. Urinary tract infections are 
defined by the presence of phagocytes and> I 05 bacterial cells per ml of urine. Infections can be 
confined to the lower urinary tract (cystitis) or may ascend via the urethra to the bladder and 
kidney, occasionally invading the bloodstream. Most UTls in both community and hospital 
practices are due to E. coli, where it accounts for up to 90% and 50% of cases, respectively 
(Bahrani-Mougeot, F et al., 2002; Marrs, Carl F. et al., 2005; Ronald, A., 2003). 
Although most of lower UTls are acute and of short duration, they still contribute to a 
significant amount of morbidity in the population. Ascending infections are much more serious 
and, if associated with bacteraemia, have significant mortality. Predisposing factors for UTls 
include age (the incidence of UTls increases with age, but cystitis is also frequent in sexually-
active women of child-bearing age), sex (short urethra in females), structural abnormalities of the 
urinary tract (e.g. calculi), catheterization and surgery, but also medical conditions such as diabetes 
mellitus and immunosuppression. 
The subset of E. coli causing UTls in humans is thought to be distinct from commensal E. 
coli strains: although they most often originate in the faecal flora, uropathogenic E. coli (UPEC) 
generally differ from commensal strains in that they possess specific attributes to cause 
pathogenesis (e.g. adhesins, fimbriae, haemolysins, LPS, capsules and siderophores). The ability of 
strains to cause UTls may be attributable to their capacity first to colonize the periurethral areas, 
and then to adhere to the urethral and bladder epithelium using specific pili such as type 1 and P 
fimbriae, but also Dr adhesins and S fimbriae (Bahrani-Mougeot, F et al., 2002). Other virulence 
factors significantly found among UPEC isolates in contrast to faecal isolates from healthy 
individuals include also haemolysin and cytotoxic necrotizing factor 1, iron-chelating siderophores 
(e.g. aerobactin, yersiniabactin), capsules (mostly Kt and K5) and a variety of extracellular 
polysaccharides (LPS a-antigens) (Donnenberg, M. S., 2002). 
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3.3. Infections of the central nervous system: meningitis 
Bacterial meningitis is a life-threatening infection, which needs urgent effective treatment. It 
generally arises through the spread of bacteria from the bloodstream to the meninges, but may also 
result from direct spread of the infection from one individual to another. The vast majority of 
bacterial meningitis cases are caused by Neisseria meningitidis, Streptococcus pneumoniae or 
Haemophilus inj1uenzae, and very rarely by E. coli (after infancy). Nevertheless, E. coli is the 
commonest cause of meningitis during the neonatal period in developing countries. Mortality and 
morbidity associated with neonatal E. coli meningitis remain high despite advances in 
antimicrobial chemotherapy, and survivors often sustain neurological sequels (Sik Kim, K, 2002). 
During or shortly after birth, E. coli may colonize external surfaces of the neonate and invade the 
bloodstream prior to crossing the blood-brain barrier. Predisposing factors include instrumentation 
(e.g. nasogastric incubation or umbilical vessel catheterization), low birth weight, but also the 
serotype of the E. coli isolate involved. Isolates possessing the KI capsular polysaccharide, which 
is associated with invasiveness, account for up to 80% of neonatal meningitis-associated E. coli 
[MAEC, (Robbins, J. B. et al., 1974)]. Other virulence factors commonly found among MAEC 
include OmpA (outer membrane protein A, which is involved in the invasion of brain 
microvascular endothelial cells), ibe proteins (invasion of brain endothelial cells), and the cytotoxic 
necrotizing factor 1 (Donnenberg, M. S., 2002). 
3.4. Septicaemia 
Septicaemia may be described as a systemic illness caused by the spread of microbes and/or their 
toxins via the bloodstream. Bacteraemia on the other hand, refer to the presence of bacteria in the 
blood, with or without septic consequences. The nature and the incidence of bacteraemia vary 
between hospitals, and depend partly on the specialities practiced. E. coli is one of the four 
commonest organisms responsible for septicaemia, along with Staphylococcus aureus, S. 
epidermidis, and Streptococcus pneumoniae, and it is by far the most frequent Gram-negative 
bacterium isolated from positive blood cultures. 
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The most common factors predisposing to E. coli (and Gram-negative organisms in general) 
septicaemia include instrumentation and surgery of the gastro-intestinal and urinary tracts, as well 
as neutropenia (e.g. in oncology and transplant patients), drug-induced immunosuppression and 
alcoholism. Septicaemia may also arise following the spread of bacteria from other sites, most 
obviously following UTls, abdominal infections, gastroenteritis or infections of the central nervous 
system. 
3.5. Intra-abdominal infections 
Intra-abdominal infections are usually polymicrobial, though E. coli is one of the most common 
Gram-negative bacilli responsible, together with anaerobes. These infections occur secondary to 
spontaneous or traumatic gastro-intestinal tract perforation, or after anastomatic disruption with 
spillage of colon contents and subsequent peritonitis. Intra-abdominal infections due to E. coli 
often result from a perforated viscus (e.g. appendix), or may be associated with intra-abdominal 
abscess, cholecystitis and ascending cholangitis, which result from the obstruction of the biliary 
system by e.g. stones. Liver abscesses can develop as a complication of a biliary tract infection. 
4. Preventing and treating infections 
The three major strategies used to control infectious diseases consist of immunisation (though 
vaccines are not available in the case of E. cob), antimicrobial chemotherapy and a range of 
environmental measures such as adequate hygiene and nutrition. These measures are applicable in 
the community [E. coli is able to spread among household members, including pets (Johnson, 1. R. 
and Clabots, C., 2006)], and in hospital settings. Hospitals concentrate infected patients and those 
vulnerable to infections, hence control measures become even more crucial. 
The vast majority of hospital-acquired (nosocomial) infections, whether involving 
endogenous (i.e. organism deriving from the patient's own flora) or exogenous (infecting organism 
deriving from the hospital environment) pathogens, are caused by E. coli, S. aureus, Klebsiella 
spp., Enterobacter spp. or Pseudomonas spp., depending on hospitals. Each of these organisms 
normally originates from various sources, uses specific routes to cause infections, and causes 
distinct types of infection even if all lead frequently to septicaemia. 
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E. coli often originates from the gastro-intestinal tract and is spread by bedpans, urinals, catheters, 
as well as soiled bedding and via the food chain (Shanson, D. C., 1999a). E. coli is not commonly 
transmitted on hands, like meticillin-resistant S. aureus (MRSA) or Klebsiella spp. UTIs are the 
most common type of nosocomial bacterial infections, with catheter-associated UTIs accounting 
for approximately 40% of all hospital-acquired infections (Stamm, W. E. and Norrby, S. R., 2001). 
Even though E. coli is more associated with community-acquired UTIs, it is also the major cause of 
nosocomial UTIs, accounting for approximately 80% of uncomplicated infections (Stamm, W. E. 
and Hooton, T. M., 1993). The causative E. coli often come via the patients' own faecal flora, but it 
is not unusual for the bacteria to originate from the hospital environment (e.g. food in the kitchen) 
or from other infected patients (cross-infection). 
Long hospital stays constitute an important risk factor for the development of hospital-
acquired UTIs, but the major precipitating factor remains catheterisation of the urinary tract (e.g. 
cystoscopy); at least 40% of patients undergoing these procedures develop an UTI (Shanson, D. C., 
1999b). Most E. coli infections, regardless if they are community- or hospital-acquired, are 
avoidable though appendicitis remains an exception and control measures will rely on appropriate 
hygiene measures, particularly (Dundas, S. and Welsby, P. D., 2002): 
Sterilisation / disinfection of contaminated materials, and appropriate waste disposal 
Use of aseptic techniques in the operating theatre and wards for procedures such as 
changing of wound dressings, catheterisation, or setting-up intravenous drips 
Adequate preparation of food 
Isolation of infected patients and isolation of vulnerable patients 
Appropriate administration of antibiotic prophylaxis (e.g. in surgery or to prevent 
recurrent UTIs) 
Rotation of antibiotics used to treat patients (in order to discourage the emergence of 
resistance though options might be limited for multi-drug-resistant bacteria) 
Implementation of strict hygiene measures (e.g. use of protective clothing and hand 
washing for healthcare workers before and after each contact with patients) 
Infection surveillance (enable early recognition of emerging problems such as 
antibiotic resistance) 
40 
Attempts to prevent and control infection may fail and, as a result, antimicrobial treatment 
may have to be started, or changed (new or additional antibiotic, new dosage, administration by a 
different route). In severe-ill patients, adequate antibiotic treatment becomes crucial, owing to the 
risk of complications such as bacteraemia or septic shock, which are often fatal for the patients. 
5. Antibiotic modes of action and classes 
Most antibiotics in clinical use are derived from natural metabolic products of fungi, actinomycetes 
or bacteria. All are used to kill or inhibit the growth of micro-organisms. They demonstrate 
selective toxicity, e.g. acting at a target site present in the infecting organism only, and absent from 
the host. Production of antibiotics is particularly associated with soil and other environmental 
micro-organisms and may provide a selective advantage in their competition for space and 
nutrients. However, some agents used as systemic antimicrobials, such as sulphonamides and 
quinolones, are totally synthetic. 
Until the 1930s, prevention was the best mean of protection against bacterial infections, but 
in 1928, Fleming accidentally discovered what was going to become the fIrst true antibiotic: 
penicillin. On his return from holidays, he noticed that a contaminant mould (Penicillium notatum) 
showed antibacterial activity on old culture plates smeared with S. aureus. However, it was only in 
1944 that penicillin fInally became commercially available. From this point, research seeking new 
antimicrobial agents intensifIed, and still remains on the agenda of many pharmaceuticals 
companies nowadays due to the constant adaptation of bacteria and to the emergence of new 
antibiotic resistance mechanisms. 
The ideal properties of any antibiotic should include: selectivity for microbial (rather than 
mammalian) targets, a broad spectrum of activity (though many narrow spectrum drugs have also 
been developed, and may be more appropriate if the infection-causing organism is known), 
bactericidal activity, non-toxicity to the host, long plasma half-life, good tissue distribution, oral 
and parenteral dosing forms, and also no interactions with other drugs, or other side effects. 
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Many further factors should be considered prior to any antibiotic therapy, including: use of 
an appropriate drug and administration route, use of the correct dosage, use of a narrow-spectrum 
antibiotic unless the cause of infection is unclear, preferential use of bactericidal antibiotics if host 
defence mechanisms are impaired, adequate duration of therapy, as well as the cost. 
There are three major ways of classifying antibiotics: 
(i) by their chemical structure 
Classification based on chemical structure alone may not be practical since there is such diversity. 
(ii) by their target site 
Although this classification may not allow an accurate prediction of which antibiotic will be active 
against particular bacterial species, it is useful in the understanding of the molecular basis of 
antibacterial action. The four main target sites for antibacterial action are cell wall synthesis (e.g. 
penicillin), protein synthesis (e.g. tetracyclines), nucleic acid synthesis (e.g. quinolones) and 
metabolic pathways (e.g. sulphonamides).These targets greatly differ from their counterparts in 
human cells, allowing good selective toxicity. 
(iii) according to whether they are bacteriostatic or bactericidal 
Bacteriostatic antibiotics (e.g. tetracycline, chloramphenicol) prevent bacterial multiplication but 
do not kill bacteria when used alone. If the host defences do not kill the bacteria, then they will 
multiply again once the drug is withdrawn. On the other hand, bactericidal antibiotics (e.g. 
aminoglycosides, fj-Iactams) kill bacteria unassisted by the host defence mechanisms. However, 
they may only have a bacteriostatic action if given in too low a dose. In general, bacteriostatic 
agents are effective except in immunosupressed patients and in endocarditis. 
The following classification of antibiotics is primarily based according to their target site 
(or mode of action), with special emphasis on antibiotics used for the treatment of E. coli 
, 
infections. Within each group, antibiotics are subdivided based on their chemical structure. 
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5.1. Inhibitors of cell wall synthesis 
Peptidoglycan and its precursors constitute optimum targets for selective toxicity, since these 
components are unique to the bacterial cell wall (and to blue-green algae). Peptidoglycan synthesis 
involves many stages starting in the cytoplasm, proceeding across the cytoplasmic membrane and 
ending at the cell wall, with each step being a potential target for inhibition. The two major families 
of antibiotics inhibiting cell wall synthesis are the /3-lactams and the glycopeptides, though only the 
former have useful activity vs. E. coli and other Gram-negative bacteria. 
5.1.1. 13-Lactams 
/3-Lactams are bactericidal and are the most heavily-used antibacterials in clinical medicine. Many 
types are registered for clinical use globally, some of which are mainly active versus Gram-positive 
bacteria (e.g. penicillin G), while other have primarily been developed against Gram-negative rods 
such as Enterobacteriaceae (e.g. cefotaxime). They specifically bind to and permanently inactivate 
peptidoglycan carboxypeptidases and transpeptidases [also known as penicillin-binding proteins 
(PBPs)]. These enzymes are located in the outer leaflet of the cytoplasmic membrane and act in the 
final stages of cell wall synthesis, cross-linking the peptidoglycan chains that surround the 
bacterium and maintain its shape and structural integrity. /3-Lactams stop bacterial cell wall 
synthesis and renewal, as illustrated in Figure 3, leading to the accumulation of peptidoglycan 
precursors in the cytoplasm. Bacterial death results from osmotic lysis, promoted by the activation 
of the cell's autolytic system, as well as by the failure to integrate new cell wall material. /3-
Lactams remain inactive against species lacking a cell wall (e.g. mycoplasma), as well as against 
mycobacteria (impenetrable cell wall) or intracellular pathogens (e.g. Chlamydia). 
Most /3-lactams are administered parenterally, although a few are orally active (e.g. 
amoxicillin). They have generally low toxicity, but may be responsible for allergic reactions in the 
form of skin rashes or fever and, rarely, fatal anaphylactic shock. /3-Lactams comprise several 
groups of compounds (e.g. penicillins, cephalosporins, cephamycins, monobactams and 
carbapenems) distinguished by the chemical structures of the secondary ring and/or the side chain 
attached to the j3-lactam ring, which is a common feature of all antibiotics ofthis family (Table 2). 
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Figure 3. Inhibition of peptidoglycan cross-linking by penicillin3 
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Table 2. Chemical structure of selected ~-lactam compounds with different spectrum of 
activity 
Penicillin G 
(MW = 334) 
Meticillin 
(MW = 380) 
Aztreonam 
(MW = 435) 
Cephalosporin 
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Cefotaxime 
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CHEMICAL STRUCTURE 
(source: http://en.wikipedia .org/wikilCephaiosporin) 
Ceftazidime 
(MW = 547) 
Cefpodoxime 
(MW = 427) 
Imipenem 
(MW = 299) 
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The history of /3-lactams began with Alexander Fleming's discovery of penicillin in the late 
1920s. Until the 1950s, {1-lactams only comprised the two narrow-spectrum compounds penicillin 
G (parenteral route of administration) and penicillin V (oral penicillin). The expansion of this 
major family of compounds occurred in the early 1960s, with the development of the semi-
synthetic penicillins (e.g. ampicillin, meticillin, oxacillin and amoxicillin), which offer a broader 
spectrum of activity than penicillins G and V. Meticillin was the first compound to be active 
against penicillin-resistant S. aureus, while ampicillin was mostly aimed against Gram-negative 
pathogens. Carbenicillin in 1967, and ticarcillin later, were the first {1-lactams to show useful 
clinical activity vs. P. aeruginosa (Rolinson, G. N., 1998). Monobactams (e.g. aztreonam) are 
monocyclic {1-lactams inactivated by extended-spectrum {1-lactamases. They have been discovered 
in 1978 and have strong activity against susceptible Gram-negative bacteria, but remain inactive vs. 
Gram-positive and anaerobes (Neu, H. C., 1988). In order to overcome the ever growing {1-lactam 
resistance problem, cephalosporins and carbapenems were then developed. Cephalosporins form a 
class of {1-lactams of their own. While the early (first-generation) cephalosporins such as 
cephalothin or cephazolin were mainly directed against Gram-positive organisms, the second-, 
third- and fourth-generation compounds were developed for increasing activity against Gram-
negative bacteria; each generation of cephalosporins was developed to have a broader spectrum of 
activity than the previous one. Third-generation cephalosporins are stable to many widespread 
conventional {1-lactamases, such as the TEM-l enzyme, which confers resistance to penicillin, and 
have a broad-spectrum of activity including Gram-positive cocci and Gram-negative bacilli (though 
ceftazidime shows weak activity against staphylococci in-vitro). These antibiotics, particularly 
ceftazidime and cefotaxime, have long been useful in treating hospital-acquired infections. 
However, their heavy use has rapidly triggered the selection of resistant bacteria, including those 
producing extended-spectrum {1-lactamases (ESBLs). By contrast, carbapenems, which exhibit an 
exceptionally broad spectrum of activity including Gram-positive, Gram-negative and anaerobic 
bacteria, are stable against most {1-lactamases including AmpC and ESBLs (Zhanel. G. G. et al., 
2007). They are not useful against MRSA. Examples of compounds belonging to this class of {1-
lactams include imipenem, meropenem, ertapenem and doripenem. The successive development of 
newer {1-lactams in order to overcome resistance is reviewed in more detail in section 7. 
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5.1.2. Glycopeptides 
Glycopeptides include vancomycin and teicoplanin. Both are large bactericidal molecules, and are 
active only against Gram-positive bacteria, since they cannot penetrate the outer membrane of 
Gram-negative organisms. They act at an earlier stage than 13-lactams, by binding to the terminal D-
ala-D-ala of pentapeptide chains and inhibiting the transglycosylation reaction, thus preventing 
incorporation of new subunits into the growing peptidoglycan. Vancomycin and teicoplanin are 
mainly used for the treatment of infections caused by multi-resistant Gram-positive bacteria, 
particularly meticillin-resistant S. aureus (MRSA) and S. epidermidis. 
5.1.3. Other inhibitors of cell wall synthesis 
Fosfomycin is a fermentation product of a Streptomyces spp. It is generally more active against 
Gram-negative bacilli (Enterobacteriaceae) than against Gram-positive cocci. It interferes with 
bacterial cell wall synthesis by inhibiting phosphoenolpyruvate transferase, an enzyme involved in 
handling an early precursor of peptidoglycan. In countries where fosfomycin is marketed (e.g. 
Belgium and Spain, but not in the UK), it is recommended for the treatment of uncomplicated 
urinary tract infections. Fosfomycin may achieve a synergistic activity against some organisms 
when used in combination with aminoglycosides or 13-lactams. 
Other inhibitors of cell wall synthesis include bacitracin and cycloserine, although they 
have very limited uses, owing to toxicity. 
5.2. Inhibitors of protein synthesis 
Translation of the messenger RNA (mRNA) into a peptide chain is complex, involving many steps. 
Several classes of antibiotics inhibit protein synthesis, exploiting the differences between the 
prokaryotic 70S ribosome and the eukaryotic 80S ribosome. These include aminoglycosides, 
tetracyclines and chloramphenicol, all of which are useful against E. coli, along with macrolides, 
lincosamides, streptogramines and fusidic acid, which are useful only against Gram-positive 
bacteria. Some of these compounds inhibit the initiation of protein synthesis, while more target the 
elongation step. 
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5.2.1. Amino glycosides 
Aminoglycosides are bactericidal antibiotics, with the most-commonly-used in clinical practice 
being gentamicin, amikacin and tobramycin. Aminoglycosides irreversibly bind to the 30S subunit 
of the bacterial ribosome and prevent the formation of the 30S initiation complex known as 
formylmethionyl-transfer RNA (fmet-tRNA), from which protein synthesis proceeds. As a result, 
no further initiation can occur. Some aminoglycosides such as streptomycin also causes misreading 
of mRNA codons, prematurely terminating protein synthesis following insertion of a "wrong" 
amino-acid (Mims, C. et al., 1999). Aminoglycosides are particularly useful in infections due to 
Gram-negative bacilli and staphylococci. Combinations with ,s-lactams are often used to broaden 
their spectrum of activity to include streptococci and anaerobes, which are not susceptible to 
aminoglycosides alone. Aminoglycosides must be administered intravenously or intramuscularly 
for systemic infections. Monitoring of drug levels is essential, especially in patients with renal 
impairments since the therapeutic window between the serum concentration required for successful 
treatment and that which becomes nephrotoxic or ototoxic is narrow. 
5.2.2. Tetracyclines 
Tetracyclines are bacteriostatic antibiotics with large cyclic structures offering many sites for 
possible chemical substitutions. Although different tetracyclines (e.g. tetracycline, minocycline, 
doxycycline) vary in their pharmacological properties, they all have a relatively similar broad 
antibacterial spectrum of activity. Like aminoglycosides, tetracyclines inhibit initiation of protein 
synthesis by binding to the 30S ribosome. However, this interaction is reversible, occurring at a 
later stage than with aminoglycosides, and acts by preventing the aminoacyl transfer RNA from 
entering the acceptor sites on the 70S ribosome. Although tetracyclines are active against a wide 
variety of bacteria including intracellular species, their use is restricted due to widespread 
resistance (Shlaes, D. M., 2006). Furthermore, tetracyclines, which are usually administered orally, 
may suppress the normal intestinal flora thus often leading to secondary infections (e.g. 
candidosis). 
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5.2.3. Chloramphenicol 
Chloramphenicol is a broad-spectrum antibiotic with bacteriostatic activity, which acts by blocking 
the action of peptidyl transferase, thereby preventing peptide bond synthesis. It inhibits bacterial 
protein synthesis selectively because it has a much higher affinity for the transferase in the 50S 
subunit of the bacterial ribosome than for the corresponding transferase in the 60S subunit of the 
mammalian ribosome. Chloramphenicol use is now restricted due to its toxicity (bone marrow 
suppression). 
5.3. Inhibitors of nucleic acid synthesis 
The selective toxicity of these agents is a result of the differences between the prokaryotic enzymes 
targeted and their eukaryotic counterparts. Antibacterial agents of this class include sulphonamides, 
trimethoprim, quinolones and rifamycins. They intervene at three different stages of nucleic acid 
synthesis: (i) preventing synthesis of precursors (folic acid), (ii) inhibiting DNA replication or (iii) 
blocking mRNA synthesis. 
5.3.1. Sulphonamides and trimethoprim 
By contrast with mammalian cells, many bacteria cannot absorb folic acid and have to synthesise 
their own. Two major groups of compounds inhibit bacterial folate synthesis: sulphonamides and 
trimethoprim. 
Sulphonamide antibiotics are analogues of para-amino benzoic acid (P AB A) and 
competitively inhibit the formation of dihydropteroic acid, a precursor of tetrahydrofolic acid, by 
binding to the active site of dihydropteroate synthase. This, in turn, affects the synthesis of purines 
and pyrimidines, and thus nucleic acid synthesis. Sulphonamides are bacteriostatic, and have long 
been useful in the treatment of urinary tract infections. They have a broad spectrum of activity, but 
are primarily used against Gram-negative organisms. Resistance to this aging family of antibiotics 
is now widespread, thereby its limited use. The most commonly used sulphonamide is 
sulphamethoxazole, which is often administered in combination with trimethoprim as co-
trimoxazole. 
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Like sulphonamides, trimethoprim is a bacteriostatic antibiotic that competitively inhibits 
tetrahydrofolic acid synthesis, but intervenes at a later stage, by inhibiting dihydrofolate reductase. 
It acts as an analogue of the aminohydroxypyrimidine moiety of the folic acid molecule. As just 
mentioned, trimethoprim is often given in combination with sulphonamides, since both compounds 
act synergisticaUy against some bacteria (though in the UK, trimethoprim alone is often preferred 
owing to the toxicity of sulphonamides). Trimethoprim and co-trimoxazole are mainly used for the 
treatment of urinary tract infections, especially those caused by Gram-negative bacilli. Resistance 
to trimethoprim alone and to co-trimoxazole is now common. 
5.3.2. Quinolones 
The quinolones are a large family of synthetic bactericidal agents, with nalidixic acid being the 
earliest compound. Newer derivatives (fluoroquinolones), such as ciprofloxacin, have improved 
pharmacological properties and antibacterial activity compared with nalidixic acid. Quinolones 
inhibit DNA gyrase (topoisomerase IV), an enzyme needed for the replication of DNA, as it breaks 
and rejoins the strands of bacterial DNA to relieve the stress that occurs during the unwinding of 
DNA during replication and transcription. Quinolones thereby prevent supercoiling of the bacterial 
chromosome, and have a broad spectrum of activity. They are mostly used to treat urinary tract and 
systemic Gram-negative infections, including those caused by Pseudomonas aeruginosa. 
Nevertheless, resistance to quinolones and their derivatives has been expanding in recent years 
(Livermore, D. M. and Paterson, D. L., 2006). 
5.3.3. Rifamycins 
Rifamycins are bactericidal antibiotics that specifically bind to bacterial DNA-dependent mRNA 
polymerase, blocking the synthesis of messenger RNA. Although they have a wide spectrum of 
activity, they are particularly used for the treatment of (i) mycobacterial infections and (ii) of 
severe infections due to Gram-positive organisms. Rifampicin is clinically the most important 
member of this family. Mutational resistance is common, hence the drugs are mostly used in 
combination therapy (Murphy, C. K. et al., 2006). 
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5.4. Miscellaneous 
The above classification outlines the most important families of antibiotics, but a few additional 
antibiotics are also available. These mostly have a narrow spectrum of activity and some are 
variably available between countries. With regard to infections caused by Gram-negative 
organisms such as E. coli, two additional agents deserve to be mentioned: colistin (polymyxin E) 
and nitrofurantoin. 
5.4.1. Polymyxins 
Polymyxins are bactericidal polypeptides that act on the membranes of Gram-negative bacteria, by 
disrupting the phospholipid structure, thus disturbing osmotic integrity and causing loss of 
important metabolites. Colistin is clinically the most important polymyxin, but its use is restricted 
due to its nephrotoxicity. Nevertheless, colistin remains often the "drug of last resort" for the 
treatment of serious infections caused by P. aeruginosa and Acinetobacter strains resistant to all 
other major classes of antibiotics (Arnold, T. M. et al., 2007). It is also used in a nebulised form for 
treating pulmonary infections caused by P. aeruginosa in cystic fibrosis. 
5.4.2. Nitrofurantoin 
Nitrofurantoin is a synthetic compound administered orally for the treatment of uncomplicated 
lower urinary tract infections, mostly those caused by coliforms (i.e. E. coli and its relatives). It 
may also be used for prophylaxis of recurrent UTIs. Although its mode of action has not yet been 
fully elucidated, it has been suggested that nitrofurantoin may interfere with the expression of 
inducible genes acting at the initiation step of messenger RNA translation (Herrlich, P. and 
Schweiger, M., 1976). Resistance rarely develops (Karlowsky, J. A. et al., 2003), though 
therapeutic failure is common, perhaps associated with silent upper UTIs. 
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6. Antibiotic resistance mechanisms 
Since the beginning of the antibacterial era in the 1940s, bacteria have proved capable of adapting 
and developing resistance to almost every agent. Clinical resistance to an antimicrobial agent 
occurs when the Minimum Inhibitory Concentration (MIC) of the drug for a given bacterial strain 
exceeds that which is safely achievable or maintainable in the particular tissue or fluid affected 
after normal dosage. Bacterial resistance may be either intrinsic (or innate) or acquired (using 
various means). Intrinsic resistance describes the situation where an entire bacterial species is 
resistant even before the affected antibiotic has been developed and introduced on to the market 
(e.g. Streptococcus pyogenes is naturally resistant to gentamicin, S. aureus to polymyxins). The 
major reasons for innate drug resistance include lack of penetration of the drug through the cell 
wall, lack of a suitable cell target, or the consistent production of a drug-destroying enzyme. By 
contrast, resistance that is selected following the introduction of an antimicrobial agent into the 
clinic is said to be acquired. Acquired resistance results either from spontaneous single or multiple 
mutation(s) or from the acquisition of resistance genes encoded by transmissible plasmids or by 
transposons (colloquially known as "jumping genes"). 
Mechanisms of antibiotic resistance, whether they are chromosomally-encoded or plasmid-
mediated, can be divided into five main categories: 
(i) Altered permeability 
(ii) Antibiotic inactivation 
(iii) Target site alteration 
(iv) Metabolic bypass (i.e. replacement of a sensitive pathway) 
(v) Efflux 
These mechanisms are described in more detail below, and are illustrated with examples for each 
class of antibiotics commonly used for the treatment of E. coli infections. Table 3 summarises the 
most common mechanisms for antibiotic resistance in E. coli. 
53 
Table 3. Summary of antibiotic resistance mechanisms commonly occurring in clinical E. coli 
isolates 
Mechanism of antibiotic resistanceb 
Altered 
Antibiotic class· Drug Target Metabolic 
permeability 
inactivation alteration bypass 
and uptake 
Aminoglycosides -1+ ++ (streptomycin 
only) 
fj-Lactams + ++ 
Chloramphenicol + 
Quinolones + +1- ++ 
Sulphonamides ++ 
Tetracyclines + 
Trimethoprim ++ 
a Only antibiotics potentially used to treat infections caused by E. coli are listed in this table. 
b (+1_, rare; +, common; ++, very common) 
Efflux 
+1-
++ 
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6.1. Altered permeability 
Altered permeability decreases the amount of drug that reaches its target site, and may be 
responsible for simultaneous resistance to several classes of antibiotics. In Gram-negative bacteria, 
most antibiotics gain access to their targets by diffusion through channels formed by porin proteins, 
which are embedded in the outer membrane. Alterations to the genes encoding these porins may 
result in decreased porin expression or function, and so with reduced uptake of the antibiotic. Since 
unrelated antibiotics may use the same porins, these alterations may be responsible for cross-
resistance. Despite being rarely reported in E. coli, resistance to 13-lactams by decreased 
permeability can arise via mutations in the genes encoding its two major porins: OmpC and OmpF 
(Viveiros, M. et al., 2007). On the other hand, aminoglycosides require active transport system 
across the cell membrane before they exert their action, and alterations to these energy-dependent 
transporters may cause aminoglycoside resistance. Growth of E. coli under anaerobic conditions 
reduces the energy potential across the cytoplasmic membrane, thus inducing transient resistance to 
aminoglycosides. 
6.2. Drug inactivation 
This is the best-known mechanism of antibiotic resistance, and is very common among many 
species. Bacteria can produce enzymes that modify or destroy antimicrobials. The best known of 
these enzymes are 13-lactamases, with over 500 variants described in the literature so far 
(http://www.lahey.orglstudies/inc webt.asp). The most clinically significant of these are produced 
by Gram-negative organisms. These enzymes hydrolyse the 13-lactam ring of penicillins, 
cephalosporins, monobactams and carbapenems, yielding microbiologically inactive derivatives 
(Figure 4). Genes encoding 13-lactamases are widespread among Gram-positive and Gram-negative 
organisms, and are found on the chromosome as well as on plasmids. I3-Lactamases are discussed 
in more detail in section 7 of this chapter. 
Aminoglycosides and chloramphenicol are other antimicrobial agents susceptible to 
enzymatic inactivation; tetracycline- and (recently) fluoroquinolone-degrading enzymes have been 
described too. 
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Figure 4. Beta-Iactamase inactivation of penicillin 
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(Source: http://www.hpa.org.uklpublicationsI2005/amrreport05/3mdr.htm) 
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Production of modifying enzymes is far the most important mechanism of acquired resistance to 
aminoglycosides in E. coli. The genes encoding these enzymes are often plasmid-mediated and the 
type of enzyme produced determines the spectrum of resistance. Hydroxyl and amino groups of 
aminoglycosides are sites at which these compounds can be inactivated by phosphorylation, 
adenylylation or acetylation. An aminoglycoside acetyltransferase variant (aac(6J-Ib-cr) that 
acetylates ciprofloxacin and norfloxacin (i.e. fluoroquinolones with an unsubstituted piperazyl 
group) has recently been described. Its action leads to decreased susceptibility only, not frank 
resistance (Robicsek, A. et al., 2006). Chloramphenicol resistance, which is also most commonly 
plasmid-mediated, generally results from modification of the drug by chloramphenicol 
acetyltransferases yielding an inactive product that fails to bind to its ribosomal target. 
6.3. Target site alteration 
Antibiotic resistance can also arise from alterations to the target site, reducing affinity so that the 
target is then capable of functioning normally in the presence of antibiotic, or by synthesis of 
additional target molecules "swamping" the antibiotic (rare, but true in e.g. vancomycin 
intermediary S. aureus). Such resistance mechanisms affects many classes of antibiotics, including 
l3-lactams, quinolones, glycopeptides, macrolides or rifamycins, and are most commonly observed 
among Gram-positive bacteria. 
In Gram-negative organisms, target modification is associated mostly with resistance to 
quinolones (Mims, C. et al., 1999). Quinolone resistance currently is most often chromosomally-
encoded, and is usually the result of multiple mutations in the genes encoding DNA gyrase and 
topoisomerase IV subunits (e.g. gyrA, gyrB, parC ... ). The activity of quinolones may also be 
altered by the acquisition of plasmid-encoded Qnr peptides, which interact with the target enzymes, 
thereby limiting drug access and efficacy. This Qnr-mediated protection mechanism, which is rarer 
than mutational resistance, leads to reduced susceptibility only, but may predispose the bacterial 
cell towards full clinical resistance (e.g. by chromosomal mutations of the genes coding for DNA 
gyrase subunits or by decreased uptake). 
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6.4. Metabolic bypass 
Many antibiotics inhibit enzymes involved in specific metabolic pathways. In order to bypass the 
effect of these drugs, bacteria may acquire a novel drug-resistant metabolic pathway, thus 
rendering the antibiotic ineffective (Smith, 1. T. and Lewin, C. S., 1993). The best example of 
resistance by metabolic bypass is meticillin-resistant S. aureus; it synthesises an additional and 
altered penicillin-binding protein (PBP) with much lower affinity for 13-lactams than the "normal" 
PBP. Cell wall synthesis then continues even though the "normal" PBPs are inhibited. Resistance 
to sulphonamides and to trimethoprim is also commonly mediated by metabolic bypass enzymes 
(Huovinen, P., 2001). Bacteria resistant to these compounds synthesise supplementary 
dihydropteroate synthase and dihydrofolate reductase enzymes, with little or no affinity for 
sulphonamides and trimethoprim, respectively, whereas their affinities for their respective 
substrates (para-aminobenzoic acid and dihydrofolic acid) remain similar to those of their 
chromosomal counterparts. These enzymes generally are plasmid-mediated (Smith, 1. T. and 
Lewin, C. S., 1993). 
6.5. Efflux 
Active export via effiux mechanisms is another mean of preventing the antibiotic of reaching its 
target. E. coli has been shown to harbour at least nine distinct chromosomally-encoded proton-
dependent effiux pump systems. If over-expressed, these systems may decrease the amount of 
antibiotic retained within the bacterial cell, thus causing resistance. The genes coding for these 
pumps are emrE, acrEF, emrAB, emrD, acrAB-toIC, mdjABC, tehA, acrD andyhiUV(Viveiros, M. 
et al., 2007). 
Effiux is commonly associated with resistance to tetracyclines and to quinolones. 
Tetracycline resistance generally results from the acquisition of new cytoplasmic membrane 
pumps, encoded by genes carried most often by transposons. Quinolone resistance in E. coli may 
also be due to decreased accumulation of the drug in the cell, to some extent. This is more often 
due to mutations in the acrAB or mar genes, which up-regulate effiux and thereby reduce 
susceptibility to quinolones. This mechanism may lead to cross-resistance or decreased 
susceptibility to unrelated antibacterial agents. 
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6.6. Multiple antibiotic resistance mechanisms 
It is not uncommon for Gram-negative bacteria (including E. coli) to manifest resistance by using a 
combination of the above mechanisms. For example, high-level quinolone resistance may be the 
result of a combination of decreased uptake, mUltiple target alterations, as well as target protection 
(e.g. by mutations in DNA gyrase and by Qnr peptides). The same may be true for carbapenem 
resistance in Enterobacteriaceae, which may be due to a combination of /3-lactamase production 
and altered permeability (Woodford, N. et al., 2007a). 
Resistance to mUltiple antibiotics on the other hand, arises via plasmids that carry multiple 
resistance genes, thus limiting treatment options. Multi-drug resistant organisms may drive the 
clinician to use and overuse the very few unaffected antibiotic, which may then contribute towards 
the selection of bacteria with an even greater spectrum of resistance. 
7. {l-Lactamases 
Although many other resistance mechanisms can affect the clinical efficacy of /3-lactams 
(e.g. mutations to PBPs, acquisition of /3-lactam-resistant PBPs, efflux, impermeability), the most 
significant mechanism in Gram-negative bacteria, particularly in Enterobacteriaceae, is 
incontestably inactivation by /3-lactamases. As illustrated earlier (Figure 4), J3-lactamases catalyse 
the hydrolysis of the /3-lactam ring of penicillins, cephalosporins, cephamycins, monobactams and 
carbapenems, inactivating the antibacterial properties of the drug molecule. These enzymes can be 
chromosomally-encoded (i.e. universal in a given species) or plasmid-mediated (i.e. transferable 
between species). The range of /3-lactam substrates varies among /3-lactamases. 
7.1. Evolution of p-Iactamases 
Abraham and Chain isolated the first recognised J3-lactamase, a chromosomal penicillinase 
(penicillin-hydrolysing /3-lactamase) from E. coli in 1940, even before penicillin entered clinical 
use (Abraham, E. P. and Chain, E., 1940). Early concern however, centred on the spread of /3-
lactamases in Gram-positive bacteria, particularly S. aureus, as the major targets of early J3-lactams. 
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It may be that these enzymes originally protected the bacteria from naturally-occurring 13-lactams, 
long before clinical usage, or that they acted upon /3-lactam-like natural regulators of cell wall 
synthesis. In any event, the spread of /3-lactamases, and the inherent resistance of Gram-negative 
bacteria to early penicillins, forced pharmaceutical companies to seek novell3-lactams (a) able to 
withstand hydrolysis by staphylococcal penicillinases, and (b) with a broader spectrum of activity 
to include Gram-negative bacteria. Compounds with activity vs. Gram-negative bacteria, including 
ampicillin and fIrst-generation cephalosporins, were introduced in the early 1960s and, concomitant 
with their use during the mid-1960s, transferable (i.e. plasmid-mediated) broad-spectrum /3-
lactamases began to be identifIed in Gram-negative bacteria. These broad-spectrum 13-lactamases, 
include (most importantly) TEM-l (Datta, N. and Kontomichalou, P., 1965; Sutcliffe, J. G., 1978), 
TEM-2 (Matthew, M. and Hedges, R. W., 1976; Ambler, R. P. and Scott, G. K., 1978) and SHV-l 
(Bradford, P. A., 1999; Levesque, C. et al., 1995; Mercier, J. and Levesque, R. C., 1990). 
By the mid-1970s, TEM-l had become common in Gram-negative bacteria and stability to 
its hydrolytic activity became the next target of pharmaceutical companies, leading to the 
development of newer /3-lactams with greater stability towards 13-lactamases, such as "extended-
spectrum" third-generation cephalosporins (e.g. cefotaxime and ceftazidime) and carbapenems. In 
parallel, "suicide-inhibitors" of these /3-lactamases (e.g. clavulanate, sulbactam and tazobactam) 
were discovered also in the mid-1970s, and were seen as a major breakthrough in the battle against 
infections. 
The success of these strategies was short-lived, as transferable extended-spectrum /3-
lactamases (ESBLs) rapidly emerged among Gram-negative bacteria following on the introduction 
of third-generation cephaJosporins in the early 1980s (Turner, P. J., 2005). The heavy use of these 
/3-lactams, especially in hospitals, was shown to select for variants of the TEM and SHY /3-
lactamases (Knox, J. R., 1995), with mutations expanding their spectrum of activity. Inhibitor-
resistant TEM 13-lactamase variants also emerged in the late 1980s. Problems for third-generation 
cephalosporins and /3-lactamase inhibitors also arose via the selection of variants, especially 
Enterobacter spp., that hyperproduced their chromosomal AmpC /3-lactamases (paterson, D. L., 
2006). 
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For many years since the 1980s, TEM and SHY variants were the most common ESBL 
types; more than 150 TEM and 100 SHY variants have now been reported 
(http://www.lahey.org/studies/webt.asp). However, a newer type ofESBL -known as CTX-M- has 
been increasingly replacing the TEM and SHY /3-lactamases in importance among clinical isolates 
in the past decade. CTX-M enzymes (described in more depth in section 8) are now the most 
prevalent ESBLs around the world (Canton, R. and Coque, T. M., 2006). 
7.2. Classification of p-Iactamases 
Two major classification schemes of j3-lactamases have been proposed: (i) a functional 
classification based upon substrate profiles as well as susceptibility to suicide inhibitors such as 
clavulanate (Bush, K. et al., 1995), and (ii) a molecular or structural classification (Ambler, R. P., 
1980), based on amino-acid sequences alone. Ambler's classification divides j3-lactamases into four 
major classes: A, B, C and D, with class A and C j3-lactamases being the most widespread among 
clinically-significant bacterial species. Ambler's class A, C and D j3-lactamases have a serine 
residue in their active site; this takes part in /3-lactam hydrolysis, forming an unstable ester with the 
opened j3-lactam ring. Class B j3-lactamases, by contrast, are metallo-j3-lactamases that require one 
or two zinc ions to exert their activity. 
7.2.1. Serine p-Iactamases 
7.2.1.1. Class A j3-lactamases 
Class A j3-lactamases, many of which are plasmid-mediated, are the most common and the best 
understood j3-lactamase types. They occur in both Gram-positive and Gram-negative bacteria, and 
are very heterogeneous in their structures and kinetic properties, though some motifs are conserved 
throughout the family. They include the chromosomal j3-lactamases of Klebsiella spp., 
staphylococcal penicillinase, the TEM and SHY j3-lactamases and their ESBL derivatives, the 
CTX-M types and the rarer PER, VEB and GES ESBLs, and finally the KPC, IMI and SME 
carbapenemases. 
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TEM and SHY type {3-lactamases are commonly found in many Gram-negative bacterial 
species, especially in Klebsiella spp. (where SHY is chromosomal and ubiquitous), E. coli and 
Enterobacter spp. The amino-acid substitutions responsible for conferring ESBL activity cluster 
around the active site, changing its configuration to allow access to oxyimino-{3-lactams (i.e. (3-
lactams such as cefotaxime and ceftazidime substituted with an oxyimino-aminothiazolyl group, 
providing stability against non-ESBL TEM and SHY types), but also enhancing their susceptibility 
to inhibitors such as clavulanic acid. CTX-M ESBLs were named as such for their greater activity 
against cefotaxime than against other oxyimino-{3-lactam substrates such as ceftazidime (Bonnet, 
R., 2004). They have migrated to plasmids from the chromosomes of Kluyvera spp. (commensal 
organisms that are rarely pathogenic). CTX-M enzymes are not closely related to TEM and SHY {3-
lactamases, only sharing approximately 40% sequence homology. 
Other plasmid-mediated class A ESBLs, including the PER, VEB and GES {3-lactamases, 
are less common and (except PER-2, which occurs in Enterobacteriaceae in Argentina) have 
mainly been found in Pseudomonas aeruginosa (Livermore, D. M. and Woodford, N., 2006). The 
KPC (highly prevalent in the USA and in Israel), IMI and SME {3-lactamase types are effective 
carbapenemases. 
7.2.1.2. Class C {3-lactamases 
Class C {3-lactamases, also known as AmpC enzymes, were first believed to be exclusively 
chromosomal, but plasmid-borne variants have been identified since the 1980s, reflecting gene 
escape e.g. from the chromosome of Citrobacter species. AmpC {3-lactamases form a very closely 
related group, sharing similar structures, particularly within their active sites. They are the 
chromosomal {3-lactamase of most Enterobacteriaceae, and may be inducible (by e.g. cefoxitin, 
ampicillin or imipenem) and are prone to mutational derepression in Enterobacter spp., Citrobacter 
freundii, Morganella morganii, Serratia spp., also P. aeruginosa. 
Six families of plasmid-mediated AmpC enzymes have been identified (perez-Perez, F. J. 
and Hanson, N. D., 2002). These comprise ACC (originating from Hafnia alvei), CIT (from C. 
freundii), DHA (from M morganii), EBC (from E. cloacae), FOX (maybe from Aeromonas spp.) 
and MOX (maybe from Aeromonas spp.). 
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In contrast to ESBLs (transferable class A (3-lactamases hydrolysing oxyimino-
cephalosporins and susceptible to clavulanate), AmpC enzymes hydrolyse cephamycins (e.g. 
cefoxitin), but remain inactive versus fourth-generation cephalosporins (e.g. cefepime). Most 
importantly, they are not much affected by {3-lactamase inhibitors such as clavulanate, owing to 
very poor affmity (Monnaie, D. and Frere, J. M., 1993). 
7.2.1.3. Class D 13-lactamases 
The class D {3-lactamase family was originally defined on phenotypic rather than genotypic criteria, 
comprising enzymes that preferentially hydrolyse oxacillin, cloxacillin and other anti-
staphylococcal penicillins. Class D {3-lactamases predominantly comprise the plasmid-mediated 
oxacillinases (also known as OXA {3-lactamases), but also intrinsic chromosomal types found in 
Aeromonas spp., Pseudomonas spp. and Shewanella spp. (Heritier, C. et al., 2004; Poirel, L. et al., 
2004). Amino-acid substitutions in OXA-type {3-lactamases can extend their spectrum of activity 
resulting in ESBL activity, just as in class A. However, while the common ESBLs (CTX-M, TEM 
and SHY variants) are predominantly found amongst Enterobacteriaceae, OXA-type ESBLs have 
been found mainly in P. aeruginosa and Acinetobacter spp (Danel, F. et al., 1997). Another 
difference compared with common ESBLs is that they are poorly inhibited by clavulanate. 
7.2.2. Metallo-I3-lactamases (class B) 
Some class B {3-lactamases show a very broad substrate spectrum (though that from Aeromonas 
spp. is a strict carbapenemase by contrast). Many are capable of hydrolysing all non-monobactam 
{3-lactam antibiotics, including carbapenems, which are generally stable against most other {3-
lactamases, and which have enjoyed longevity in the clinic since their introduction in the mid-
1980s. These enzymes also evade the inhibitory activity of clavulanate and other {3-lactamase 
inhibitors. 
Class B {3-lactamases, also known as metallo-{3-lactamases, require the binding of zinc 
metal ions to their active site in order to exert their hydrolytic activity. 
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These {3-lactamases include the chromosomal {3-lactamase of Aeromonas spp., Chryseobacterium 
spp. and Stenotrophomonas maltophilia, as well as the plasmid-mediated IMP, VIM, SPM and 
GIM carbapenemases, amongst which the VIM enzymes are the most prevalent. Although class B 
{3-lactamases display considerable structural variation and do not share any close evolutionary 
relationships, the active site residues that coordinate the binding of the zinc ions are conserved. The 
plasmid-mediated types, which pose the greatest threat as they can spread among different species, 
have been found in Gram-negative enteric organisms, but are commoner in Pseudomonas and 
Acinetobacter species. Except for SPM, they are normally encoded within integrons, which may 
assist their mobility. They have a wide geographic distribution, and are most commonly found in 
the Far East, Europe and South America. 
8. CTX-M extended-spectrum B-Iactamases 
As mentioned already, extended-spectrum /3-lactamases (ESBLs) were fIrst detected in the 1980s 
[ftrst report from Germany in 1983, (Knothe, H. et al., 1983)], soon after the introduction on to the 
market of oxyimino "third-generation"-cephalosporins (e.g. cefotaxime, ceftazidime, ceftriaxone). 
ESBLs may be deftned as {3-lactamases capable of hydrolysing oxyimino-cephalosporins and 
monobactams, but not cephamycins and carbapenems, and are susceptible to inhibition by {3-
lactamase inhibitors (the class D ESBLs are a rare exception in this regard). They are frequently 
encoded by plasmids and, until recently, mostly were derivatives of the TEM-l, TEM-2, or SHV-l 
{3-lactamases, with changes to the amino-acids around the active site, extending the spectrum of {3-
lactams susceptible to hydrolysis. These "classical" ESBLs were most commonly produced by 
Klebsiella spp. (and, less so, Enterobacter spp.), and were largely found in isolates causing 
nosocomial infections. Later, in the 1980s, a novel plasmid-mediated ESBL type now known as 
CTX-M was detected, initially in Japan in 1986 (Matsumoto, Y. et al., 1988) and subsequently in 
Germany and Argentina [1989, (Bonnet, R., 2004)]. CTX-M ESBLs preferentially hydrolyse 
cefotaxime rather than ceftazidime, in contrast to most TEM and SHV-type ESBLs. 
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S.l. Emergence and geographic dissemination of CTX-M enzymes 
Although the fIrst CTX-M enzyme was reported in the late 1980s, accounts of this type of 
extended-spectrum l3-lactamase remained very rare throughout the 1990s, except in South America 
(particularly Argentina) where CTX-M-2 spread widely and rapidly (power, P. et al., 1999). 
Otherwise, reports were sporadic in Europe [Germany (Bauernfeind, A. et al., 1990), France 
(Bernard, H. et al., 1992) and Poland (Gniadkowski, M. et al., 1998)], and also in Asia [Japan, 
(Ishii, Y. et al., 1995)]. Since around year 2000, however, CTX-M l3-lactamases have become a 
fast-growing group of ESBLs, and have spread rapidly, including in the UK. CTX-M l3-lactamases 
have replaced TEM and SHY derivatives as the predominant ESBLs worldwide, except maybe in 
the United States (Canton, R. and Coque, T. M., 2006). They have been found among a wide range 
of species of the Enterobacteriaceae family, including: E. coli, Klebsiella spp., Enterobacter spp., 
Salmonella spp, Citrobacter spp., Morganella morganii, Shigella spp., Proteus spp, Serratia spp. 
and Hafnia spp. There are also a few reports of CTX-M ESBLs production by species such as P. 
aeruginosa, Acinetobacter spp. and Stenotrophomonas ma/tophilia (al Naiemi, N. et al., 2006; 
Celenza, G. et al., 2006). 
CTX-M ESBLs are particularly associated with E. coli and as a result, the past five years 
have seen a dramatic change in the epidemiological landscape of ESBL-producing organisms. 
Nosocomial Klebsiella spp. with TEM or SHY ESBLs are now outnumbered in many centres by E. 
coli with CTX-M enzymes, which are fast spreading in hospitals but also, and more worryingly, in 
the community. CTX-M enzymes are also overtaking TEM and SHY ESBL types in prevalence in 
Klebsiella spp. itself. Moreover, CTX-M ESBLs are not confined to bacterial strains isolated from 
humans; isolates producing those enzymes have also been detected in pets, farm animals, wild 
birds, sewage and even in products ofthe food chain (Canton, R. and Coque, T. M., 2006). 
In the UK, the first CTX-M enzyme was reported in 2000. Specifically, a K oxytoca strain, 
isolated from a stool sample of a six-year-old child in Leeds, was found to produce CTX-M-9, a 
variant that had previously been described in China and Spain (Alobwede, I. et al., 2003). A 
retrospective study later revealed that CTX-M enzymes emerged earlier in this country, in the mid 
1990s, as these ESBLs were detected among Salmonella enterica serotype Virchow isolates 
(Hopkins, K. L. et al., 2006a). The fIrst hospital outbreak caused by an organism with CTX-M 
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ESBL, which occurred during 2001-2002, was reported in 2003 and involved a K. pneumoniae 
strain with CTX-M-25 at the City Hospital in Birmingham (Brenwald, N. P. et al., 2003). In the 
same year, four genetically-distinct E. coli isolates were shown to produce the CTX-M-15 enzyme, 
a variant that had been reported previously in Japan, India, France, Poland and Bulgaria (Mushtaq, 
S. et al., 2003). These isolates were from a survey that examined c. 1,000 E. coli from in-patients 
from the UK. and Ireland. Since 2003, there has been a sharp and continuing increase in referrals to 
the Antibiotic Resistance Monitoring Reference Laboratory (ARMRL) of isolates with the CTX-M 
phenotype, mirroring the global epidemiological scenario. 
8.2. Origin and evolution of CTX-M ~Iactamases 
The CTX-M family comprises well over sixty members (67 on the 11 th June 2007, based on amino-
acid sequences), with new variants described and added to the literature regularly 
(http://www.lahey.org/studies/other.asp#tablel). On the basis of their amino-acid sequences, these 
13-lactamases are divided into five distinct phylogenetic groups: group-I, group-2, group-8, group-9 
and group-25/26. Figure 5 shows a dendrogram constructed on the basis of the amino-acid 
sequence alignment for the first 33 CTX-M enzyme variants, illustrating the five distinct CTX-M 
phylogenetic groups. The vast majority ofCTX-M variants belong to phylogenetic groups-l and -9. 
Within each phylogenetic group, CTX-M enzymes share at least 95% sequence homology, usually 
differing by one amino-acid only, while members from different groups share 80 to 90% sequence 
homology. 
Several studies have focused on identifying the sources of CTX-M enzymes (Humeniuk, C. 
et al., 2002; Olson, A. B. et al., 2005; Poirel, L. et al., 2002b; Rodriguez, M. M. et al., 2004). 
These have shown that blacrx-M genes most likely originated from the chromosomes of various 
Kluyvera spp. (commensal Gram-negative bacilli that are rarely pathogenic). It appeared also that 
CTX-M enzymes from different phylogenetic groups originated from different species of Kluyvera. 
This association is clear because the chromosomally-encoded 13-lactamases of Kluyvera spp. share 
up to 100% amino-acid identity with acquired CTX-M enzymes (e.g. for KLUY-l of K. georgiana 
and CTX-M-14). 
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Figure 5. Dendrogram showing the relatedness of the first 33 reported CTX-M variants constructed on the basis of amino-acid sequence homology, also 
indicating the source Kluy vera spp. 
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Moreover, the genetic regions flanking acquired blacrx-M genes exhibit high nucleotide similarity 
with those surrounding the chromosomal bla genes of Kluyvera spp. (Canton, R. and Coque, T. M., 
2006). In brief, phylogenetic group-l and group-2 CTX-M enzymes originated from K. ascorbata 
(blaKLUA), while the chromosomally-encoded KLUG (j-Iactamases of K. georgiana appear to be the 
progenitors of CTX-M enzymes belonging to phylogenetic groups-8 and -9. No progenitor of the 
CTX-M enzymes from phylogenetic group-25/26 has yet been identified. Furthermore, the 
chromosomally-encoded blaKLuc-1 of K cryocrescens has been shown to share 86% identity with a 
few blacrx-M genes from phylogenetic group-l [blacrx-M-J. -3, -10, _11 and -12, (Decousser, J. W. et al., 
2001)]; this enzyme may therefore be the progenitor of CTX-M enzymes for a potential sixth 
phylogenetic group that have not yet emerged (or been recognised) in clinical isolates. It is also 
worth mentioning that the chromosomal {j-Iactamases of Kluyvera spp. are very weakly expressed 
(Bonnet, R., 2004), and so do not confer an ESBL phenotype in their original host. The various 
mechanisms responsible for the escape of blacrx-M genes from the chromosome of Kluyvera spp. 
and for their expression post mobilisation in their new host are discussed later (section 8.5). 
Figure 6 shows the worldwide dissemination of CTX-M ESBLs, with lists of the most 
prevalent CTX-M variants in various countries. Phylogenetic group-25/26 CTX-M enzymes are the 
least common variants so far, having been reported only from Canada and from the UK (Munday, 
C. J. et al., 2004a). 
8.3. Global epidemiology of E. coli with CTX-M p-lactamases 
The sudden emergence of E. coli with CTX-M enzymes somehow started in South America with an 
explosive dissemination of isolates producing CTX-M-2 enzymes in Argentina, which then spread 
to its neighbouring countries (Canton, R. and Coque, T. M., 2006; Radice, M. et al., 2002). 
Subsequently, rises in prevalence of isolates with other CTX-M types were observed in South-East 
Asia and in Europe. Since around 2002, CTX-M enzymes have been reported from all around the 
world [with maybe the exception of North America, where TEM and SHY mutant ESBLs still 
remain dominant (Livermore, D. M. et al., 2007)], and were exhibiting an ever growing diversity. 
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Figure 6. Worldwide dissemination of CTX-M ESBLsa 
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In some countries, such as Spain and Poland, the rise and spread of CTX-M ESBLs is 
largely explained by horizontal transfer of plasmids encoding blacrx-M-9/-14 and blaCTX-M-3, 
respectively (Baraniak, A. et al., 2002b; Velasco, C. et al., 2007). In other countries, such as France 
and the UK., however, the sudden rise in CTX-M ESBLs is thought to be mostly associated with the 
dissemination of epidemic strains that produce these enzymes [e_g. nationwide dissemination of 
epidemic clone A with CTX-M-15/3-lactamase in the UK., see section 9, (Lavollay, M. et al., 2006; 
Woodford, N. et al., 2004)]. As mentioned in section 8.5, another factor contributing to the global 
spread of CTX-M enzymes is the capacity of blacrx-M genes to be mobilised among plasmids, 
owing to the genetic structures that surround them (e.g. insertion sequences). These 
recombinational events, which may occur within one plasmid or among different plasmids, have 
been demonstrated recently in Spain and in France, with isolates harbouring plasmids coding for 
blacrx-M-9 (Novais, A. et al., 2006) and blacrx-M-Is (Lavollay, M. et al., 2006), respectively. 
The incidence of E. coli with CTX-M enzymes has increased rapidly in the community 
and also, significant faecal carriage of these isolates in the general community has been shown in 
Israel and in Spain (Ben Ami, R. et al., 2006; Valverde, A. et al., 2004). It is thought therefore that 
the rise of these organisms within hospital settings might in fact be the consequence of an influx 
from the community (Ben Ami, R. et al., 2006). 
8.4. General characteristics of CTX-M p-Iactamases 
8.4.1. Biochemical properties ofCTX-M (j-Iactamases 
The mature CTX-M proteins are made of 291 amino-acid residues and have a molecular mass of 28 
kDa. These enzymes have an alkaline isoelectric point, ranging from 7.4 to 9.0 (Bonnet, R., 2004). 
Although they are predominantly cefotaximases, a growing number of variants have increased 
activity against ceftazidime owing to mutations (see next section). Overall, CTX-M enzymes show 
strong hydrolytic activity against all true cephalosporins, including fourth-generation compounds 
such as cefepime and cefpirome, though not against cephamycins or carbapenems. 
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They are less active against penicillins compared with TEM and SHV penicillinases. Like other 
class A ESBLs, CTX-M enzymes are well inhibited by clavulanate and other available 13-lactamase 
inhibitors, which restore the activity of oxyimino-cephalosporins, such as cefotaxime and 
ceftazidime. Tazobactam is the most active inhibitor, while sulbactam is the least active (Bonnet, 
R.,2004). 
8.4.2. Structure and function ofCTX-M 13-lactamases 
The spectrum of 13-lactams hydrolysed by CTX-M enzymes is dictated by the amino-acid 
conformation of their active site. Residue Ser237 has been shown to be critical for the hydrolysis of 
cefotaxime (Knox, J. R., 1995); when mutated, both hydrolytic activity against cefotaxime and 
susceptibility to inhibition by clavulanate are decreased (Gazouli, M. et al., 1998). Various studies 
have demonstrated that two other amino-acid residues independently play key roles in the evolution 
ofCTX-M enzymes, and especially in expanding their spectrum to include ceftazidime. Pro167 and 
Asp240 are found in typical CTX-M enzymes with poor catalytic activity against ceftazidime. 
Increased activity against ceftazidime, as seen in a growing number of variants (sometimes at the 
cost of losing some activity against cefotaxime) has been associated with substitutions such as 
Pro167Ser and Asp240Gly. 
Overall, at least seven variants from three of the five phylogenetic groups of CTX-M 
enzymes confer increased resistance to ceftazidime. These include the group-l variants CTX-M-15, 
-23 and -42; the group-9 enzymes CTX-M-16, -19, and -27; and finally CTX-M-25 (Bonnet, R., 
2004; Munday, C. J. et al., 2004a; Poirel, L. et aI., 2001; Poirel, L. et al., 2002a; Stepanova, M. et 
al., 2005; Sturenburg, E. et al., 2004). CTX-M-15, the commonest CTX-M variant worldwide 
(Figure 6) is thought to be a ceftazidime-hydrolysing variant of CTX-M-3, differing from its 
"parent" only by the aspartate to glycine substitution at position 240. 
8.4.3. Phenotypic detection ofESBLs 
Ceftazidime resistance was for long the primary indicator of ESBL production, as being generally 
the best substrate for TEM and SHY ESBLs. 
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However, ceftazidime resistance is not obvious in all organisms with CTX-M ESBLs. As a result, 
national (BSAC) and international (e.g. EUCAST, CLSI) committees have issued revised 
guidelines on the phenotypic detection of ESBLs. These guidelines stipulate that microbiological 
laboratories should test for both ceftazidime and cefotaxime resistance, or if a single agent must be 
used, for resistance to cefpodoxime, as a third-generation cephalosporin readily hydrolysed by all 
TEM, SHY and CTX-M ESBLs. For isolates found resistant, these third-generation cephalosporins 
must also be tested in combination with c1avulanate to conftrm or refute an ESBL mechanism. 
8.5. Dissemination and mobilisation of blacTX-M genes 
8.5.1. Genetic support and dissemination of blacTx-M genes 
Although there have been a very few reports of acquired blacrx-M genes becoming chromosomally-
located (Bonnet, R., 2004), these genes are generally found on plasmids in clinical isolates. 
These plasmids have been the subject of many studies (Canton, R. and Coque, T. M., 
2006). In brief, plasmids harbouring blacrx-M genes were shown to be (i) transferable in the vast 
majority of cases (with transfer frequencies ranging from 10-7 to 10-2 per donor cell), (ii) of both 
narrow or broad host-ranges, and (iii) with sizes varying from 7-kb (Cao, V. et al., 2002) to more 
than 300-kb (Novais, A. et al., 2006). PCR replicon typing assays (Carattoli, A. et al., 2005) have 
also shown blacrx-M genes to be associated with plasmids belonging to a wide range of 
incompatibility groups including IncFI, IncFII, Incl, IncN and IncLIM. 
As previously mentioned, CTX-M-15 is the most widespread CTX-M variant worldwide 
having been detected on every inhabited continents, except Antarctica. CTX-M-15 is also the most 
prevalent ESBL encountered in many different geographical areas, including in much of Europe 
(though group-9 CTX-M enzymes have long been the most common in Iberia), India and North 
Africa. International dissemination of blacrx-M-ls may be explained by the fact that this gene has 
repeatedly been found on epidemic conjugative plasmids, especially of the narrow host-range 
IncFII incompatibility group. Such plasmids have been detected in clonal and non-clonal E. coli 
clinical isolates from Canada, France and North Africa (Canton, R. and Coque, T. M., 2006). 
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By contrast blacrx-M-9, one of the most prevalent CTX-M-encoding alleles in Spain, has regularly 
been linked to epidemic broad host-range plasmids [e.g. IncP-Ia plasmids, (Novais, A. et al., 
2006)]. Although very rarely reported so far, these plasmids may be responsible for the spread of 
CTX-M ESBLs to species other than Enterobacteriaceae (e.g. P. aeruginosa or Acinetobacter spp.). 
Finally, a given blacrx-M gene may be found on different genetic supports in a same 
geographical area, suggesting that blacrx-M genes are mobilisable between plasmids. There have 
also been reports of blacrx-M genes being mobilised from plasmids to chromosomes (Yagi, T. et al., 
1997). Mobilisation of blacrx-M genes most often results from recombinational events involving 
e.g. transposable elements. It may involve different plasmids; e.g. blacrx-M-Is was found on mosaic 
plasmids among clonally-related E. coli isolates in the Paris area (Lavollay, M. et al., 2006). 
Mobilisation also may happen within the same plasmid; e.g. blacrx-M-9 has been found on plasmids 
with similar restriction profiles, belonging to the same incompatibility group, but located within 
highly variable integrons in a tertiary-care hospital in Madrid (Novais, A. et al., 2006). 
8.5.2. Genetic environment and mobilisation of blacTX-M 
genes 
Three different mechanisms have been described for the original mobilisation of the blacrx-M genes 
from Kluyvera spp., involving distinct genetic elements. These elements include (i) ISEcpl-like 
insertion sequences, (ii) the putative ISCRl transposase (Common Region I), coded by orf513, and 
(iii) phage-associated sequences (Canton, R. and Coque, T. M., 2006; Lartigue, M. F. et al., 2004). 
The last route is the least common, having been reported only once, reflected by the genetic 
surroundings of the blacrx-M-Io gene harboured by distinct plasmids in several species of 
Enterobacteriaceae in a Spanish hospital (Oliver, A. et al., 2005). 
Some blacrx-M genes have been found linked to different genetic environments: e.g. blacrx-
M-IO has been found in association with both ISEcpl and with the phage-related sequences just 
mentioned (Canton, R. and Coque, T. M., 2006). Moreover, blacrx-M genes of the same 
phylogenetic group may be associated with different mobilisation mechanisms: while blacrx-M-9 is 
associated with ISCRl, blacrx-M-14 has mainly been found downstream of ISEcpl. 
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ISEcpl-like elements have repeatedly been shown to be responsible for the mobilisation of 
several blacrx-M alleles (e.g. ORFs encoding CTX-M-I, -2, -3, -14, -15, -19 enzymes). These 
insertion sequences, which are usually located between 42 and 266-bp upstream of the blacrx-M 
gene, can mobilize structurally-unrelated genes by a one-ended transposition mechanism (Canton, 
R. and Coque, T. M., 2006). On the other hand, the ISCRI element participates in gene 
mobilisation by a rolling-circle replication mechanism. This element is embedded within highly 
variable class I integrons (Garcia, A. et al., 2005), and has been found in association with several 
antibiotic resistance genes including blacrx-M, blacMY, blaoHA-I. and qnrA. The ISEcpl-like family 
of mobilisable elements provides also a promoter responsible for high-level expression of enzymes 
such as CTX-M-14, -17, 18 and -19 (poirel, L. et al., 2005); this also applies for the ISCRI 
element, which is able to promote the expression of distinct antibiotic resistance genes including 
blacrx-M-9, the plasmid-mediated quinolone resistance gene qnrA and the trimethoprim resistance 
gene dJrAlo (Rodriguez-Martinez, J. M. et al., 2006). 
Finally, dissemination of blacrx-M genes in both nosocomial and community settings may 
also have been influenced by association with transposable elements. Both blacrx-M.2 and blacrx-M-9 
alleles have repeatedly been found within complex class I integrons associated with transposons of 
the Toll family. The Toll family is disseminated worldwide in both environmental and clinical 
Gram-negative bacteria, often on large conjugative plasmids (Canton, R. and Coque, T. M., 2006). 
The blacrx-M genes linked to ISEcpl-like elements also may be part oftransposons. For example, 
the association ISEcpllblacrx_M_19 has been found within a Tnl72l transposon (poirel, L. et al., 
2003)]. 
8.6. Risk factors for infection with CTX-M-producing isolates 
Risk factors for nosocomial infection with CTX-M-positive isolates may be regarded as similar as 
those for infection with bacteria producing other ESBL types. However, since CTX-M enzymes are 
more prevalent in the community (by contrast with TEM and SHY derivatives), it becomes useful 
to differentiate the risks of acquiring such an infection within the hospital settings from the risks in 
the community. 
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The main risks factors for infection with isolates producing ESBLs (including CTX-M 
types) in the hospital include prolonged hospitalisation, use of invasive medical devices (e.g. 
urinary catheters), and previous antibiotic treatment (especially with third-generation 
cephalosporins). Even though outbreaks of infections due to isolates with CTX-M enzymes have 
been reported in many hospital unit types, patients admitted to intensive care units have a greater 
risk of acquiring those organisms (Livermore, D. M. and Paters on, D. L., 2006). 
For community-acquired infections due to isolates producing CTX-M enzymes, gut flora 
carriage also represents a risk factor, as does recent antibiotherapy (with cephalosporins, or even 
quinolones). Many "community-acquired" infections are contracted by people that had recent 
hospital admission and it becomes hard to distinguish whether the bacteria was truly acquired in the 
community or during the earlier hospital stay. People over the age of 65, especially females, are at 
a greater risk of acquiring an infection caused by organisms with CTX-M enzymes (Livermore, D. 
M. and Paterson, D. L., 2006). Finally, there have been a number of reports of faecal carriage of 
CTX-M-positive isolates in both hospital and community patients, as well as in healthy volunteers 
(Munday, C. J. et al., 2004b; Valverde, A. et al., 2004). Colonization of the gut flora often precedes 
infection, not only for the colonized person, but also for the other patients sharing the same ward. 
8.7. Therapeutic options for infections due to isolates with CTX-M 
enzymes 
The emergence of isolates producing CTX-M enzymes has lead clinicians to review the protocols 
for treatment of infections. Isolates with CTX-M enzymes can be responsible for severe life-
threatening infections as well as uncomplicated UTIs. Adequate treatment strategies have therefore 
become a necessity. 
Isolates with CTX-M enzymes should be considered resistant to all penicillins (except 
temocillin), all cephalosporins (including fourth-generation compounds but not cephamycins) and 
to aztreonam. Carbapenems and {3-lactaml{3-lactamase inhibitor combinations are not affected by 
CTX-M enzymes alone. However, OXA-l enzyme is often co-produced with CTX-M-15 and is 
poorly inactivated by {3-lactamase inhibitors and confer resistance e.g. to piperacillinltazobactam. 
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Additionally, a few isolates with CTX-M tJ-Iactamases, principally Klebsiella spp., exhibit 
permeability changes owing to loss of outer membrane proteins; these changes reduce the activity 
of carbapenems, particularly ertapenem (Mena, A. et al., 2006; Woodford, N. et al., 2007a). More 
generally, isolates with CTX-M enzymes often are multi-drug resistant, including to 
aminoglycosides, tetracyclines, sulphonamides, and quinolones (note the parallel increases in 
prevalence of cephalosporin and quinolone resistant E. coli in England and Wales, see Figure 7). 
Co-resistance means that aminoglycosides and quinolones cannot be recommended as first-line 
treatments for severe infections caused by isolates with ESBLs, unless susceptibility has been 
microbiologically demonstrated. The effective treatment options for infections caused by CTX-M-
positive isolates, particularly UTls and bacteraemias, are therefore narrow. 
Many studies have demonstrated that inappropriate empirical therapy (i.e. that which 
proves inactive vs. the pathogens subsequently identified) is associated with increased mortality 
among patients with infections (other than UTls) caused by isolates producing ESBLs such as 
CTX-M (Paterson, D. L. et al., 2004; Rodriguez-Bano, 1. et al., 2006). Currently, the best 
therapeutic options for hospitalised patients infected (or likely to be infected) with isolates 
producing CTX-M or other ESBLs are carbapenems, as this class of antibiotics has consistently 
been associated with better outcomes by comparison with other agents (Rodriguez-Bano, 1. and 
Paterson, D. L., 2006; Rodriguez-Bano, 1. et al., 2006). This was illustrated in an international 
study carried in 2004, involving twelve hospitals from seven countries, showing the use of a 
carbapenem for the treatment of bacteraemias caused by Klebsiella spp. producing ESBLs was 
associated with a significantly lower mortality than was the use of other agents apparently active 
in-vitro (Paterson, D. L. et al., 2004). However, it is worth stressing that increased prescribing of 
carbapenems will generate further selective pressure for carbapenemases and other mechanisms of 
carbapenem resistance (Denton, M, 2007). 
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Figure 7. (A) Increase of reported cases of E. coli bacteraemias, and (B) prevalence of 
resistance to cepbalosporins and ciprofloxacin in E. coli from bacteraemias, in England and 
Wales between 2000 and 20043 
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a Source: Health Protection Agency (2006). 
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Temocillin, a semi-synthetic drug highly stable against most /3-lactamases including 
ESBLs, tigecycline (a glycylcycline compound that overcomes resistance mechanisms to 
tetracyclines) and polymyxins may also be considered as alternatives, but clinical data versus 
Enterobacteriaceae producing CTX-M ESBLs are limited for these drugs (Denton, M, 2007). 
Furthermore, the polymyxin colistin is associated with nephrotoxicity and also, is inactive against 
some species such as Proteus spp. and Serratia spp. 
Treatment options are even more problematic for non-hospitalised patients since 
carbapenems are not available for oral therapy. Oral /3-lactaml/3-lactamase inhibitor combinations 
and quinolones may be considered if susceptibility to these drugs is proven, but many isolates are 
resistant. Fosfomycin (not marketed in the UK at present) and nitrofurantoin may also be 
considered for the treatment of uncomplicated urinary tract infections due to CTX-M-producing E. 
coli isolates. 
Finally, it is worrying that no truly novel agents with activity against multi-resistant 
Enterobacteriaceae are currently being under development, as therapeutic failure and mortality will 
only increase as a result of limited treatment options and inadequate antibiotic prescribing. 
9. The rise of E. coli producine; CTX-M B-lactamases in the United 
Kingdom 
Prior to 2000, there was no report of organisms with CTX-M ESBLs from the UK, and as 
elsewhere, most ESBL producers had TEM and SHY variants. Most were Klebsiella spp., often 
involved in nosocomial outbreaks (Livermore, D. M. and Hawkey, P. M., 2005). Early reports of 
CTX-M type ESBLs in the UK are outlines in section 8.1, but these enzymes reached a major 
milestone by mid-2003, when many geographically scattered laboratories across the UK informed 
the Health Protection Agency of a sudden rise in ESBL-producing E. coli isolates responsible for 
urinary tract infections, most often in community patients (Livermore, D. M. and Hawkey, P. M., 
2005). Since then, E. coli isolates producing CTX-M enzymes have been high on the agenda of the 
Antibiotic Resistance Monitoring and Reference Laboratory (ARMRL) and the Health Protection 
Agency, reported or referred by an ever-growing number of clinical microbiology laboratories from 
across the UK. Most of these isolates are from urinary infections, with minorities from 
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bacteraemias or other sites. Even though the referred isolates represented only a fraction of all the 
producers, it was clear that the incidence of CTX-M enzymes was increasing year-on-year 
(Livermore, D. M. and Hawkey, P. M., 2005). A survey undertaken by the HPA in 2004, covering 
South-East England (potz, N. A. et al., 2006), revealed the majority of cephalosporins-resistant 
Enterobacteriaceae to be E. coli with CTX-M enzymes. This was the first report showing these 
organisms overtaking Klebsiella spp. with TEM and SHY ESBLs and Enterobacter spp. with 
derepressed AmpC, as the leading cephalosporin-resistant Gram-negative group in part of the UK. 
CTX-M enzymes were not only dominant among E. coli isolates, but also among Klebsiella spp., 
and were scattered in Enterobacter spp. They were also found in few isolates of Citrobacter spp., 
Morganella spp and Proteus spp. At the molecular level, the majority (c. 90%) of E. coli isolates 
referred during the 2003-2004 period had group-1 CTX-M {j-lactamases, mostly CTX-M-15 
(Woodford, N. et al., 2004). CTX-M-3, -9 and -14 variants were also detected, but more rarely. An 
early investigation of CTX-M-positive E. coli in 2004 showed that isolates with CTX-M-15 
enzyme included five major serotype 025 epidemic clones (designated A-E), as defined by pulsed-
field gel electrophoresis (pFGE), as well as many unrelated producers (Woodford, N. et al., 2004). 
Epidemic clone A was the most prevalent, being nationally distributed and recovered from over 
forty different centres across the UK (see Figure 8), and being dominant in some, such as in 
Preston, Southampton or Telford. Epidemic clones B-E were much more localised, and most areas 
across the UK had diverse producers ofCTX-M-15 enzyme. Interestingly, it was also shown that 
most representative of clone A required lower cephalosporin MICs compared with other producers 
of CTX-M-15 {j-Iactamase. Preliminary examination indicated an IS26 insertion element, located 
between blacrx-M_\S and its normal promoter, which is provided by ISEcpJ, was probably 
responsible for lowering resistance level to these compounds (Woodford, N. et al., 2004). This 
molecular feature has since then become an important epidemiological tool, facilitating recognition 
of the clone. 
Finally, E. coli with CTX-M enzymes have spread rapidly across the UK, mirroring what 
happened in South America a decade earlier (though different CTX-M enzyme variants were 
involved) and it is now a concern that CTX-M ESBLs might one day become as widespread in E. 
coli as TEM-l (Livermore, D. M. and Hawkey, P. M., 2005). 
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Figure 8. Geographic dissemination of E. coli epidemic clone A in the United Kingdom, based 
on referrals to ARMRL a 
a Centres where epidemic clone A with CTX-M-15 ,6-1actamase is dominant are circled in blue 
colour (Source: HP A, 2006). 
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10. Aims of the project 
The sudden rise of E. coli producing ESBLs in 200312004 was alarming, with sharp rises in 
the number of E. coli isolates exhibiting a CTX-M phenotype. To a lesser extent, the same pattern 
was seen for Klebsiella and Enterobacter spp. There was a rise also in clinical microbiology 
laboratories across the UK referring such isolates. 
The main objective of this project therefore consisted in exploring the emergence and the 
dissemination of E. coli producing CTX-M enzymes in the UK. It especially aimed at identifying 
the factor(s) contributing to the epidemiological success of the five major national epidemic clones. 
In order to pursue this objective, the antibiotic resistance mechanisms of clonal and non-clonal 
CTX-M-positive E. coli isolates, and their genetic context, were rigorously compared using various 
molecular methods. Additionally, the virulence potentials of these organisms were assessed and 
compared, also being compared to that of E. coli isolates with other ESBL types. 
Much emphasis was directed towards the five major national epidemic clones and 
especially towards epidemic clone A, as being the most clinically successful, yet also the least 
resistant to cephalosporins. In this context, it became important to draw a complete and detailed 
map of the ESBL-encoding plasmid from epidemic clone A, so as to evaluate whether it played any 
role in the epidemiological success of its host. 
Finally, as the CTX-M family was growing and diversifying fast, this study also included 
an in-vitro evolution investigation of CTX-M-3 (j-Iactamase, a variant that has long been regarded 
as the parent ofCTX-M-15. This part of the study was undertaken in order to assess the ease with 
which CTX-M-3 could evolve the broader spectrum of activity associated with CTX-M-15. 
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MATERIALS & METHODS 
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1. Bacterial isolates and growth conditions 
1.1. Clinical isolates and reference strains 
A total of 176 clinical isolates of E. coli were used in this study, most of which produced CTX-M 
extended-spectrum /3-lactamases (n = 156), as shown by PCR in a previous study (Woodford, N. et 
al., 2004). These isolates were selected from a large collection of isolates referred by various 
hospitals and laboratories from across the UK to the Antibiotic Resistance Monitoring & Reference 
Laboratory in Colindale. The isolates with CTX-M enzymes investigated here were selected as 
illustrating the epidemiological situation in the UK at the time of the study (July 2004 - December 
2006). They included hospital isolates (ca. 50% confmned by senders) as well as isolates from the 
community (ca. 25% confmned); clonal (32/156) and non-clonal (124/156) E. coli isolates, as 
determined previously by PFGE (Woodford, N. et al., 2004); and also isolates producing various 
types of CTX-M /3-lactamases, most of them group-l CTX-M enzymes (109/156) according to 
PCR (Woodford, N. et al., 2006). At least half the isolates with CTX-M enzymes were known to 
have been isolated from urine samples, and approximately 10% from blood cultures. Table 4 details 
the variety of clinical isolates included in this study. 
The different reference strains used in this study are listed in Appendix 1. Most of these 
isolates were employed as control strains in a variety of experiments, including antibiotic 
susceptibility testing, detection of antibiotic-resistance genes by PCR, detection of virulence factor 
genes by PCR, plasmid extraction, estimation of plasmid size, and characterisation of /3-lactamases 
by IEF. E. coli K-12 DH5a and J-53-2 strains were used as recipient strains for resistance transfer 
studies. 
1.2. Media and growth conditions 
E. coli isolates were grown aerobically overnight (16 - 24 hours) at 3TC. The different 
types of media used in this study and their suppliers are summarised in Appendix 2. Unless 
specified, bacteria were generally grown on agar. 
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Table 4. Overview of clinical isolates studied 
Representative isolatesb of strain A 13 
Representative isolatesb of strain B 3 
Clonal isolates8 with CTX-M-
Representative isolatesb of strain C 9 
I5-like enzymes 
Representative isolatesb of strain D 3 
Representative isolatesb of strain E 4 
Isolates with group-l CTX-M enzymes 77 
Non-clonal isolates8 with 
Isolates with group-9 CTX-M enzymes 42 
CTX-M enzymes 
Isolates with unusual CTX-M enzymes 5 
Isolates with non-CTX-M type ESBLsc 20 
Total number of isolates 176 
a As defined by PFGE. 
b These isolates were selected to represent each of the five major UK epidemic E. coli strains (A-E) with 
CTX-M-15-like (j-Iactamase. For each given strain, representatives from different centres were selected for 
study. 
C According to antibiotic resistance phenotypes and to PCR for the detection of blaCTX-M genes. 
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If grown in liquid media, cultures were incubated overnight at 3TC on an orbital shaker (New 
Brunswick Scientific, Edison, N.l, USA) at a rotation speed of 100 rpm. If antibiotic selection was 
required, e.g. to ensure that a strain conserved a specific resistance phenotype, discs impregnated 
with the appropriate antibiotic were firmly applied to the surface of the agar plate using sterile 
forceps. For long term storage of bacterial strains, loopfuls of freshly grown E. coli cultures (e.g. 
from a NA plate) were re-suspended in 2 mL vials containing 1 mL 10% glycerol, and were then 
transferred to the freezer at -70°C. 
2. Apparatus and chemicals 
Equipment and chemicals used in this study are detailed in the relevant sections. The list of 
suppliers can be found in Appendix 3 and Appendix 4. 
3. Identification of E. coli isolates 
E. coli isolates were identified biochemically using API20E kits (BioMerieux, La Balme-les-
Grottes, France) according to the manufacturer's instructions. 
4. Antibiotic susceptibility testing 
Minimal Inhibitory Concentrations (MICs) of antibiotics were usually determined by agar dilution 
following the British Society for Antimicrobial Chemotherapy (BSAC) guidelines, which are 
reviewed on a yearly basis (Andrews, J. M., 2006). 
4.1. Antibiotics 
Antibiotics used in this study and their suppliers are listed in Appendix S. When stored at -70·C, 
antibiotic stock solutions were thawed for at least 30 min at room temperature prior to use. 
Clavulanate and tazobactam were used at a final concentration of 4 mgIL in 13-lactamase inhibition 
studies, while EDT A was used at 320 mgIL. 
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4.2. Incorporation of antibiotics into agar 
Bottles containing 40 ml agar were melted in a steamer and kept at 56°C prior to the addition of 
antibiotic(s). With the exception of ertapenem, imipenem and meropenem, which were 
incorporated into Mueller-Hinton (MH) agar (Oxoid, Basingstoke, UK) due to its higher zinc 
content (Walsh, T. R. et al., 2002), most antibiotics were prepared in IsoSensitest agar (ISO, Oxoid 
Ltd, Basingstoke, UK) using a two-fold serial dilution. Table 5 summarises the ranges of antibiotic 
concentrations tested versus Gram-negative bacteria as a standardised method. 
4.3. Cell suspensions and inoculation 
Single colonies of clinical isolates were sub-cultured on to fresh nutrient agar and incubated 
overnight at 37°C. Cell suspensions with an opacity of 0.5 on McFarland's scale were prepared 
from freshly grown cultures in IsoSensitest broths using an API densitometer (BioMerieux). This 
cell density corresponds to approximately 104to 105 colony-forming units (cfu) per spot when 0.3 
JlL amounts are dispensed with a multipoint inocula tor (Mast Diagnostics, Merseyside, UK). Agar 
plates were incubated for 16 h at 37°C. Nine reference strains (see Appendix 7, which also 
summarises their expected MICs), used as controls, were tested in parallel using the same 
methodology. 
4.4. Reading of Minimum Inhibitory Concentrations (MICs) 
MICs were read as the lowest concentrations of antibiotic to inhibit visible bacterial growth using 
the Sorcerer - version 2.1 (perceptive Instruments Ltd, Haverhill, UK). MICs were interpreted 
according to BSAC guidelines, except for minocyc1ine and sulbactam where CLSI guidelines were 
adopted in the absence of published criteria from the BSAC. 
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Table 5. Concentration range and MIC breakpoints (mgIL) of antibiotics routinely tested by 
ARMRL a versus E. coli 
Breakpoints 
Antibiotic Concentration range 
R> I s:s: 
Amikacin 0.5 - 64 16 16 8 
Ampicillin 0.5 - 64 16 16 8 
Augmentin 0.125 -64 16 16 8 
Aztreonam 0.125 - 64 1 
Cefotaxime 0.125 - 256 1 
Cefotaxime + Clavulanate 0.06 - 32 1 1 
Cefoxitin 1 - 64 8 8 
Cefpirome 0.125 - 64 1 1 
Cefpirome + Clavulanate 0.06 - 32 1 1 
Ceftazidime 0.125 - 256 2 2 
Ceftazidime + Clavulanate 0.06 - 32 2 2 
Ciprofloxacin 0.125 -32 1 1 0.5 
Colistin 0.5 - 32 4 4 
Ertapenem 0.125 -16 2 2 
Gentamicin 0.125 - 32 4 4 2 
Imipenem 0.06 - 32 4 4 
Imipenem + EDTA 0.03 - 16 4 4 
Meropenem 0.06 - 32 4 4 
Minocycline 0.125 -32 8 8 4 
Piperacillin 1- 64 16 16 
Piperacillin + Tazobactam 1- 64 16 16 
Sulbactam 1 - 32 8 8 4 
a Breakpoints changed while thesis in preparation. Version 5 criteria were used throughout data analysis and 
retained here (Andrews, 1. M., 2006). 
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Breakpoints 
Antibiotic Concentration range 
R> I S:s: 
Tigecycline 0.25 - 16 2 1 
Tobramycin 0.125-32 4 4 2 
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4.5. MIC determinations by E-test® 
MICs were determined using E-test strips (BioStat, Stockport) when those of only a few antibiotics 
(~6) for a small number of isolates were required. E-test were also used to determine the MICs of 
antibiotics absent from the standard battery of compounds tested by agar dilution; e.g. fosfomycin, 
nalidixic acid, nitrofurantoin, ofloxacin and rifampicin. 
Cell suspensions were prepared to a density of 0.5 McFarland from freshly grown cultures 
as described above (section 4.3). This inoculum resulted in semi-confluent growth after overnight 
incubation at 37°C. The complete surface of an ISO plate was inoculated using a sterile swab and 
left to dry prior to application of the E-test antibiotic strips using sterile forceps, making sure no air 
bubbles were trapped under the strips. Plates were incubated 16 to 24 h at 37°C. MICs were 
determined following the manufacturer's instructions and interpreted according to BSAC 
guidelines. 
5. Detection of antibiotic resistance genes by Polymerase Chain Reaction 
Table 6 summarises the various antibiotic resistance genes investigated and sought by PCR in this 
study. 
5.1. peR reaction 
Template DNA was obtained by lysing two to three colonies from a NA plate in 100 p.L tissue 
culture water (Sigma-Aldrich, Poole). Following a short vortex (Vortex Whirlmixer™, Fisons 
Scientific Equipment, Herts) and centrifugation (IEC Micromax RF micro-centrifuge, Thermoquest 
Scientific Equipment, Basingstoke) at 10,000 x g for 15 sec, 2 ilL of the supernatant, containing the 
released DNA, were added to 23 p.L of PCR reaction mix (Taq DNA polymerase kit [Invitrogen 
BV, Renfrew, UK]). The PCR reaction mix contained: 1 x Taq buffer, 0.05% W-l solution, 1.5 
mM MgCh, 1 U Taq DNA polymerase, 0.2 mM of each dNTP [dATP, dCTP, dGTP and dTTP 
(Invitrogen BV)], 0.5 p.M of each primer [(Sigma Genosys, Haverhill), see Appendix 6] and tissue 
culture water, up to 23 JlL. 
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Table 6. List of antibiotic resistance genes sought by PC~ and antibiotic-resistance 
mechanisms implicated 
Genes Antibiotic class affected Resistance mechanisms 
blaTEM (all ORFs) Antibiotic inactivation 
blaslN(all ORFs) Antibiotic inactivation 
blaoxA-I-like Antibiotic inactivation 
blacrx-M (Group-I, -2, -8, -9 13-lactams 
Antibiotic inactivation 
and -25/26) 
blaclTo blaMox, blaoHA, blaAcc, 
Antibiotic inactivation 
blaEBC, blaFOx 
aac3-IIa Acetylation of antibiotic 
aac(6 ,)-Ib-cr Aminoglycosides Acetylation of antibiotic 
armA Methylation of antibiotic 
QRDRs of gyrA, gyrB, pare Target alteration 
qnrA, qnrB and qnrS Quinolones Protection of antibiotic target 
aac(6,)-Ib-cr Acetylation of antibiotic 
tet(A) and tet(B) Tetracyclines Efflux pump 
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Amplification was performed in 0.5 mL polypropylene microfuge tubes (Anachem, Luton) 
or in 0.2 mL low profile 96-well PCR plates (AB gene, Epsom), using a Techne Genius (Techne, 
Cambridge) or Hybaid PCR ExpressIPx2 thermocycler (Thermo Life Sciences, Basingstoke). For 
each PCR, one or more isolates known to carry the gene(s) of interest was/were tested in parallel as 
positive controls, while tissue culture water was used as a negative control. PCR reactions were 
stopped with the addition of 10 ilL loading buffer (25% [w/v] Ficoll, 50 mM Na2EDTA, 0.25% 
[w/v] bromophenol blue). 
5.2. peR conditions and primers 
PCR conditions for DNA amplification were dictated by the melting temperature (Tm) of the 
primers used, as well as the length of the DNA fragment to be amplified. As a rule, the annealing 
temperature was approximately 2°C below the lowest Tm of the primers used in order to avoid non-
specific amplification. The duration of the DNA extension step was directly proportional to the 
length of the DNA fragment to be amplified. Typical PCR conditions were: 
Initial denaturation at 94°C for 5 min 
30 to 35 cycles of 94°C for 30 sec; (lowest Tm - 2°C) for 30 sec; 72°C for 60 sec (if 
DNA fragment ~1.5 kb) 
Final extension at 72°C for 7 min 
Appendix 6 summarises the annealing temperature of the different primers used in this 
study. In some cases (e.g. primers with similar Tm and PCR products of different sizes), two or 
more genes were amplified at once, in the same reaction. 
5.3. Agarose gel electrophoresis of peR products 
PCR amplicons were analysed in agarose gels (size: 165 x 120 x 7 mm) of various concentrations, 
ranging from 0.7 to 2.5% (w/v), depending on the PCR product size; the shorter the product, the 
more concentrated the gel. Agarose (Helena BioSciences, Sunderland) gels were prepared with 0.5 
x TBE (40 mM Tris-borate, pH 8.0, 1 mM Na2EDTA [Invitrogen BV). peR product/loading 
buffer mixtures were loaded into the agarose gel wells, along with a 123-bp DNA ladder 
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(lnvitrogen By), which was used as a DNA size standard. Gels were electrophoresed in 0.5 x TBE 
buffer at 120 V for approximately 80 min and then stained with a 1 mg/mL ethidium bromide 
solution. DNA products were visualised under UV light and photographed using the IN Genius 
Syngene Bio Imaging system (Syngene, Cambridge). 
6. Phylogenetic typing of E. coli 
Template DNA was obtained by lysing bacterial cells in tissue culture water. Phylogenetic typing 
of clinical isolates was performed using a triplex PCR as described previously (Clermont, o. et al., 
2000). PCR products were electrophoresed in 2% agarose gels and visualised under UV light. 
Results were interpreted as shown in Figure 9. 
7. Detection of virulence factor genes 
The presence of 32 known or suspected virulence factor genes (Table 7) of extra-intestinal 
pathogenic E. coli, as well as a pathogenicity-associated island marker (pAl), were sought using six 
multiplex PCR assays (I-VI), according to a method described previously (Johnson, J. R. and Stell, 
A. L., 2000). All six assays required the same PCR conditions: initial denaturation at 95°C for 12 
min, followed by 30 cycles of 94°C for 30 sec, 63°C for 30 sec and noc for 3 min, ending with a 
final extension step at noc for 10 min. PCR reactions were undertaken in 0.2-mL low-profile 96-
well PCR plates, as described in section 5.1. PCR products were electrophoresed in 2% agarose 
gels and visualised under UV light. Tissue culture water was used as the negative-control. E. coli 
positive-control isolates (Table 7, Figure 10 and Appendix 1), namely 2H16, 2H25, J96, L31, PM9 
and V27 (Johnson, J. R. and Stell, A. L., 2000), were gifts from Or James R Johnson, MD 
(Minneapolis, MN, USA). The prevalence of virulence factor genes among the different 
populations of isolates tested was compared using Fisher's exact test (GraphPad: 
http://www.graphpad.comlquickcalcs/index.cfm). 
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Figure 9. Interpreting PCR-based phylogenetic typing results for E. coli 
PCR of isolate 
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Table 7. List of virulence factor genes investigated in this study, and their respective E. coli 
positive-control strains 
Product Positive-Multiplex Gene Function & comments 
size (bp) control 
strain 
ibeA Invasion of brain endothelium 170 2H25 
papEF Minor tip pilins; connect PapG to PapA 336 J96 
kpsMTIII Group III capsular polysaccharide 
392 J96 
synthesis 
fimH D-mannose-specific adhesion, type 1 
I 508 J96 
fimbriae 
papA Major structural subunit of P fimbrial 
720 J96 
shaft; defmes F antigen 
malX Pathogenicity-associated island (P AI) 
930 J96 
marker 
kpsMTKl Kl-specific group 11 kpsM 153 2H25 
papG allele III Cystitis-associated (pap-2) 258 2H25 
iutA Ferric aerobactin receptor (iron uptake 
300 PM9 
and transport) 
11 sfalfocDE Central region of sfa (S fimbriae) and 
410 2H25 
foe (F 1 C fimbriae) operons 
bmaE Blood group M-specific adhesin 507 PM9 
fyuA Yersinia siderophore receptor (ferric 
880 PM9 
yersiniabactin uptake) 
papC Pilus assembly; central region of pap 
200 J96 
operon 
III kpsMTII Group 11 capsular polysaccharide 
272 B1-1-1 
synthesis 
papG allele I J96-associated papG variant (rare) 474 B1-1-1 
nfaE Non-fimbria1 adhesin 559 J96 
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Product Positive-Multiplex Gene Function & comments 
size (bp) control 
strain 
rfc 04 LPS synthesis 788 J96 
hlyA a-Haemolysin 1177 J96 
papG allele 11 Pyelonephritis-associated papG 190 V27 
traT Surface exclusion; serum survival outer 
290 2H25 
membrane protein 
focG Pilus tip molecule; FIC funbriae (sialic 
360 2H25 
IV acid -specific) 
cdtB Cytolethal distending toxin 430 V27 
cvaC CoIV; on plasmid 680 PM9 
gajD N -acetyl-D-gI ucosamine-specific 
952 PM9 
fimbriae adhesin 
kpsMTK5 K5 specific group 11 kpsM 159 L31 
sfaS Pilus tip adhesin; S-fimbriae (sialic 
240 L31 
acid-specific) 
cnfl Cytotoxic necrotizing factor 1 498 L31 
V afaldraBC Dr-antigen-specific adhesin operon 559 2H16 
papG n,m Gal( al-4)Gal-specific pilus tip adhesin 
1070 2H16 
molecule 
papGI Gal( al-4)Gal-specific pilus tip adhesin 
1190 J96 
molecule 
usp Uropathogenic-specific protein 
440 V27 
(bacteriocin) 
VI 
uidA t3-D-glucuronidase 508 V27 
ompT Outer membrane protein T (protease) 559 J96 
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Figure 10. Agarose gel electrophoresis showing amplicons from virulence factor multiplex peR (MP) I-VI of positive-control isolates 
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8. Detection of integrons, insertion sequence elements and addiction system 
genes 
Integrons were sought by PCR using primers specific for type I,ll and III integrases [Appendix 6, 
(Mazel, D. et al., 2000)]. Cycling conditions were as follows: 94°C for 5 min, followed by 30 
cycles of 94°C for 30 sec, 62°C for 30 sec, and noc for 1 min with a final extension ofnoC for 5 
minutes. 
Gene cassettes carried by class I integron were investigated using the Expand Long 
Template PCR system (Roche Diagnostics, Burgess Hill) with the primer pair int-5'CS and int-
3'CS (Levesque, C. et al., 1995), as well as primers specific for genes likely to be integron-
mediated (Appendix 6). With the amplification of long sequences requiring high-quality DNA, 
template DNA was obtained using the MagNA Pure Compact Nucleic Acid Isolation Kit 1 (Roche 
Diagnostics). PCR conditions when using the Expand Long Template PCR system were as follows: 
1 min of denaturation at 95°C, 1 min of annealing at 55°C, and 10 min of extension at 68°C for a 
total of 30 cycles. A final extension of 10 minutes finalised the reaction. Amplicons were 
electrophoresed in 1 % agarose gels and visualised under UV light. 
Insertion sequences, such as ISEcpl and IS26, and the plasmid addiction system ccdAlccdB 
were sought by conventional PCR as described earlier in section 5.1, with the primer pairs 
prom+/preCTX-M-3B, IS26-CTX-M forIIS26-CTX-M rev, and ccdAlccdB, respectively (see 
Appendix 6). 
9. Plasmid incompatibility grouping 
Template DNA was obtained using the MagNA Pure Compact Nucleic Acid Isolation Kit 1 (Roche 
Diagnostics, Burgess Hill). Plasmid incompatibility grouping was performed by a PCR-based 
replicon typing method (Carattoli, A. et al., 2005), with the assistance of Dr Katie Hopkins 
(Laboratory of Enteric Pathogens, Health Protection Agency - Centre for Infections, London, UK). 
PCR products were electrophoresed in 2% agarose gels and visualised under UV light. 
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Figure 11. Agarose gel electrophoresis of positive-control replicons amplified by peR for plasmid incompatibility grouping 
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10. Cloning ofPCR products using the TA Cloning® kit 
Antibiotic resistance genes to be fully sequenced, i.e. including the primer binding sites, which are 
not always covered when directly sequencing PCR products, were cloned using the TA Cloning® 
kit with pCR®2.1 (Invitrogen, Paisley, UK), used according to the manufacturer's instructions. 
This kit provided a very rapid and efficient mean of cloning Taq-polymerase-amplified PCR 
products into a plasmid vector. PCR amplicons to be cloned were fIrst purifIed using the 
GENECLEAN®Turbo kit (Q-BIOgene, Cambridge, UK) as instructed by the manufacturer. To 2 
J.lL oflinearised PCR®2.1 vector in 1 x ligation buffer, were added 2 ilL of purified PCR product 
as well as 1 ilL T4 DNA ligase, in a fmal volume of 10 J.lL made up with PCR-quality water. 
Cloning reactions were incubated overnight at 14°C prior to transformation. On the following day, 
2 J.lL volumes of the ligation mixtures were added to vials containing 50 ilL of pre-thawed 
OneShot® competent E. coli cells. These cells were then held on ice for 30 minutes, heat-shocked 
at 42°C for 30 sec and immediately returned onto ice. BRI broths (250 to 500 ilL) were added to 
each vial, and after 60 min incubation at 37°C with horizontal shaking (lOO rpm), 10 to 200 J.lL of 
the transformant cell suspensions were spread on to NA plates supplemented with 100 mglL 
ampicillin and 50 mgiL 5-bromo-4-chloro-3-indolyl-I3-D-galactoside (X-gal, Invitrogen). To select 
clones with blacrx-M genes, CTX at 2 mgiL was included in the selective NA. The agar plates were 
then incubated overnight at 37°C. 
Vector pCR®2.1 has an inducible lacZ gene, which is responsible for a blue coloration of 
colonies in the presence of X-gal. If lacZ was to be disrupted, e.g. by the insertion of a PCR 
product, the colonies remain white even in presence of X-gal. This colorimetric reaction allowed 
rapid screening for potentially successful clones, and its effectiveness was enhanced by incubating 
agar plates at 4°C for 2 to 3 h after the overnight incubation at 37°C. The DNA inserts from white 
colonies were amplified by PCR as described in section 5.1 using the M13 primer pair (Appendix 
6) and the following PCR conditions: initial denaturation for 5 min at 94°C, followed by 35 cycles 
of 30 sec at 94°C, 30 sec at 50°C and 3 min at 72°C, ending with a final extension at 72°C for 7 
min. PCR products were analysed by gel electrophoresis, purifIed and sequenced. 
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11. Seguencing 
11.1. Purification of DNA samples using commercial kits 
Prior to sequencing, DNA products were purified using one of two commercial kits, depending on 
the nature of the DNA product: 
For PCR products (up to 10 kb): GENECLEAN®Turbo kit (Q-BIOgene, Cambridge) 
For any other DNA products (up to 300 kb), either in solution or in agarose gel: 
GENECLEAN®SPIN kit (Q-BIOgene) 
11.2. Sequencing reactions 
Both strands of the purified DNA samples were sequenced in a microtitre sequencing plate using 
the Beckman Coulter CEQ 8000 system (Beckman Coulter, High Wycombe). Approximately 50 to 
500 ng of DNA was used per sequencing reaction. Following an initial DNA denaturation step at 
96°C for 3 min, 0.64 ilL of primer (1 1lg/IlL) and 8 ilL of DTCS Quick Start Solution (Beckman 
Coulter) were added per reaction, with sterile water added up to a final volume of 20 ilL. The 
following conditions were used for the sequencing reactions: 30 cycles of 96°C for 20 sec, 50°C for 
20 sec, and 60°C for 4 min, with a final holding step at 4°C. Each sequencing reaction was stopped 
by the addition of: 
2 ilL 0.1 M Na2EDTA (Sigma-Aldrich) pH 8.0 
2 ilL of 3 M sodium acetate (Sigma-Aldrich) pH 5.2 
1 ilL of 20 mg/mL glycogen (Beckman-Coulter) 
60 ilL of 95% ice-cold ethanol 
The microtitre plates were then centrifuged at 5,000 x g for 30 min at 4°C in a plate 
centrifuge (Allegra ™ X-22R, Beckman-Coulter) and the DNA pellets were washed twice with 200 
III 70% ethanol by centrifugation at 5,000 x g for 10 min each time. The plates then were briefly 
spun upside down for 15 sec at 500 x g in order to remove any residual traces of ethanol, and left to 
dry at room temperature for about 30 minutes. 
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The dried DNA pellets were re-suspended in 40 JlL of sample loading solution and left at room 
temperature for 15 minutes. Finally, the microtitre plates were loaded inside the Beckman Coulter 
CEQ 8000 system following the manufacturer's instructions. 
11.3. Sequence analysis 
DNA sequence chromatograms were imported into BioNumerics (version 3.5, Applied Maths, St. 
Marten-Latem, Belgium) for editing and analysis. Multiple sequence alignments were obtained 
using the BioEdit Sequence Alignment Editor (version 7.0.1). The online BLAST (Basic Local 
Alignment Search Tool) tool (http://www.ncbi.nlm.nih.govIBLASTD was used for comparing 
edited sequences with those held in GenBank (http://www.ncbi.nlm.nih.gov/Genbanklindex.htmn. 
11.4. Sequencing ofplasmids pEK499 
Plasmid pEK499 (the blacrx_M_Is-encoding plasmid from representative isolates Al of epidemic 
clone A) was sequenced by MWG Biotech AG (Ebersberg, Germany). The 2- to 3-kb fraction of 
the randomly sheared plasmid was cloned using the pGEM-Teasy vector system (promega GmbH, 
Mannheim) and transformed into E. coli DHI0b. DNA inserts were sequenced by dye terminator 
chemistry and sequences were assembled using the Staden Package software 
(http://staden.sourceforge.net). Combinatorial and directed PCR assays, and walking reads on 
selected clones were used to assemble the sequences and to fill-in gaps. Plasmid sequence 
compilation and annotation were accomplished in collaboration with Dr Anthony Underwood 
(Health Protection Agency, Centre for Infections, Bioinformatics Unit, Colindale). Genes were 
predicted and annotated using BASys web-server 
(http://wishart.biology.ualberta.ca/basys/cgilsubmit.pl) and compared with other plasmids 
sequences using the Artemis Comparison tool (http://www.webact.org). The online databases 
GenBank, EcoGene database of E. coli, and the Insertion Sequence database (http://www-
is.biotoul.frO were also exploited for plasmid sequence analysis. 
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12. Endonuclease digestion of DNA 
Endonuclease digestion of DNA, regardless of its type (total DNA, PCR amplicons or plasmids), 
was undertaken overnight in 0.5 mL polypropylene microfuge tubes according to the enzyme 
supplier's instructions (Table 8). A typical reaction contained approximately 10 ilL of DNA 
preparation, 2 ilL of enzyme buffer (xlO concentrated), 1 to 10 U of restriction enzyme and PCR-
quality water up to a final volume of 20 ilL. Reactions were stopped by the addition of 5 /-LL 
volumes ofloading buffer and the restricted DNA was visualised under DV light following agarose 
gel electrophoresis (0.8 to 2% agarose gels, 80 to 120 V for 90 to 150 min) and staining in 1 
mg/mL ethidium bromide. 
13. Nucleic acid extraction 
13.1. Extraction of total genomic DNA 
Chromosomal DNA from E. coli clinical isolates with CTX-M enzymes was extracted according to 
the method of Pitcher (pitcher, D., 1989). Bacteria were grown overnight at 37°C in 5 mL LB 
broths, shaken at 100 rpm on an orbital shaker platform. One-and-a-half mL volumes of the 
bacterial cultures were centrifuged for 1 min at 10,000 x g to harvest cells, which were then re-
suspended in 100 /-LL of TE buffer (10mM Tris, 1mM Na2EDT A, pH 8.0). Five hundred /-LL 
volumes ofGES reagent (5 M guanidium thiocyanate, 0.1 M Na2EDTA, 0.5% w/v Sarkosyl~ were 
added to the cell suspensions and tubes were gently mixed in order to lyse the cells. Two hundred 
and fifty /-LL volumes of 7.5 M ammonium acetate (Sigma-Aldrich) were then added, and tubes 
were left on ice for 10 min. Following the addition of 500 III of phenol: chloroform: isoamyl 
alcohol [(25: 24: 1), Sigma-Aldrich], the tubes were vigorously shaken by hand for 10 minutes to 
ensure the two phases (phenol and aqueous phases) mixed well. After a 10 min centrifugation at 
10,000 x g, 350 ilL of the upper aqueous phase was transferred to a clean microfuge tube 
containing 875 ilL ice-cold 100% ethanol, then gently mixed and kept at -20°C for at least 1 h, 
allowing precipitation of the DNA. 
103 
Table 8. List of restriction enzymes· used in this study 
Optimal 
Enzyme Restriction site temperature Purpose of use 
for activity 
ApaI GGGCC/C 25°C Plasmid RFLP, digestion of total DNA, 
excision of DNA insert from pCTX-M-3 
recombinant vector 
BamHI G/GATCC 37°C digestion of total DNA 
EcoRI GI AATTC 37°C Digestion ofpBBRIMCS-2 
FokI GGATGI 37°C PCR-RFLP of aac(6 J-Ib 
HindIII AI AGCTT 37°C Plasmid RFLP 
HpaI GTT/AAC 37°C Plasmid RFLP and plasmid cross-
hybridization studies 
NdeI CA/TATG 37°C PCR-RFLP of aac(6 J-Ib 
NlaIV GGN· IN·CC 37°C PCR-RFLP ofCIT-type AmpC 
PstI CTGCA/G 37°C Plasmid RFLP 
SmaI CCC/GGG 25°C Excision of DNA insert from pCTX-M-3 
recombinant vector 
XbaI T/CTAGA 37°C PFGE of E. coli genomic DNA 
a Manufactured and supplied by New England BioLabs (Hitchin, UK) 
• N = A or C or G or T 
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Chromosomal DNA was spooled on to a plastic loop and washed with a few drops of ammonium 
acetate (7.5 M) I 100% ethanol I water (2:7:1) mix, followed with a few drops of ice cold 100% 
ethanol. DNA pellets were eventually dissolved in 100 ilL ofTE buffer and kept overnight at 4°C, 
before use for enzymatic restriction. 
13.2. Extraction of plasmids 
13.2.1. Extraction of plasmids by alkaline lysis 
Plasmids from E. coli clinical isolates were extracted by alkaline lysis, as originally described by 
Birnboim and Doly (Birnboim, H. C. and Doly, l, 1979). Plasmids from control E. coli strains 
V517 (NCTC 50193) and 39R861 (NCTC 50192) were extracted in parallel and used as molecular 
size markers (Figure 12, Appendix 1). Briefly, loopfuls (rice grain-size) of freshly grown bacterial 
cultures from NA were re-suspended in 100 ).1L volumes of solution I (25% w/v sucrose, 10 mM 
Tris-HCl pH 8.0, 1 mM Na2EDTA and 10 mglmllysozyme) in 1.5 mL microfuge tubes. These 
tubes were left to stand at room temperature for 5 min. Bacterial cells were then lysed with the 
addition of 200 p.L of solution II [0.2 M NaOH, 1 % w/v sodium dodecyl sulphate (SDS)]. Proteins, 
as well as chromosomal DNA were precipitated by the addition of 150 p.L of solution III (3 M 
potassium acetate, pH 4.8). The tube contents were then mixed by inversion, centrifuged for 10 min 
at 13,400 x g and the supernatants were transferred to fresh 1.5 mL microfuge tubes. One volume 
(approximately 400 ).1L) of phenol: chloroform: isoamyl alcohol [(25: 24: 1), Sigma-Aldrich] was 
added and the samples were mixed by flicking the tubes. Following centrifugation at 13,400 x g for 
10 mill, the upper aqueous layers were carefully removed to clean tubes. Plasmid DNA was then 
precipitated by the addition of 2 volumes of ice-cold 100% ethanol (approximately 400 ).1L). After 
2 min incubation at room temperature, plasmid DNA was harvested by centrifugation at 13,400 x g 
for 5 min. Pellets were dried at room temperature or at 37°C for at least 30 min and re-suspended in 
39 ilL of tissue culture water, to which was added 1 ilL of RNAse A (l mglmL stock, previously 
heated at 80°C for 10 min). 
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Figure 12. Agarose gel electrophoresis (0.8%) of plasmids from E. coli control strains V517 
and 39R861a extracted by alkaline lysis 
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For gel electrophoresis analysis, 10 J.lL of loading buffer were added to 20 J.lL of plasmid 
preparation (0.8% agarose gel, 2 h 30 min at 80Y). The remaining 20 J.lL of plasmid preparation 
were kept aside at -20°C for further manipulations such as enzymatic restriction or electroporation. 
The plasmids preparations were then loaded on to agarose gels, a I-kb DNA ladder (Invitrogen 
BY) was used as DNA size standard, along with the plasmid preparations from reference E. coli 
strains VS17 and 39R861. For gels requiring Southern blotting and hybridization studies, a Dig-
labelled DNA molecular-weight marker 11 [A. HindIlI digest (0.12 - 23.1 kb), Roche Diagnostics 
GmbH, Mannheim] was also loaded onto the agarose gels. 
13.2.2. Extraction ofplasmids by a modified alkaline lysis protocol 
To minimise chromosomal DNA contamination of plasmid preparations (for e.g. plasmid cross-
hybridization studies), the alkaline lysis protocol described in section 13.2.1 was slightly modified, 
as described below: 
Following the addition of solution 11, the tubes were incubated 1 h at 56°C 
After the addition of solution III and prior to the 10 min centrifugation at 13,400 x g, 
the tubes were incubated on ice for 15 min 
Supernatants from the first centrifugation were decanted through a double thickness of 
medical gauze prior to addition ofthe phenol: chloroform: isoamyl alcohol mixture 
At the end of the protocol, plasmid DNA was re-suspended in 24 p.L of tissue culture 
water, to which was added 1 J..lL ofpre-heated (80°C for 10 min) 1 mg/mL RNAse A 
Gel electrophoresis analysis was performed as with plasmids extracted by conventional alkaline 
lysis, i.e. in low-concentration agarose gel (usually 0.8%), using 10 J.lL plasmid preparations, to 
which 5 J.lL volumes of loading buffer were added. 
13.2.3. Extraction ofplasmids using commercial kits 
Most commercially available kits for plasmid extraction, such as those used in this study, are based 
on the alkaline lysis method. Depending on the size of the plasmids, two different kits were utilised 
(following the manufacturer's instructions): (i) the Rapid Plasmid Miniprep System (Marligen 
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Biosciences, Ijamsville, USA) for extraction of plasmid vectors of ~5 kb (e.g. pBBRIMCS-2), or 
(ii) the High Purity Plasmid Miniprep System (Marligen Biosciences) for plasmids of> 45 kb (e.g. 
pEK499) 
13.3. Extraction of total RNA from bacteria 
Total RNA from E. coli clinical isolates was extracted using the RNeasy® Mini kit (Qiagen Ltd, 
Crawley) according to the manufacturer's instructions. An on-column DNase treatment using the 
RNase-free DNase Set (Qiagen Biosciences) was performed in order to remove any traces of DNA 
contamination. RNA quantification and purity assessment were carried out using a UNICAM UV 
500 spectrophotometer (Thermo Electron Corporation, Hemel Hempstead, UK). The concentration 
of RNA was determined by measuring the absorbance at 260 nm (A260), knowing that an 
absorbance of 1 unit at 260 nm corresponded to 40 J,lg of RNA per mL. The ratio of absorbance 
readings at 260 nm and 280 nm (A260 / A280) provided an estimate of the purity of the RNA 
preparations. A pure RNA extract has a ratio between 1.9 and 2.3. 
14. Reverse transcription and reverse transcriptase (RT)-PCR 
RT-PCR was performed in order to assess visually and to compare the expression of blacrx-M-Is and 
blaoxA-1 in various E. coli clinical isolates. RT-PCR was carried out in two steps: (i) reverse 
transcription and (ii) standard PCR. Messenger RNA (mRNA) from the total RNA extract was first 
reverse transcribed into cDNA with an oligo-dT primer [(Sigma Genosys), since mRNA possesses 
a poly-A tail] using the Omniscript™ RT kit (Qiagen Biosciences) following the recommendations 
of the supplier. This reverse transcription step was followed by a standard PCR using the primers 
of interest (e.g. group-l CTX-M or OXA-l-like primers). The expression levels of blacrx-M-Is and 
blaoxA-1 genes were assessed visually in 2% agarose gels (electrophoresed at 140 V for 90 min) 
under DV light. 
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15. Isoelectric Focusing (lED of B-Iactamases 
15.1. Preparation of crude bacterial cell extracts by sonication 
Two or three colonies of an overnight bacterial culture on NA were inoculated into 10 mL nutrient 
broths, which were incubated at 37°C for 16 to 24 h on an orbital shaker platform (100 rpm). One 
hundred JlL volumes of the bacterial culture were then transferred to fresh 10 mL nutrient broths 
and the cells were grown into logarithmic (log) phase by incubating at 37°C for approximately 4 h 
with agitation (100 rpm on an orbital shaker). The cells were then harvested by centrifugation 
(CR412 refrigerated benchtop centrifuge, Jouan Inc, San Francisco, USA) at 5,000 x g for 10 min 
and re-suspended in 5 ml of sterile phosphate buffer (10 mM, pH 7.0) in disposable glass vials. 
These cell suspensions were kept on ice until sonication, when the bacterial cell walls were 
disrupted by immersion of a sonication probe (Ultrasonic Disintegrator, MSE Scientific 
Instruments Ltd., Crawley) into the cell suspensions. Two 30 sec-burst at 150 W, with a 30 sec 
interval to allow cooling of the vials, were applied to disrupt bacterial cell walls. The vials were 
cooled in plastic cups filled with iced water during the whole process. Residual cells were removed 
by centrifuging for 30 minutes at 5,000 x g in a CR412 Bench Top centrifuge at 4°C. The 
supernatants were then divided into 1 mL aliquots and stored at -20°C until required. 
15.2. Preparation of acrylamide gel for IEF 
A rubber gasket was positioned in between two glass plates (230 x 115 mm), one of which was 
covered "inside" with a plastic sheet, ensuring that no air bubbles were trapped underneath. Since 
polyacrylamide sticks to glass but not to plastic, this assisted the subsequent removal of one glass 
plate without breaking the gel. Two plastic supports were then positioned on each side of the glass 
plates, and were tightly held by bulldog clips. The acrylamide gel was prepared as follows. To 27 
ml of acrylamide stock solution [25 g sucrose, 59.5 mL of 30% Acrylagel (BDH, VWR 
International, Poole, UK), 25 mL of 2% bis-acrylagel (BDH) and 165.5 mL of sterile distilled 
water] were added: 1 mL ampholine pH range 5.0 - 8.0 (Amersham Biosciences), 1 mL ampholine 
pH range 3.5 - 9.5 (Amersham Biosciences) and 0.6 mL of 0.1 mg/mL riboflavin solution (Sigma-
Aldrich). The mixture was then degassed for 10 minutes using a vacuum pump, and 90 ilL of 
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N,N,N',N'-tetramethylethylenediamine (TEMED, Sigma-Aldrich) and 45 ilL of freshly-prepared 
100 mg/mL ammonium persulphate (Sigma-Aldrich) were finally added. The acrylamide gel 
mixture was then slowly poured at a constant speed (to prevent the formation of bubbles) between 
the two glass plates via a 50-mL syringe using a 5-cm long needle. The gel was left to set for at 
least 2 h before all the clips were removed and the plastic-covered glass plate peeled off, leaving 
the acrylamide gel on one glass plate, ready to be loaded. 
15.3. Enzyme focusing 
The p-Iactamase activity of the crude bacterial cell extracts was checked by mixing one drop (c. 5 
J1.L) of 0.5 mM nitrocefin (BD Biosciences, Oxford, UK) with one drop of extract. Nitrocefin 
(yellow) is a colorimetric substrate of p-Iactamases and becomes red following hydrolysis. The 
speed at which the reaction occurs is a good indicator of the amount of 13-lactamase present in the 
cell extract. Furthermore, it was essential to work with cell extracts that contained relatively similar 
enzymatic activities. The ideal change in colour took place between 30 and 60 sec. If a cell extract 
showed stronger p-Iactamase activity, it was diluted with phosphate buffer. 
IEF electrode strips (Amersham Biosciences AB, Uppsala, Sweden) were placed at the top 
and bottom ends of the gel using a pair of forceps; the anode strip was soaked with 1 M phosphoric 
acid and the cathode strip with 1 M sodium hydroxide. Small pieces of filter paper (10 x 5 mm, up 
to 20 pieces per gel) were positioned approximately 20 mm from the anionic end of the gel, and 20 
~L of crude cell extracts obtained by sonication of the test isolates were applied on each piece. Cell 
extracts from control isolates producing TEM-l (PI 5.4), OXA-IO (PI 6.1), SHV-l (PI 7.6) or SHV-
5 (PI 8.2) p-Iactamase were also loaded in parallel (Appendix 1). The loaded acrylamide gel was 
then transferred on to the cooling platform of the electrophoresis unit (Flat bed apparatus FEB 
3000, Pharmacia Fine Chemicals, Uppsala, Sweden) set to a temperature of approximately 4°C, 
and which was covered with 1 % Triton-X-lOO (a non-ionic detergent, Sigma-Aldrich) beforehand 
to ensure good contact between the glass plate/gel and the platform. A drop of lysed blood was 
applied to each end of the gel in order to indicate correct migration of the samples. The gel was 
then electrophoresed at a constant power of 15 W until the two drops of blood met, usually after 50 
110 
to 60 min. All the filter papers were then removed using forceps and the gel was electrophoresed 
for further 10 min, prior to the detection of {3-lactamases. 
15.4. Gel developing 
After removing the electrode strips with a scalpel, the gel was overlaid with 0.5 mM nitrocefin. The 
presence of {3-lactamases (red bands on the gel) was recorded on graph paper. Their pI values were 
estimated by comparing the distance they had migrated with the distances migrated by the control 
enzymes with known pI values. 
15.5. Detection of AmpC p-Iactamases 
If the presence of AmpC {3-lactamases was suspected (e.g. owing to the resistance to the (3-
lactamlclavulanic acid combination and to cefoxitin), samples were loaded in duplicate on two 
halves of an IEF gel. Following conventional electrophoresis, one half was overlaid with 0.5 mM 
nitrocefin as described in the previous section, while the second half was first overlaid with 
cloxacillin (0.3 mM, Sigma-Aldrich), a competitive inhibitor of AmpC enzymes. After 5 min 
incubation at room temperature, the second half of the gel was then also overlaid with nitrocefin 
(double strength, i.e. 1 mM) and results were recorded on graph paper. AmpC enzymes were only 
revealed in the absence of cloxacillin, since this antibiotic inhibits hydrolysis of nitrocefin. 
16. Molecular typing by pulsed-field gel electrophoresis (PFGE) 
16.1. DNA preparation 
E. coli isolates were grown overnight at 37°C on NA. Organisms were re-suspended in 1 mL Salt-
EDTA (SE) buffer (75 mM NaCI, 25 mM Na2EDTA, pH 7.5) to a turbidity of2.3 to 2.8 McFarland 
using an API densitometer. For each isolate, blocks of 2 x 6 mm were prepared by mixing equal 
volumes (e.g. 400 ilL) of bacterial suspension with molten 2% low-gelling agarose (FMC 
BioProducts, Rockland, USA) in SE buffer at 50 to 56°C, prior to dispending in appropriate 
moulds. Moulds were kept at 4°C until the agarose had set. The agarose plugs were then transferred 
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to bijou bottles containing 3 mL of buffer A [6 mM Tris, 100 mM EDTA, 1 M NaCI, 0.5% 
Sarkosyl® (BDH), 1 mM MgCh, 0.5 mglmL lysozyme, pH 7.5] and were incubated overnight at 
37°C on an orbital shaker (300 rpm). Buffer A was replaced on the next day with buffer B (1 % 
Sarkosyl®, 0.5 M Na2EDTA, 0.5 mglmL proteinase K, pH 9.5) and the blocks were re-incubated 
overnight in a water-bath at 56°C with gentle agitation. The plugs were then washed four times for 
30 mill, each time with 3 mL TE buffer (10 mM Tris, 10 mM Na2EDTA, pH 7.5) at 4°C, prior to 
digestion. 
16.2. Digestion of genomic DNA in agarose plugs 
Genomic DNA was digested with Xbal. Agarose strips of 2 x 1 mm in size were cut from the 
blocks using a scalpel and were pre-incubated in 100 ).lL XbaI enzyme buffer at 4°C for at least 30 
min. The restriction buffer was then replaced with 100 ).lL of fresh buffer containing 20 units of 
XbaI enzyme and the agarose plugs were incubated at 37°C for at least 4 h (preferably overnight), 
prior to electrophoresis and analysis. 
16.3. PFGE gel electrophoresis 
Digested plugs were loaded into wells of a 1.2% pulsed-field certified agarose gel containing 2.04 
g agarose (BioRad, Hemel Hempstead) in 170 mL 0.5 x TBE; the gel dimensions were 206 x 140 
mm. A lambda (A.) concatamer ladder (BioRad), previously treated at 52°C for 8 min, was loaded in 
parallel to the test samples and was used as a size standard. The wells were sealed with molten 
agarose and the gel was transferred into a contour-clamped homogeneous-field CHEF DRII 
electrophoresis apparatus (BioRad), then covered with pre-cooled (4°C) 0.5 x TBE buffer, and 
electrophoresed under the following conditions: 5 sec initial switching time, 35 sec final switching 
time, 6 V/cm, for 30 h at 12°C. After electrophoresis, the gel was stained for 90 min in 1 ).lglmL 
ethidium bromide and de-stained for 60 min in distilled water. DNA fingerprints were visualised 
under UV light and photographed using the IN Genius Syngene Bio Imaging system. 
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16.4. Data analysis 
PFGE data were analysed with the BioNumerics software (version 3.5). Banding patterns for test 
isolates were normalised against the A. ladder and dendrograms were constructed using the Dice 
product-moment correlation, with 1 % position tolerance, 0.5% optimisation and the unweighted 
pair group method (UPGMA). Isolates sharing at least 85% homology in banding patterns were 
considered to belong to a same strain (Tenover, F. C. et al., 1995; W oodford, N. et al., 2004). 
17. Hybridization studies 
Hybridization studies were undertaken in order to detect blacrx.M genes in plasmid extracts as well 
as in extracts of total DNA from clinical isolates of E. coli. 
17.1. Southern blotting 
Digested and undigested plasmid DNA, as well as digested total DNA, were electrophoresed in 
0.8% agarose gels and then transferred on to Hybond™-N-membranes (Amersham Biosciences UK 
Limited, Chalfont) by vacuum blotting under a constant suction of 45 to 60 mBar, using a LKB 
VacuGene XL system (Pharmacia Fine Chemicals, Uppsala). A Dig-labelled DNA molecular-
weight marker 11 (Roche Diagnostics GmbH), acting as a DNA size standard as well as a positive 
control for hybridization using digoxigenin (Dig)-labelling, was also loaded in the agarose gels and 
transferred to the nylon membrane. Once the gel was correctly positioned on top of the nylon 
membrane with the vacuum applied, the DNA present in the agarose was fragmented for 4 min 
with 0.25 M HCI, and then denatured for 3 min with 1.5 M NaCI / 0.5 M NaOH, prior to 3 min 
neutralisation with 1.5 M NaCI / 0.5 M Tris / 1 mM Na2EDTA, pH 7.2. Between each step, the 
liquid was carefully soaked up from the gel with tissue paper. Following this treatment, the DNA 
was transferred for approximately 60 min on to the membrane by pouring sufficient SSC solution 
(3 M NaCI, 0.3 M tri-sodium citrate) to completely cover the gel. The transfer of DNA on to the 
blot was checked under UV light, using a dual intensity UV transilluminator (Ultra-Violet 
Products, Cambridge). Membranes covered with DNA were finally baked at 80°C for at least 2 h 
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(preferably overnight), or cross-linked using a Stratalinker® 2400 UV crosslinker (Stratagene, La 
Jolla, USA), prior to hybridization. 
17.2. Preparation of digoxigenin-labelled DNA probes 
Dig-labelled probes for the detection of blacrx-M genes were derived from PCR products. A 
primary PCR using the primer pair CTX-M MAli CTX-M MA2 (Appendix 6) was carried out as 
described in section 5, amplifying a DNA sequence portion common to all blacrx-M allele variants. 
The incorporation of Dig-ll-dUTP (Roche Diagnostics GmbH, Mannheim, Germany) into the 
blacrx-M DNA probe was accomplished in a secondary PCR, in which the volume of dTTP was 
reduced in favour of Dig-labelled dUTP (2:1 ratio of dTTP:dUTP volumes). Secondary PCR 
reactions were undertaken in 0.5 mL microfuge tubes using 1 ilL of primary PCR product as 
template. The secondary PCR reaction mixture consisted of 1 x Taq polymerase buffer, 0.05% W-l 
buffer, 2 mM MgCh, 0.3 mM dATP, 0.3 mM dCTP, 0.03 mM dGTP, 0.2 mM dTTP, 0.1 mM Dig-
I1-dUTP, 1 J-lg of each primer and 1 U Taq DNA polymerase in a final volume of 100 ilL. PCR 
conditions were identical for both primary and secondary reactions, with an initial denaturation at 
94°C for 5 min, followed by 35 cycles of 94°C for 30 sec, 50°C for 30 sec and 72°C for 60 sec, 
ending with a flnal extension at 72°C for 5 min. PCR products were analysed by gel electrophoresis 
on a 2% agarose gel run at 120 V for 90 min and visualised under UV light. Incorporation of Dig-
Il-dUTP into the secondary product retarded its migration and thus it appeared larger than the 
unlabelled primary PCR product (see Figure 13). Following the incorporation of digoxigenin, 
secondary PCR products were purified using the GENECLEAN®SPIN kit (Q-BIOgene) and stored 
at -20OC until required. 
17.3. Hybridization with Dig-labelled DNA probes and stringency 
washes of nylon membranes 
Nylon membranes with fixed DNA were placed in HYBAIDTM HB-OV-BS hybridization bottles 
(Thermo Life Sciences, Basingstoke) and incubated at 70°C with 20 mL hybridization solution for 
at least 1 h under constant and low-speed rotation in a Shake on' Stack hybridization oven. 
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Figure 13. Gel electrophoresis (2% agarose) of primary and secondary (Dig-labelled probe) 
blacTX_M peR products for hybridization studies 
615-bp 
492-bp 
369-bp 
246-bp 
123-bp 
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The hybridization solution consisted of 4 x SSC, 0.02% SOS, 0.1 % Sarkosyl and 1 x buffer III 
from the Dig Wash and Block set (Roche Diagnostics GmbH, Mannheim). The hybridization ofthe 
membrane with a denatured DNA probe (30 JlL of DNA probe in 10 mL hybridization solution 
denatured 3 min at 95°C) was undertaken overnight at 70°C under constant rotation. Hybridized 
membranes were then washed twice at low stringency (2 x SSC I 0.1 % SOS, at room temperature) 
for 5 mill, followed by further two washes at high stringency (0.1 % SSC I 0.1 % SOS, at 70°C) for 
15 min. 
17.4. Detection ofDNAlDNA hybrids 
All the steps involved in the detection of hybrids were undertaken at room temperature. Following 
30 min incubation with Blocking buffer (Dig Wash and Block set, Roche Diagnostics GmbH), 
nylon membranes were soaked in 20 mL Washing buffer (Dig Wash and Block set, Roche 
Diagnostics GmbH) supplemented with 4 ilL anti-digoxigenin antibody-conjugate (Fab fragments 
bound to alkaline phosphatase, Roche Diagnostics GmbH) for 30 min. The membranes were then 
rinsed for 3 min in developing buffer (Dig Wash and Block set, Roche Diagnostics GmbH) and 
transferred into plastic bags. Hybrids were detected by a colorimetric reaction involving nitroblue 
tetrazolium chloride/5-bromo-4-chloro-3-indolylphosphate solution (NBT IBCIP, Roche 
Diagnostics GmbH, 400 JlL in 10 mL Developing buffer), a substrate of alkaline phosphatase 
enzyme. Plastic bags containing NBT IBCIP were sealed and kept in the dark until the appearance 
of hybrid bands (purple colour) of sufficient intensity on the blot. The membranes were finally 
rinsed with distilled water and dried at 70°C for 15 min. 
17.5. Plasmid cross-hybridization studies 
A Dig-labelled HpaI-digested-pEK499 probe was produced in order to estimate the relative 
homology between various other plasmids and pEK499 itself. Plasmids encoding CTX-M enzymes 
were transferred into a laboratory strain of E. coli DH5a by electroporation (section 18.2), and 
subsequently extracted by modified alkaline lysis and digested with HpaI. pEK499 restriction 
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fragments were random-primed labelled with Dig-lt-dUfP using the DIG High Prime DNA 
Labelling and Detection Starter Kit I for colour detection with NBTIBCIP (Roche Diagnostics 
GmbH) following the manufacturer's procedure. The test plasmids, also digested with Hpal, were 
electrophoresed at 80 V for 150 min in 0.8% agarose gels, then transferred on to nylon membranes 
and hybridized overnight with the Dig-labelled pEK499 fragments. Hybrids were revealed by 
colorimetric reaction with NBTIBCIP. It was assumed that the amount of digested DNA fragments 
of a given plasmid hybridised by the Dig-labelled reference pEK499 was proportional to the 
relatedness of both these plasmids. 
18. Transfer of cefotaxirne resistance 
18.1. Transfer of cefotaxirne resistance by conjugation 
Conjugative transfer of CTX resistance from clinical isolates with CTX-M enzymes (donor 
strains) to the cefotaxime-susceptible, rifampicin-resistant E. coli K-12 strain J53-2 (NCTC 50006) 
recipient strain was carried out by a filter-mating method. Donor and recipient strains were grown 
overnight at 37°C in 5 mL Brain Heart Infusion (BHI) broths. The cells were then sub-cultured into 
5 mL amounts of fresh BHI broths and grown up to log phase, then harvested by centrifugation (10 
min at 5,000 x g) and re-suspended in 1 mL amount of phosphate-buffered saline (PBS). Small 
squares (20 x 20 mm) of sterile Hybond™-N-membrane were firmly applied on to antibiotic-free 
NA plates using sterile forceps and 100 J.lL amounts of each separate bacterial suspension 
(controls), as well as 100 J.lL ofa 1:1 donor I recipient strain mixture, were inoculated on top of 
each piece of membrane. The plates were incubated overnight at 37°C, and the bacterial growth 
from each filter was then collected and re-suspended in 1 mL ofPBS. The cell suspensions (donor, 
recipient and mixture of both strains) then were diluted in ten-fold steps up to 10.7 with PBS and 
1 00 ~L of each dilution (neat to 10-7) were spread on to NA supplemented with either 200 mg/L 
rifampicin to suppress the donor strains, or 2 mg/L CTX to suppress the recipient strain, or 200 
mg/L rifampicin and 2 mg/L CTX to suppress both parent strains. Viable cell counts were carried 
out in parallel by inoculating each bacterial dilution on to non-selective media (NA). All plates 
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were incubated for 16 to 24 h at 37°C. Conjugation frequencies were calculated by dividing the 
number oftransconjugants obtained by the number of input donor cells. 
18.2. Transfer of cefotaxime resistance to E. coli K-12 strain DHSa by 
electroporation 
18.2.1. Preparation of electrocompetent E. coli DH5a cells 
E. coli K-12 DH5a was grown up to log phase in 50 mL of LB broth. The culture was then chilled 
on ice and the cells were harvested by centrifugation for 10 min at 5,000 x g at 4°C. The cells were 
then re-suspended in 50 mL of ice-cold sterile distilled water, and repeatedly centrifuged and re-
suspended in decreasing ice-cold water volumes of successively 50, 25, 10 and 1 mL. After a final 
centrifugation, the cells were re-suspended in 1 mL ice-cold sterile 10% glycerol solution, and were 
divided into 100 JlL aliquots for storage at -70°C until required. 
18.2.2. Transformation of competent E. coli DH5a cells 
Competent E. coli DH5a cells were transformed by electroporation using a Gene-Pulser™ (Bio-
Rad, Hemel Hempstead). Five J.lL of plasmid extract (prepared as described in section 13.2.1) were 
added to 100 J.lL ofpre-thawed competent cells. The mixtures were then transferred into pre-cooled 
(-20°C) Gene pulser® cuvettes (Bio-Rad) and electroporated at 2,500 V, 25 J.lF and 200 n. In 
parallel, competent cells were electroporated also in absence of DNA extracts as a (negative) 
control measure. Soon after electroporation, the cells were transferred to small bijoux containing 1 
mL BHI, and were incubated for approximately 1 h at 37°C with constant shaking (100 rpm). 
Volumes of 50, 100 and 200 JlL were spread onto NA plates supplemented with 2 mg/L CTX, to 
select CTX-resistant transformants .. 
19. Fitness studies 
The growth rates of native E. coli DH5a and E. coli DH5a transformed with pEK499 were 
compared in order to determine whether the carriage of pEK499 was associated with a fitness cost. 
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Both organisms were grown overnight in 10 rnL amounts of nutrient broth (NB) at 37°C with 
constant agitation (100 rpm). Afterwards, 1 rnL from each culture was transferred to sterile 250-mL 
conical flasks containing 100 rnL NB and, after a quick agitation, 1 rnL was rapidly sampled from 
each flask and was serially diluted to 10-8 with NB allowing viable counts on drug-free NA plates. 
Similar measurements were taken after 1,2,4,8,24 and 32 h incubation of the cultures at 37°C. 
20. Outer membrane protein profiles 
Outer membrane proteins (OMPs) from E. coli clinical isolates were characterised using a method 
adapted from Chart (Chart, H., 1994a; Chart, H., 1994b). 
20.1. Extraction of outer membrane proteins (OMPs) 
Bacteria were grown to log phase (4 h at 37°C, with shaking) by transferring 5 rnL of overnight 10-
mL LB cultures into pre-warmed (37°C) conical flasks containing 100 rnL LB. The cells then were 
harvested by centrifugation (30 min at 5,000 x g) and re-suspended in 5 rnL of ice-cold 25 mM 
Tris-HCI, pH 7.5 containing ImM Na2EOTA. These cell suspensions were chilled on ice and 
sonicated as described in section 15.1. The resulting cell extracts were transferred to pre-cooled 
centrifuge tubes containing 25 mM Tris-HCI (PH 7.4) buffer and residual cells were removed by 30 
min centrifugation at 4°C at 5,000 x g. The cell envelopes were collected from the supernatants 
(and separated from cytoplasmic materials) by centrifugation for 60 min at 45,000 x g in a Sorvall 
ultracentrifuge (Kendro Laboratory Products, Bishop's Stortford). The resulting pellets were re-
suspended in 20 mL of25 mM Tris-HCI (PH 7.4) and cytoplasmic membranes were solubilised by 
adding 1 rnL of Sarkosyl and shaking for 30 min at 200 rpm at room temperature. OMPs were 
finally sedimented by centrifugation at 45,000 x g for 60 min at 4°C, re-suspended in 200 ilL 25 
mM Tris-HCI (PH 7.4) and stored at -20°C until analysis by SOS-PAGE. 
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20.2. OMP profiles analysis by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) 
OMPs were resolved in 12.5% polyacrylamide gels using the ATTO (Model AE-6530) minigel 
system (Genetic Research Instrumentation, Braintree, UK) powered by a Bio-Rad model 1000/500 
power supply. The 12.5% separation (resolving) gel was prepared by mixing 5 mL of 1.5 M Tris-
HCl (PH 8.8), 0.4% SDS buffer with 6.7 mL distilled water, 8.3 mL 30% acrylamide / 0.8% bis-
acrylamide (37.5:1, Severn Biotech Ltd, Kidderminster, UK), 60 ilL freshly prepared 10% 
ammonium persulphate solution and 60 ilL TEMED. After approximately 45 mill, allowing the 
polymerisation of the acrylamide, the separation gel was overlaid with a 4% acrylamide stacking 
gel consisting of2.5 mL of 0.5 M Tris-HCl (pH6.8), 0.4% SDS, 6 mL distilled water, 1.5 mL 30% 
acrylamide / 0.8% bis-acrylamide solution, 30 ilL 10% ammonium persulphate and 20 ilL 
TEMED. A 12-well comb was inserted in the stacking gel, which was left to polymerise for 30 
min. 
Prior to electrophoresis, the OMP extracts and the SDS-PAGE Molecular Weight Standard 
ladder, High Range (Bio-Rad) required denaturation. This was achieved by adding 5 ilL of protein 
preparation to 15 ilL of solubilisation buffer (62.5 mM Tris-HCI, 10% glycerol, 5% (3-
mercaptoethanol, 3% SDS, 0.01 % bromophenol blue, pH 6.8), which was then incubated for 5 min 
at 100°C. The protein samples and the ladder, also mixed with solubilisation buffer in a 1:4 ratio, 
were also denatured for 45 min at 100°C in presence of 8 M urea in order to improve the resolution 
(separation of proteins). Eight ilL of the denatured samples and ladder (± urea) were then loaded 
into the wells of the stacking gel and electrophoresed at a constant current of 50 mA in 200 mL 
running buffer (25 mM Tris-HCl, 250 mM glycine, 0.1 % SDS) for approximately 45 min. 
Acrylamide gels were stained overnight in a coomassie blue solution [0.025% (w/w) coomassie 
brilliant blue R-250 (BDH), 50% (v/v) methanol, 10% (v/v) acetic acid] with gentle agitation, and 
de-stained in repeated changes of 10% (v/v) acetic acid until OMP profiles appeared with a 
satisfactory contrast (3 to 5 h de-staining were usually required). 
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21. Measurement of CTX-M enzymes specific activity 
21.1. Preparation of bacterial cell extracts 
Crude bacterial cell extracts were prepared by sonication as described earlier. These were used to 
measure the specific activity of CTX-M ,8-lactamases from various clinical isolates and their 
respective CTX-resistant-derived transformants. Estimation of CTX-M specific activity was 
achieved by assessing both the cefotaxime hydrolysis rate and the protein content ofthe sonicates. 
21.2. Determination of protein concentration 
Protein concentrations in cell extracts were measured using the Bio-Rad Protein Assay Reagent kit 
(Bio-Rad, Hemel Hempstead, UK), which is based on the method of Bradford (Bradford, M. M., 
1976). To 100 ilL of each cell extract (undiluted and diluted 115 and 1110) and to 100 ilL of 
standard bovine serum albumin (BSA, Sigma-Aldrich) at 50, lOO, 150 and 200 Ilg/mL, were added 
5 mL of dye reagent. After a quick vortex and 5 min incubation at room temperature, absorbances 
were measured at 595 nm using the UNICAM UV 500 spectrophotometer. For each sample, 
measurements were made in triplicate. Protein concentrations in cell extracts were calculated 
against the calibration curve generated from the results obtained with the BSA standards. 
21.3. Cefotaxime hydrolysis assay 
Cefotaxime hydrolysis was assessed using the UNICAM UV 500 spectrophotometer. Ten to 100 
ilL amounts of cell extracts were added to 1 mL ofpre-warmed (37°C) CTX solution (50 IlM fmal 
concentration in 10 mM phosphate buffer, pH 7.0) in I-cm light-path quartz cuvettes. Changes in 
absorbance were monitored over 5 min at 255 nm against a blank (cell extract in antibiotic-free 
phosphate buffer), starting as soon as the cell extracts was added. A decrease in absorbance 
indicated hydrolysis ofCTX (Lorian, V., 1996). 
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21.4. Determination of CTX-M specific activity 
The amount ofCTX hydrolysed I min I mL of cell extract was determined using the Beer-Lambert 
law: 
IAbs255 = em x I x Cl 
Absm = absorbance at 255 urn (optical density unit) 
em = molar extinction coefficient (M-lcm-1) 
1 = path length (1 cm) 
c = concentration (M) 
The amount of CTX hydrolysed I mL of cell extract over 5 min was directly proportional to 
the decrease in absorbance at 255 urn over the same period of time. The CTX-M specific activity 
(mol of CTX hydrolysed I min I mg of protein) for a given cell extract was calculated by dividing 
the amount of CTX hydrolysed I min I mL of cell extract by the protein concentration of the cell 
extract. 
22. In-vitro evolution of ceftazidimase activity of CTX-M-3 B-Iactamase 
In order to investigate the evolution of ceftazidimase activity by the CTX-M-3 ,s-lactamase, we 
compared the frequencies of emerging ceftazidime resistance in isogenic wild-type and 
hypermutable CTX-M-3-producing E. coli strains, and sequenced the mutant blacrx-M alleles 
following selection pressure. This was achieved by cloning blacrx-M-3 into a vector subsequently 
transferred to isogenic strains of E. coli. The resulting recombinant clones were each exposed to 
four x the CAZ MIC for the original isolate producing CTX-M-3 enzyme, and mutations 
frequencies were recorded. The blacrx-M genes from randomly-selected mutants were then 
sequenced. 
22.1. Vector preparation 
The 5,144 bp low-copy number plasmid pBBRIMCS-2 (Kovach, M. E. et al., 1995) was used as 
the vector, and was extracted using the Rapid Plasmid Miniprep System (Marligen Biosciences) 
according to the manufacturer's protocol. This vector, which encodes kanamycin resistance, was 
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then digested overnight at 37°C (as described in section 12) with EcoRI, which has a unique 
restriction site in the multiple cloning site (MCS). Following gel electrophoresis analysis (0.8% 
agarose, 100 V for 120 min), the linearised vector was purified with the GENECLEAN®SPIN kit 
(Q-BIOgene), then de-phosphorylated (at the 5'-end) in a 20 J-lL reaction using bacterial alkaline 
phosphatase (BAP, Invitrogen BY) to prevent self-religatioll, and finally purified one more time 
with the GENECLEAN®SPIN kit. The resulting linearised and de-phosphorylated pBBR1MCS-2 
vector was stored at -20°C until required. 
22.2. Amplification of blacTX-M-J 
The blacrx-M-3 gene was amplified from an E. coli clinical isolate by PCR with the primer pair 
prom+ / preCTX-M-3B (poirel, L. et al., 2002a) using the following PCR conditions: initial 
denaturation at 94°C for 5 mill, followed by 30 cycles of 94°C for 25 sec, 52°C for 40 sec and 72°C 
for 90 sec, with a final extension at 72°C for 7 min. The PCR product was purified using the 
GENECLEAN®Turbo kit (Q-BIOgene) and stored at -20°C until required. 
22.3. Ligation of blacTX-M-J into pBBRIMCS-2 and transformation 
Prior to ligation, the blacrx-M-3 PCR product obtained as described in section 22.2 first required to 
be blunt-ended, and this was achieved with DNA Polymerase I, Large (Klenow) Fragment [New 
England BioLabs (NEB), Hitchin], used as instructed by the supplier. Following a purification step 
using the GENECLEAN®SPIN kit (Q-BIOgene), the blunt-ended amplicon was then treated with 
T4 Polynucleotide kinase (NEB) following the supplier's instructions, and was finally purified 
again. The blacrx-M-3 gene was ligated into the MCS ofpBBRIMCS-2 (Figure 14) using 1 U ofT4 
DNA ligase (NEB) as advised by the supplier, in a 20 J-lL reaction incubated overnight at 14°C. The 
recombinant vector, designated pCTX-M-3, was transformed into electrocompetent isogenic E. coli 
wild-type 1411 (WT) and hypermutable MutS-negative 1413 (mutS) strains (Miller, K. et al., 
2002). Preparation of electrocompetent WT and mutS cells, and electroporation were as described 
in section 18.2. Transformants were selected overnight at 37°C on NA supplemented with 
kanamycin at 50 mgIL and cefotaxime at 2 mgIL. 
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Figure 14. Construction of pCTX-M-3 
pBBRIMCS-2 
5, 1 44-bp 
blacTX-M-3 
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22.4. Confirmation of cloning of blaCTX-M-J 
Ligation of blacrx-M-3 into pBBRIMCS-2 and transfer of the recombinant vector into E. coli WT 
and mutS strains were conflrmed by extracting plasmids from at least three colonies of each strain 
from the selective plates, using the Rapid Plasmid Miniprep System (Marligen Biosciences). The 
plasmids were then digested overnight at 25°C with ApaI to linearise the vector, and with both 
Apal and SmaI enzymes to excise the insert (see Figure 14). The restriction products were analysed 
by gel electrophoresis (1 % agarose gel, 100 V for 120 min) and visualised under UV light. The 
sizes of the DNA fragments were checked against the 1 kb DNA ladder. Insertion of DNA into the 
MCS ofpBBRIMCS-2 was further conflrmed by PCR using the primer pair T3 / T7 (Appendix 6), 
and the presence of blacrx-M-3 was sought using prom+ and preCTX-M-3B primers. Finally, 
expression of the CTX-M-3 phenotype by the recombinant clones was assessed by antibiotic 
susceptibility testing, as described earlier in section 4. 
22.5. Mutant selection and sequencing of blaCTX-M-J 
Ceftazidime-resistant mutants of the pCTX-M-3-carrying WT and mutS strains were selected from 
three independent cultures in quadruple experiments on NA containing ceftazidime (CAZ) at 4 
mgIL for the WT and 6 mgIL for mutS. The methodology has been detailed elsewhere (Miller, K. et 
al., 2002). After 18 h incubation at 37°C, CAZ-resistant colonies were counted, and mutation 
frequencies were calculated, taking plate counts of viable bacteria on drug-free agar as the 
denominator. Both strands of the blacrx-M gene from (i) the parental WT and mutS recombinant 
strains and, (ii) randomly selected WT and mutS mutants, were sequenced using the primer pair 
T3/T7. 
23. In-vitro development of high-level ceftazidime resistance in isolate Eo499 
A similar approach to that described previously in paragraph 21.4 of this section was used in order 
to promote the loss of IS26 from the promoter region of blacrx-M-Is in clinical isolate E0499, a 
representative of UK epidemic E. coli strain A (also referred to as AI). Since this insertion element 
125 
was suspected of reducing the expression of CTX-M-15 enzyme, the blacrx_M_ls-positive E0499-
derived transformant was exposed to 4 x CAZ MIC {i_e. 16 mgIL}. In order to induce the SOS-
response and thus promote mutations, ciprofloxacin at ~ x MIC (i.e. 0.008 mg/L) was also 
incorporated into the selective plates (Vila, J., 2006). Mutation frequencies were recorded and 
randomly selected CAZ-resistant mutants were then screened by PCR for the presence of IS26. In 
parallel, blacrx-M-ls and its normal promoter were amplified by PCR from clinical isolates E0499 
(IS26-positive) and E0516 (IS26-negative) using the primer pair prom+ / preCTX-M-3B. 
Amplicons were cloned into PCR®2.1 and the resulting clones had their CTX and CAZ MICs 
determined using E-test® strips. 
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RESULTS 
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Chapter I. Molecular characterisation of Escherichia coli epidemic 
clones A-E with CTX-M-lS-like beta-Iactamases 
1. Introduction 
ARMRL started to monitor E. coli with CTX-M enzymes in 2003, and since then, more 
than 2,000 clinical isolates with a CTX-M phenotype have been referred, from approximately 180 
centres across the UK. Until 2005, those referred isolates were typed by PFGE in order to plot the 
spread of clones of E. coli with CTX-M J3-lactamases in the UK. Most of the 2,000 isolates were 
also tested for antibiotic susceptibility and were conftrmed as CTX-M-producers by PCR 
(Woodford, N. et al., 2006). About 85% of those subjected to this analysis produced a group-I 
CTX-M enzyme, usually CTX-M-15. PFGE of 772 clinical isolates with group-l CTX-M 13-
lactamases identifted ftve major epidemic clones at the national level (representing approximately 
30% ofthe referred isolates), as well as many unrelated producers (Woodford, N. et al., 2004). The 
ftve clones were designated A, B, C, D and E. PCR and DNA sequencing showed that all ftve 
clones and most of the unrelated isolates produced CTX-M-15-like enzymes (mostly CTX-M-15 
itself). The present study ftrstly focused on the ftve epidemic clones A-E, since these were 
prevalent at the national level. Non-clonal E. coli isolates with CTX-M-15-like j3-lactamases, as 
well as isolates with different variants ofCTX-M enzymes are discussed in subsequent chapters. 
Table 9 summarises the MIC ranges and geometric mean MICs for each E. coli epidemic 
clone A-E. All ftve clones had typical ESBL phenotypes with synergy between clavulanic acid and 
third-generation cephalosporins and, had a CTX-M phenotype, with cefotaxime and cefpodoxime 
MICs exceeding those of ceftazidime. Most clone A isolates required lower MICs of third-
generation cephalosporins, particularly ceftazidime, which is normally a good substrate for CTX-
M-I5 enzymes. Interestingly, clone A isolates sometimes even appeared susceptible to ceftazidime 
by the disc diffusion method. 
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Table 9. MIC ranges and geometric mean (GM) MICs (mgIL) for E. coli epidemic clones A-E with CTX-M-l5-like ,s-lactamases 
R>a Clone A (n=119) Clone B (n=13) Clone C (n=47) Clone D (n=11) Clone E (n=14) 
Range GM Range GM Range GM Range GM Range GM 
AMP 16 64 - >256 78 64 - >256 101.6 64 - >256 81 64 - >256 161 64 - >256 106 
AMX/CLA 16 8 - 64 16 16 - 128 16 8 - 32 22.6 16 - 32 16 16 - 32 16 
CTX 1 8 - 256 57 8 - >256 82.3 16 - >256 76.1 64 - >256 161 64 - >256 93.4 
CTXlCA 1 ~.06 - 8 0.08 ~.06 -1 0.23 ~.06 - 0.25 0.1 0.125 - 1 ~.06 - 0.5 0.16 
CAZ 2 0.5 - 64 5 4 - 128 69 1 - 128 32 32 - >64 55.8 8 - >64 36.8 
CAZ/CLA 2 ~.125 - 4 0.18 0.25 - 2 0.6 ~.125 - 2 0.27 0.25 - 1 0.6 0.125 - 1 0.4 
CPD 1 32 - >256 58.4 32 - >256 152 256 256 256 256 256 256 
CPD/CLA 1 0.5 - 2 0.7 2 2 1-2 1.5 1 - 2 1.5 1 - 2 1.5 
FOX 8 4 - 64 9.9 8 - 16 12.7 8 - 32 12.22 8 - 16 10.1 8 - 32 16 
PIP 16 64 - >256 77.5 64 - >256 97 64 - >256 81 64 - >256 181 64 - >256 106 
PIP /TZB 16 8 - >256 25.2 4 - 32 29.3 2 - 256 17.5 8 - 64 16 4 - >64 22.6 
ETP 2 ~.125 - 0.5 0.08 0.06 - 0.125 0.09 0.06 - 0.125 0.1 0.06 - 0.125 0.07 0.03 - 0.064 0.05 
a BSAC breakpoints defining resistance (Andrews, J. M., 2007) 
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MEM 
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AMI( 
GEN 
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4 
4 
1 
16 
4 
8 
4 
2 
32 
128 
Clone A (n=119) 
Range GM 
~.l25 - 0.5 0.13 
~.06 -0.5 0.05 
0.25 ->256 12.1 
1 - 32 14.6 
0.5 - 8 2.4 
1 - >32 32 
~.5 - 4 0.5 
256 256 
8 8 
0.5 - 2 0.8 
Clone B (n=13) 
Range GM 
0.125 - 0.25 0.125 
0.03 - 0.064 0.05 
8 - 256 16 
4 - 16 8 
0.5 - 256 41.2 
4 - 16 8.8 
~.5 -1 0.5 
256 256 
8 8 
0.5 - 1 0.8 
Clone C (n=47) Clone D (n=11) Clone E (n=14) 
Range GM Range GM Range GM 
~.125 - 0.5 0.16 0.125-0.5 0.125 0.125-0.5 0.125 
0.03 - 0.064 0.06 0.03 - 0.064 0.04 0.03 - 0.125 0.05 
8 - 128 10.8 8 - 128 43.5 8 - 256 18 
2 - 64 5 4 - 16 16 4 - 256 11.7 
1 - 64 32.6 32 - 256 58.7 4 - >32 29.3 
0.5 - 8 2 4 4 1 - 32 5.3 
~.5 - 8 0.6 ~.5 - 1 0.5 ~.5 -1 0.5 
~.25 - 32 0.7 256 256 0.25 0.25 
4 - 16 5.7 8 - 16 9.2 8 8 
0.5 -1 0.6 0.5 - 1 0.6 0.5 - 1 0.6 
All five clones were multi-drug resistant and among the drugs tested, only carbapenems, 
cephalosporinlclavulanic acid combinations, nitrofurantoin and fosfomycin retained good activity. 
Overall, the five epidemic clones had similar antibiograms with only a few minor exceptions, most 
of which concerned epidemic clone A. In addition to requiring lower MICs of third-generation 
cephalosporins, clone A was also exceptional in being gentamicin-susceptible and more 
minocycline-resistant, in contrast to clones B-E. Although trimethoprim was only tested on a few 
representative isolates of each clone (A, n = 17; B, n = 2; C, n = 6; D, n = 5; E, n = 2), only clones 
A, B, D, as well as few clone C isolates appeared resistant to that drug. 
These antibiograms formed the background for the molecular investigation of the different 
resistance mechanisms present in epidemic clones A-E. In particular, the study focused on locating 
the genes encoding CTX-M /3-lactamases in representative isolates of the five epidemic clones, as 
well as characterising their genetic support, i.e. plasmid. To reach this objective, cefotaxime 
resistance from various representative clonal isolates was first transferred to fully susceptible 
laboratory strains, and the transferred plasmids were subsequently characterised in detail. In 
addition, since these five clones were (by defmition) clinically successful, I also explored their 
phylogenetic backgrounds as well as their virulence genotypes, and compared them with those of 
sporadic ESBL producers. 
2. blacTX-M detection and localisation 
2.1. Plasmid extraction and hybridization 
The plasmid profiles of a representative isolate of each epidemic clones A and D are shown in 
Figure lS(A). In order to localise the gene encoding CTX-M enzymes in these isolates, the plasmid 
extracts were blotted on to a nylon membrane and subsequently hybridized with a digoxigenin-
labelled blacrX-M probe [Figure lS(B)]. This revealed the gene to be encoded by ca. 120-kb and 70-
kb plasmids in clones A and D, respectively. The localisation of the blacrx-M genes in 
representative isolates of strains B, C and E is discussed later in this chapter. 
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Figure 15. CA) Plasmid profiles of clone A and D representatives; (B) Southern blot hybridized with blacTx_M probe" 
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a Plasmids from E. coli control strains VSl 7 and 39R861 were used as molecular size markers and the Dig-labelled A. DN A HindIII was used as control for 
hybridization. 
2.2. Transfer of cefotaxime resistance by conjugation 
Conjugative transfer of cefotaxime resistance to E. coli J53-2 rif (rifampicin MIC> 256 mglL) 
was attempted from one representative isolate of each clone A-E referred to as A), B), C), DI and 
E), respectively. Rifampicin MICs for AI-El were 12 to 16 mgIL as determined using E-test strips. 
Conjugative transfer was successfully achieved from isolates BI-E" but not from A" which 
consistently failed to transfer its cefotaxime resistance in more than five separate attempts. The 
transfer also failed when using two other clone A representative isolates, each from different UK 
centres (A2 and A3). 
The conjugative transfer rates for cefotaxime resistance-encoding plasmids from isolates 
B" C" D1 and El were 3.5 x 10-6,3.6 X 10-4, 7.6 X 10-6 and 1.3 x 10-4 per donor isolate, respectively. 
Detection of the blacrx-M-universal gene by PCR in the resulting cefotaxime- and rifampicin-resistant 
transconjugants confirmed the successful transfer of cefotaxime resistance into E. coli J53-2. 
Subsequent plasmid extractions from transconjugants further confirmed the transfer of single 
plasmids from the donor clinical isolates, which by contrast harboured multiple plasmids. The 
blacrx-M gene was therefore mediated by conjugative plasmids in clone B, C, D and E. Although 
conjugative transfer of cefotaxime resistance from clone A representatives was not achieved, the 
plasmid may only be mobilisable (transfer) with the contribution of a helper plasmid. 
2.3. Transfer of cefotaxime resistance by electroporation and 
estimation of the size of plasmids encoding blaCTX-M 
The plasmids harbouring blacrx-M from isolates AI-E), as well as from three additional clinical 
isolates (A2' A3 and D2), were transferred to the fully susceptible E. coli K-12 DH5a strain by 
e1ectroporation. Transfer of cefotaxime resistance was checked by antibiotic susceptibility testing 
[~32-fold increase in CTX MICs, (Table 10)]. Plasmid extraction from transformants confirmed 
the transfer of a single plasmid in each case (Figure 16), and the detection of a DNA product by 
PCR using the blacrx-M-universaJ primers verified that the plasmids transferred were responsible for 
the resulting cefotaxime resistance. 
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Table 10. MICs (mg/L) for transformants (TrAI-TrEI) derived from representative isolates 
AI-El 
Transformants 
DII5a 
TrAI TrBI TrCI TrDI TrEI 
AMP 8 >64 >64 >64 >64 >64 
AMX/CLA 4 16 16 8 16 16 
CTX ~.125 4 >64 16 >64 256 
CTX/CLA ~.060 ~.060 ~.060 ~.060 ~.060 ~.060 
CAZ ~.25 1 32 0.5 32 64 
CAZ/CLA 0.125 0.125 0.125 0.125 0.25 0.125 
PIP 2 >64 >64 >64 64 >64 
PIP/TZB 2 4 4 2 4 16 
ETP ~.125 ~.125 ~.125 ~.125 ~.125 ~.125 
IPM 0.125 0.125 0.25 0.125 0.125 0.25 
MEM ~.060 ~.060 ~.060 ~.060 ~.060 ~.060 
NAL 0.25 0.25 0.5 0.25 0.5 0.5 
CIP 0.03 0.25 0.25 0.03 0.125 0.125 
AMK ~.5 2 2 0.125 2 4 
GEN ~.125 ~.125 16 ~.125 8 32 
TOB 0.25 8 8 0.25 8 32 
TET 1 64 64 1 >64 64 
SFM 4 16 4 4 4 nt8 
TMP ~.25 >32 ~.25 ~.25 ~.25 nta 
ant = not tested 
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Figure 16. Plasmid profiles of cefotaxime-resistant transformants derived from representative clinical isolates of epidemic clones A-E 
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The blacrx-M gene was harboured by plasmids with different sizes in the five epidemic E. coli 
clones, suggesting different plasmids were involved. The plasmid sizes ranged from approximately 
70-kb in clone D to 150-kb in clone E (ca. 120-kb plasmid in clones A and B, and 100-kb in clone 
C). Figure 16 also shows slight variations in size of the blacrx_M-encoding plasmid in the three 
isolates A.-A3. Furthermore, the plasmid profiles of eight additional clone A isolates (At-All. 
Figure 17), all from different UK centres, also appeared slightly different. Although the number of 
plasmids per isolate was different, ranging from two to five, it is noteworthy that some clone A 
isolates harboured similarly-sized plasmids. Hybridization studies revealed the blacrx-M gene was 
always encoded by the largest plasmid (> 1 OO-kb) in each of the 11 representatives. The variation 
in size of the CTX-M-encoding plasmids from various isolates of clone A is discussed in more 
detail in section 8.2 ofthis chapter. 
3. Interpretative reading ofantibiograms for transformants TrAI-TrEI 
MICs for cefotaxime-resistant transformants (Table 10) suggested that additional antibiotic 
resistance mechanisms were co-transferred with the blacrx-M gene. In addition to the CTX-M 
phenotype (cefotaxime resistance, and synergy of third-generation cephalosporins with 
clavulanate), transformants were also resistant to tobramycin (except TrC.) and gentamicin (except 
TrA. and TrC.), to tetracycline (except TrC.) and to trimethoprim (TrA. only). Although formal 
quinolone resistance (i.e. MIC > breakpoint) was not transferred, ciprofloxacin MICs were 
increased at least 4-fold for most of the transformants (except TrC.). The clone A-derived 
transformants also showed reduced susceptibility to sulphamethoxazole. 
Cefotaxime and ceftazidime MICs for the transformants derived from clone A and clone C 
(ceftazidime only) were significantly lower than those for other transformants. This was subject to 
further investigations and is discussed in section 1.2 of RESULTS-Chapter IV. MICs for the three 
additional transformants (TrA2. TrA3 and TrD2) are shown in Table 11. Overall, MICs were 
consistent among the three clone A-derived transformants (e.g. low-level resistance to cefotaxime 
and ceftazidime). MICs for TrD2 were comparable to those for TrD •. 
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Figure 17. Plasmid profiles of various clone A representative isolates 
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Table 11. MICs (mgIL) for E. coli DIISa and for transformants TrA2' TrA3 and TrD2 \. ,1 
'I ;j. 
Recipient Transformants 
strain (DIISa) TrAl TrA3 TrDl 
AMP 8 >64 >64 >64 
AMX/CLA 4 16 16 16 
AZT ~.125 2 1 64 
CTX ~.125 8 4 >64 
CTX I CLA ~.060 ~.060 ~.060 ~.060 
CAZ ~.25 1 1 32 
CAZ/CLA 0.125 0.125 0.125 0.25 
CPM ~.125 0.5 0.5 16 
CPM I CLA ~.060 ~.060 ~.060 ~.060 
FOX 4 4 4 4 
PIP 2 >64 >64 >64 
PIP/TZB 2 8 8 4 
ETP ~.125 ~.125 ~.125 ~.125 
IPM 0.125 0.125 0.125 0.125 
MEM ~.060 ~.060 ~.060 ~.060 
CIP 0.03 0.25 0.125 0.25 
AMK ~.5 1 1 2 
GEN ~.125 ~.125 0.25 8 
TOB 0.25 4 4 8 
SUL 32 32 32 32 
MIN 1 4 4 0.5 
COL ~.5 ~.5 ~.5 ~.5 
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4. Isoelectric focusing (lED and identification of beta-Iactamases 
The ,s-lactamase enzymes from various representatives of clones A-E were characterised by IEF. 
Data are summarised in Table 12. With the exception of clone D isolates (referred to ARMRL from 
a single centre only) and 4/9 clone C isolates, most representatives selected for this investigation 
originated from different centres. 
Overall, the clinical isolates produced either one, two or three ,s-lactamase(s) according to 
IEF (see Figure 18) and four different ,s-lactamases with pI values of 5.4, 7.4, 8.4 and 8.6 were 
detected, in various combinations, for each isolate. None of the ,s-lactamases detected among the 
30 clonal isolates tested was inhibited by cloxacillin and therefore, none corresponded to the AmpC 
/3-lactamase type. The three clone D isolates consistently produced three ,s-lactamases (PI values of 
5.4, 7.4 and 8.6) and the four isolates of clone E consistently expressed two ,s-lactamases (pIs of 
7.4 and 8.6). In contrast, variations in ,s-lactamases production were noticeable among clone A, B 
and C isolates. Clone B isolates always had two ,s-lactamases in common (PIs of 5.4 and 8.6), but 
two isolates additionally produced an enzyme with a pI of 7.4. The ,s-lactamase at pI 8.4 was only 
detected in 4/9 clone C representatives, all originating from Belfast. These also produced an 
additional enzyme with a pI of 5.4. The remaining clone C representatives either produced two 
[119, (PIs of 5.4 and 8.6)] or three ,s-lactamases [4/9, (pIs of 5.4, 7.4 and 8.6)]. Finally, IEF detected 
only one or two ,s-lactamase(s) among clone A representative isolates. All had a band at pI 7.4; 
four had no other enzyme detected, and six additionally produced an enzyme with a pI of 5.4. The 
remaining clone A representative had two I3-lactamases with pIs of7.4 and 8.6. 
The cell extracts of the eight transformants TrA.-TrE. were also tested on IEF; all showed 
exactly the same I3-lactamase profiles as their respective plasmid donor strains. This therefore 
suggested that the ,s-lactamases produced by each clinical isolates A.-E. were co-transferred to E. 
coli DH5a, and were thus co-encoded by single plasmids (Figure 16). 
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Figure 18. Picture of IEF gel for the detection of jS-lactamases from six randomly selected 
clonal isolates (as examples) in absence of cloxacillin" 
Wells 
pI S.4 
(TEM-I) 
pI 7.4 
(OXA-I) 
pI 8.6 
(CTX-M-1S) 
Test samples 
Anode (HP03) 
Controls 
Cathode (NaOH) 
S.4 (TEM-l) 
6.1 (OXA- IO) 
8.2 (SHV-S) 
a Similar profiles were obtained in presence of cloxacillin at 0.3 mM; proteins migrated from the 
anode to the cathode as indicated by the arrow. 
140 
Table 12. Summary of isoelectric focusing and PCR data for representative isolates of 
epidemic clones A-E 
Clone Rep. Origin No. of pI values of (3- bra gene(s) detected by bands lactamases· PCRb 
Al Shrewsbury 2 5.4 7.4 blaTEM, blaoxA-I-like, blacrx-M 
A2 Coventry 2 7.4 8.6 blaoxA-I-like, blacrx-M 
A3 Southampton 2 5.4 7.4 blaTEM, blaoxA-I-like, blacrx-M 
~ London 1 1 7.4 blaoxA-I-like, blacrx-M 
As London 2 1 7.4 blaoxA-I-like, blacrx-M 
A ~ Belfast 1 7.4 blaoxA-I-like, blacrx-M 
A7 Winchester 2 5.4 7.4 blaTEM, blaoXA-I-like, blacrx-M 
As Southend 2 5.4 7.4 blaTEM, blaoxA-I-like, blacrx-M 
Ag Milton Keynes 1 7.4 blaoxA-I-like, blacrx-M 
AIO Stevenage 2 5.4 7.4 blaTEM, blaoxA-I-like, blacrx-M 
All London 3 2 5.4 7.4 blaTEM, blaoxA-I-like, blacrx-M 
BI Stoke 3 5.4 7.4 8.6 blaTEM, blaoxA-I-like, blacrx-M 
B B2 Birmingham 3 5.4 7.4 8.6 blaTEM, blaoxA-I-like, blacrx-M 
B3 Shrewsbury 2 5.4 8.6 blaTEM, blacrx-M 
Cl Belfast 2 5.4 8.4 blaTEM, blacrx-M 
C2 Kingston on Thames 3 5.4 7.4 8.6 blaTEM. blaoxA-I-like. blacrx-M 
C3 Chertsey 3 5.4 7.4 8.6 blaTEM. blaoxA-I-like. blacrx-M 
C4 London city 2 5.4 8.6 blaTEM, blacrx-M 
C Cs Salisbury 3 5.4 7.4 8.6 blaTEM, blaoxA-I-like, blacrx-M 
C6 Southend 3 5.4 7.4 8.6 blaTEM, blaoxA-I-like, blacrx-M 
C7 Belfast 2 5.4 8.4 blaTEM. blacrx-M 
Cs Belfast 2 5.4 8.4 blaTEM. blacrx-M 
C9 Belfast 2 5.4 8.4 blaTEM. blacrx-M 
DI Shrewsbury 3 5.4 7.4 8.6 blaTEM. blaoxA-I-like, blacrx-M 
D D2 Shrewsbury 3 5.4 7.4 8.6 blaTEM. blaoxA-I-like, blacrx-M 
D3 Shrewsbury 3 5.4 7.4 8.6 blaTEM. blaoxA-I-like. blacrx-M 
El Kingston on Thames 2 7.4 8.6 blaoxA-I-like. blacrx-M 
E2 Portsmouth 2 E 
7.4 8.6 blaoxA-I-like. blacrx-M 
E3 Chertsey 2 7.4 8.6 blaoxA-I-like, blacrx-M 
E4 Papworth 2 7.4 8.6 blaoxA-I-like. blacrx-M 
a pI ofTEM-l is 5.4; pI ofOXA-l is 7.4; pI ofCTX-M-3 is 8.4; pI ofCTX-M-15 is 8.6. 
b blaSHV was not detected by PCR in any of the investigated isolates. 
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In parallel, all 30 clinical isolates detailed in Table 12 and the eight transformants were screened by 
PCR for the presence of blaTEM, blasfN, blaoxA-l-like and blacrx-M (entire ORFs), as these genes 
encode the most common plasmid-mediated /3-lactamases. None of the tested isolates was positive 
for blasfN by PCR. On the other hand, the remaining three genes were detected in various 
combinations among all isolates (Table 12) and the transformants. All blacrx-M genes belonged to 
phylogenetic group 1 (CTX-M-1S-like). The blaTEM, blaoxA-I-like and blacrx-M_grOUp-1 amplicons 
detected in representative isolates AI-El were cloned into pCR®2.1 and sequenced fully. 
Comparing the various combinations of genes detected by PCR to the combinations of enzymes 
detected by IEF, and with reference to the Lahey clinic database 
(http://www.lahey.org/studies/other.htm). it was deduced that the 13-lactamases with pI values of 
5.4, 7.4, 8.4 and 8.6 were encoded by blaTEM-h blaoxA-h blacrx-M-3 and blacrx-M-15, respectively. 
Although no band at pI 8.6 was detected in the majority of clone A representatives (10/11), the 
blacrx-M gene was consistently detected by PCR. This disparity was investigated further and is 
discussed in Chapter IV. The low ceftazidime MIC for TrCI (Table 10) was considered due to the 
fact that it produced CTX-M-3 /3-lactamase, a variant that does not hydrolyse ceftazidime as 
efficiently as CTX-M-1S. While blacrx-M-3 was always linked to blaTEM-1 only, blacrx-M-Is was 
variably linked to blaTEM-1 and I or blaoxA_I. 
The geometric mean MIC of the piperacillinltazobactam combination for the 24 OXA-I-
positive clonal isolates was 20.4 mgIL, three-fold higher than that for the six isolates lacking this 
enzyme (geometric mean MIC = 6.3 mgIL). This may be explained by the fact that OXA enzymes 
are poorly inhibited by tazobactam, and by the other available /3-lactamases inhibitors in general. 
5. Resistance mechanisms co-transferred with blacTX-M 
Mechanisms of resistance to antibiotics other than /3-lactams were identified by PCR and DNA 
sequencing. According to the antibiograms of transformants TrAI-TrEI (Table 10), the CTX-M-
encoding plasmids were also responsible for resistance or reduced susceptibility to most 
aminoglycosides (except in TrCI). DNA sequencing showed that resistance to gentamicin in clone 
B-, D- and E-derived transformants was encoded by a classical aac3-Ila gene. 
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Tobramycin resistance and reduced susceptibility to amikacin in all transformants except TrC1 was 
associated with the presence of an aac6'-Ib gene. This gene was identified by PCR and DNA 
sequencing among clone A, B, D and E representative isolates. It is noteworthy that clone C 
representative isolates, which lacked this gene, generally required lower amikacin MICs than 
clones A, B, D and E representatives (2 vs. 8 mg/L). 
Interestingly, sequencing of the aac6'-Ib allele from each positive transformant 
consistently revealed the presence of the two crucial nucleotide substitutions responsible for 
Trpl02Arg and Asp179Tyr substitutions in the resulting AAC6'-1b enzyme (Figure 19). The 
combination of these mutations has previously been shown to broaden the spectrum of activity of 
the aminoglycoside acetyltransferase to include fluoroquinolones with an unsubstituted piperazinyl 
group [i.e. ciprofloxacin and norfloxacin, (Robicsek, A. et al., 2006)]. The allele variant, 
designated aac6'-Ib-cr, was therefore responsible for the four-fold increase in ciprofloxacin MICs 
for clone A-, B-, D- and E-derived transformants, in addition to the resistance to tobramycin. 
Acquisition of aac6'-Ib-cr did not affect the activity of nalidixic acid however, since this antibiotic 
lacks the relevant piperazinyl group (Table 10). 
The other plasmid-mediated amikacin resistance-encoding gene, armA (coding for a 
methylase) was not present among clones A-E representatives and their derived transformants, 
according to PCR. Additionally, qnrA, qnrB and qnrS genes, which also are plasmid-mediated and 
reduce the susceptibility to fluoroquinolones, were also sought by PCR, but were not found among 
the clone A-E representatives and their cefotaxime-resistant transformants. These data support the 
view that reduced susceptibility to ciprofloxacin in clones A-, B-, D- and E-derived transformants 
was likely to be solely due to acetylation by AAC6'-Ib-cr. 
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Figure 19. Partial alignments of (A) nucleotide and (B) amino acid sequences of aac(6')-Ih-cr from TrA. and of the classical aac(6 ')-Ih aUele (GenBank 
AA V59012t highlighting the double nucleotide/amino acid substitution 
(A) 
, IC OOOO ... CGOA ,v'Ci"Gi'GOG ...... o ...... o ......... C co ... · 
aac(6 ')-Ib ~)coooO"'C()O"" TI OO T OOOA"'O"''''O'''''''''cco",' 
, { ;coooo ... coO ... ,CIOOTOOO ...... O ...... O ... IIIICCOA· 
aac(6 ,)-lb- ; C 00 0 OACGO ... t lo OT 0 0 0 ... AO A AO ... A A CCO .. · 
)COOOOIICOOII QOO T OOOII ... OAIIOAA ACCOA· 
iCOOOO ... CGOA a OOTOOGAAOA ... OA ... ACCOA 
1 sI base substitution: 
T to C 
IITAOACCAOT T ACTOOCG ...... I0C ... TCACA ... ( 
A T A 0 A CC AO T C;AC TOO CO A A T ° CA T CA CAA C+--
... T AO ACCAOT 1,' '''C TGG COA A TOCA TCACAA ( } ATAOACCAOT ~AC T OOCOAATOCATCACAA ( 
A T A 0 A C C A 0 T 11" C TOO C 0 A A Toe Al e A C A A 
IITIIOIICCAOT ~ACTOOCOAATOCATCACIIA ( 
ATAOACCAGT n llCTOOCOAATOCATC"CAA ! 
IITIIOIICCAO T ~TIICTOOCOAATOCATCACAA ( 
ATAGAC CAO TT IICTGGCGAATOCATCACAA C 
ATIIOACCAOT T ACTOOCOAATOCATCAC ...... ( 
AT"O ... CC ... OT ... CT OOCO ... ATOCATCACAA C 
aac(6 ')-Ib 
aac(6 j-Ib-cr 
2nd base substitution: 
C to T 
(B) AAC6'-Ib 
AAC6 '-Ib-cr 
' VAL :8 : D ,WT,I EEE T DI? VR I DQSLANASQL R L ,T RL VRALVE LL F NDP EVTKI QT DP S P SNL R.l"I RC·£ E RA F E RQ T VTTP D P AV">."MVQT 
. R . • •. • . . 
t 
WI02R 
substitution 
a Similar results were obtained with TrB " TrD, and TrEI. 
'" . . .. . .... . . . . . . . . 
t 
D179Y 
substitution 
Long range PCR assays involving separate primer pairings (i) aac6' -Ib F / aac3-IIa R, (ii) aac3-IIa 
F / CTX-M-l M13L, or (iiz) aac6'-Ib F / CTX-M-l M13L, suggested aac3-IIa was located 
downstream of aac(6'}-Ib-cr and upstream of blacrx-M-J5 in TrDJ. Also, while no amplicon was 
obtained for TrDl using the primer pair aac6'-Ib F / CTX-M-l M13L (maybe due to the fact that 
the DNA segment was too long to be amplified, as a result of the insertion of aac3-IIa), a ca. 3-kb 
DNA fragment was amplified from TrAJ. 
Identification of potential aac6' -Ib-cr variant by PCR-RFLP: 
In order to differentiate rapidly potential aac6'-Ib-cr from classical aac6'-Ib alleles [approximately 
30 variants have been described to date (Robicsek, A. et al., 2006)], a PCR-RFLP using the two 
restriction enzymes FokI and NdeI was developed. 
A portion of the aac6' -Ib gene, which includes the two nucleotides prone for mutations, 
was first amplified with the primer pair aac(6')-Ib CR-2F / aac(6')-Ib CR-2R (see Appendix 6), 
yielding a 519-bp DNA fragment. Only two possible restriction profiles then resulted from the 
double digestion of the PCR product using the two restriction enzymes mentioned above (Figure 
20): 
aac(6'}-Ib-cr profile: NdeI digested only aac(6'}-Ib-cr amplicons, yielding two 
fragments of 453-bp and 66-bp, while FokI failed to digest. 
non-aac(6 '}-Ib-cr profile: FokI digested only the native aac(6 '}-Ib amplicons, yielding 
two fragments of 224-bp and 295-bp, while NdeI failed to digest. 
Finally, the resistance of transformants TrAh TrBh TrDJ and TrEJ to tetracycline was 
attributable to the presence of the tet(A) gene, which encodes an efflux pump. The tet(B) gene was 
absent from these transformants based on PCR. 
145 
Figure 20. PCR-RFLP assays to distinguish aac(6')-Ih-cr from classical aac(6')-lh variants3 
295-bp 
b 224-bp 
a 1-2, aac(6 '}-Ib-cr; 3-4, classical aac(6')-Ib variants; 5, I 23-bp ladder. 
519-bp (undigested) 
453-bp 
_ 66-bp 
b The 224-bp band reSUlting from FokJ restriction ofnon-aac(6'}-Ib-cr allele appeared only very weakly in 
every repeated experiment. 
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6. Detection of integrons in clone A-E-derived transformants 
Integrons, which frequently carry antibiotic resistance gene cassettes, were fIrst sought by PCR 
among all eight transformants using primers specifIc for intl, int2 and int3 (type I-Ill integrase, see 
Appendix 6). A class I integra se gene was detected in the three clone A-derived transformants only 
(TrAI-TrA3). Neither type 11, nor type III integrases were present on the blacrx_M-encoding 
plasmids from clones A-E, based on PCR assays. Using the primer pair 5'CS 13'CS (specifIc to the 
5' and 3' conserved sequences of class I integrons, respectively, see Appendix 6), it was shown that 
the length of the integron was consistent among all three clone A-derived transformants 
investigated (ca. 1.8-kb). DNA sequencing identified the streptomycin and trimethoprim resistance 
gene cassettes aadA5 and dfrl7, in all three cases, whilst the presence of sun at the 3' end 
conserved sequence of the integron explained the higher sulphamethoxazole MIC for TrAI (see 
Table 10, sulphamethoxazole MICs for TrA2 and TrA3 were not determined, but both had sun as 
shown by DNA sequencing). 
7. Molecular characterisation of high-level resistance to guinolones 
Epidemic clones A-E isolates required ciprofloxacin MICs >8 mg/L. Such levels of resistance to 
quinolones is not explainable by aac(6,)-Ib-cr alone, suggesting the presence of multiple 
chromosomal mutations in the genes encoding DNA gyrase and topoisomerase IV, or, maybe 
effiux and permeability changes (Robicsek, A. et al., 2006). The quinolone resistance determining 
regions (QRDRs) of the gyrA (190-bp), parC (265-bp) and parE (265-bp) genes (not gyrB. since 
alterations in this gene are rarely associated with quinolone resistance) from each representative 
isolates AI-A3, Bh Ch DI-D2 and El were therefore sequenced on both strands. The three amplicons 
(shown in Figure 21) were 100% identical for all eight representative isolates, harbouring the same 
multiple nucleotide changes when compared with the fluoroquinolone-susceptible E. coli K-12 
(GenBank accession NC_000913). These substitutions, some of which were silent, are summarised 
in Table 13. The double amino acid substitutions in the QRDRs of gyrA and parC had been 
described previously, though independentlY, and are associated with high-level resistance to 
fluoroquinolones (Everett, M. J. et al., 1996). 
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Figure 21. Agarose gel electrophoresis of gyrA (A, 190-bp amplicon), pare (B, 265-bp 
ampUcon) and parE (C, 265-bp amplicon) QRDRs PCR products for representative isolates 
of epidemic clones A-E with a CTX-M-15-like 13-lactamase 
(A) 
(B) (C) 
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Table 13. Summary of mutations in the quinolone resistance determining region of gyrA, 
parC and parE genes of epidemic clones A-E representative isolates with CTX-M-1S-1ike {J-
lactamase 
Nucleotide 
Gene Amino acid substitutions 
substitutions 
C249T SerS3Leu 
C256T Silent mutation 
gyrA G260A AspS7Asn 
C274T Silent mutation 
T30lC Silent mutation 
G240T SerSOlle 
parC 
A252T GluS4Val 
G1403C Silent mutation 
C1431T Silent mutation 
T144SC Silent mutation 
parE 
A1454G Silent mutation 
Cl466G Silent mutation 
G1475T Silent mutation 
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8. Relatedness of blacTX_M-encoding plasmids from epidemic clones A-E 
8.1. Plasmid incompatibility grouping 
According to replicon-based PCR assays, the CTX-M-encoding plasmids extracted from 
transformants TrAI-TrEI harboured the F-plasmid origin of replication [repF, Figure 22(A)] 
indicative of incompatibility group IncFII. Plasmids from A., BI and Cl also carried a second 
replicon; repFIA, which was not present on the CTX-M-encoding plasmids from the clone D and E 
representatives tested [Figure 22(B)]. This additional replicon did not affect the grouping of the 
plasmids and all were typed as IncFII, thus sharing a common origin. The assigned incompatibility 
groups were further confIrmed by Dr A. CarattoIi (lstituto Superiore di Sanita, Rome, Italy). 
8.2. Investigation of plasmid size variations among representative 
clone A isolates 
The slight variations in sizes of the blacrx_wharbouring plasmids from different representatives of 
clone A (Figure 17), added to the fact that not all of these plasmids encoded TEM-l /3-lactamase 
(Table 12), led me to undertake comparative studies by restriction analysis, as well as cross-
hybridization studies using the HpaI-digested Dig-labelled pEK499 probe (CTX-M-encoding 
plasmid of representative AI). The CTX-M-encoding plasmids from fIve strain A representative 
isolates (AI-As) were investigated for their degree of similarity. As shown in Figure 17, the blacrx_ 
M-harbouring plasmids from isolates AI and At appeared to be slightly smaller compared with those 
from representatives A2, A3 and As. Moreover, only isolates Al and A3 had been shown to harbour 
blaTEM-I. There was therefore no correlation between the presence or absence of blaTEM-1 and the 
plasmid size. Although the HpaI restriction profIles of the fIve plasmids appeared highly similar, 
none were completely identical [Figure 23(A)]. The plasmid profIles from isolates Al and A3, 
which both produced TEM-l /3-lactamases, had no additional band in common compared with the 
plasmid profIles of isolates lacking TEM-l; furthermore, the restriction profIles of plasmids from 
isolates Al and At were not the most related, even though both were smaller than the remaining 
three plasmids. 
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Figure 22. Agarose gel electrophoresis of repF (A), and repFIA, repFIB and repW (B) peR 
products of representative isolates AI-El 
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Figure 23. (A) HpaI restriction protlles of the blacTX_M_ls-harbouring plasmids from isolates AI-As a, and (8) Southern blot hybridized with dig-labelled HpaI-
digested plasmid pEK499 from TrAI 
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Overall, plasmid digests from isolates A3 and ~ appeared the most similar and that from AI 
(pEK499, reference plasmid) showed the least similarity to the remaining four profiles. Cross 
hybridization of each plasmid restriction profiles with the Dig-labelled digested pEK499 [Figure 
23(B)] suggested all five plasmids shared a high degree of similarity; every band of each profile 
hybridized with the probe. Therefore, although the CTX-M-encoding plasmids from various 
representatives of epidemic clone A presented some minor variations, all appeared highly related. 
The small variations (e.g. loss or gain of blaTEM-I) probably occurred subsequent to the initial 
spread of clone A isolates. 
8.3. Homology studies between the plasmids encoding CTX-M 
enzymes from epidemic clones A-E 
In order to estimate the degree of similarity between the CTX-M-encoding plasmids from epidemic 
clones A-E, plasmids from representative isolates were subjected to HpaI restriction (plasmid 
RFLP) and cross-hybridization with the Dig-labelled HpaI-digested pEK499 probe (reference 
plasmid from isolate AI)' Also, since these plasmids belonged to incompatibility group IncFII, a 
specific part of their repF replicon (intervening in the sub-classification of IncFII plasmids, Dr 
Carattoli, A. personal communication) was sequenced in order to further estimate their degree of 
relatedness. 
8.3.1. Cross-hybridization studies 
The CTX-M-encoding plasmids from representatives of clones A, B, D and E had mUltiple bands 
in common by size [Figure 24(A)], suggesting therefore some degree of relatedness. On the other 
hand, the plasmid profile from the clone C representative appeared significantly different. This 
plasmid, which harboured blacrx-M-3 instead of blacrx-M-Is, and encoded less antibiotic resistance 
compared with the other four plasmids (e.g. no resistance to aminoglycosides, nor reduced 
susceptibility to ciprofioxacin, Table 10), had considerably more restriction fragments. None, or 
very few of these fragments were shared with the plasmids extracted from clone A, B, D and E 
representative isolates. 
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Figure 24. (A) Hpal restriction prordes of the CTX-M-encoding plasmids from representatives of E. coli epidemic clones A-E, and (B) Southern blot 
hybridized with dig-labeJJed HpaI-digested plasmid pEK499 from TrA, 
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The HpaI restriction profiles of the CTX-M-encoding plasmids from isolates D\ and D2 were 
identical, as might be expected since all members of this strain were from a single centre 
(Shrewsbury). Cross-hybridization with the Dig-labelled pEK499 probe [Figure 24(B)] supported 
these conclusions, showing a high-level of similarity and relatedness between the plasmids of 
clones A, B, D and E. Most, or all of the restriction fragments ofthese plasmids hybridized with the 
clone A reference plasmid probe. In contrast, only a few restriction fragments from the clone C 
plasmid hybridized with pEK499, suggesting much less relatedness. However, since the clone C 
plasmid also belonged to incompatibility group IncFII and was therefore relatively related to 
pEK499, it was not surprising that a few bands still hybridized with the probe. Also, the positive 
hybridization with the Dig-labelled pEK499 may have been due to the fact that both plasmids had a 
few antibiotic resistance genes in common, including blacrx-M and blaTEM_\. 
8.3.2. Comparison ofrepF sequences 
DNA sequencing of a c. 50-bp segment within repF revealed that the blacrx_wharbouring plasmids 
from Ab Bb D\ and E\ were highly related. The DNA sequence of this gene section, which is used 
in the sub-classification of IncFII plasmids (A. Carattoli and K. Hopkins, personal communication), 
was identical in all four cases. In contrast, the sequence of this gene fragment was significantly 
different in the plasmid encoding CTX-M-3 from isolate Cb presenting seven nucleotide 
substitutions compared with the sequences from Ab Blo D\ and E\ (Figure 25). This further 
confirmed the reduced relatedness of the clone C plasmid to those of the remaining four epidemic 
clones, even though all belonged to the same incompatibility group. 
9. Fitness cost associated with carriage of pEK499 
Clone A is the most successful (i.e. widespread) E. coli lineage with CTX-M-15 enzyme in the UK, 
and, since this enzyme is plasmid-mediated, it was important to investigate whether harbouring the 
plasmid was associated with a fitness cost. 
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Figure 25. Alignment of partial repF nucleotide sequencesa from the blacTX_wencoding plasmids ofrepresentative isolates AI_E lb 
Chromatogram for AI, B I, 
D, andE, 
Chromatogram for Cl 
Al AATCTT TTC GTA CTCGCCAAA GT TG AA GAAGATTATCGGGG 
BI AATCTT TTCGTA CTCGCCAAA GT TG AA GAAGATTATCGGGG 
Cl AATCTT CTC TTA GTCGCCAAA CC TG GT GAAGAT TA TCGGGG 
DI AATCTT TTC GTA CTCGCCAAA GT TG AA GAAGATTATCGGGG 
R, AATCTT~TC G TA C TCGCCAAA GT TG AA GAAGATTATCGGGG 
a Relevant to the sub-classification of IncFII plasmids. 
b Chromatogram colour code: Adenine = green; Cytosine = blue; Guanine = black; Thymine = red; black circles indicate nucleotide changes. 
The fitness cost of pEK499 was investigated by comparing the growth rate of E. coli DHSa with 
that of the same strain transformed with pEK499 (TrAI); the same culture conditions were used in 
both cases. The growth rates of both organisms were nearly identical (see Figure 26). As a result, 
although pEK499 was a large molecule (c. 120-kb), it was not associated with any major fitness 
cost under these growth conditions. It is worth noting that pEK499 likewise did not accelerate the 
growth rate of its host in an antibiotic-free environment. 
10. Phylogenetic typing and virulence factor screenine: 
Fourteen clonal E. coli clinical isolates (four representatives of clone A, two of clone B, three of 
clone C, three of clone D and two of clone E) were phylogenetically typed using a previously 
published method (Clermont, O. et al., 2000) and screened for the presence of32 virulence factor-
associated genes, as well as for a pathogenicity-associated island (PAl, also known as malX). 
All 14 isolates showed identical phylogenetic profiles according to the triplex PCR (chuA-, 
yjaA- and TspE4.C2-positive, see Figure 27 for representative isolates AI-El). This profile is 
specific for the virulent E. coli phylogenetic group B2. 
Overall, the diversity and prevalence of virulence factor genes were comparable among 
representatives of the five clones, with seven to nine virulence genes per isolate on average (Table 
14). P AI (pathogenicity-Associated Island), fimH (type 1 fimbriae), fyuA (yersiniabactin), iutA 
(aerobactin receptor), traT (serum survival gene), uidA ({3-D-glucuronidase) and usp 
(uropathogenic-specific bactericin) were the most prevalent virulence genes and were detected in 
most representatives of each clone. Moreover, all five clones were defined as extra-intestinal 
pathogenic E. coli (ExPEC), as each representative harboured at least two of the five ExPEC gene 
markers (Table 14). Nineteen virulence factor genes, notably including the toxin-encoding genes 
hlyA and cnfJ, were not detected among any of the clonal repres.entative isolates (Table 14), but 
were confirmed in their respective control strains. 
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Figure 26. Logarithmic representation of E. coli DH5~ and TrAI growth rates over 32 hours 
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Figure 27. Agarose gel electrophoresis of the phylogenetic typing triplex peR products of 
isolates AI-El, taken as representatives oftheir respective clones. 
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Table 14. Virulence factor gene repertoires a of epidemic clones A-E representativesb 
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a Key virulence marker genes of ExPEC isolates are highlighted in grey. 
b + indicates the presence of the corresponding virulence gene. 
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Based on the key ExPEC markers, three groups of isolates were distinguishable: 
(i) Clone A group: isolates harboured iutA and afaldraBC, but not papA nor kpsMT ll. 
(ii) Clone D group: isolates harboured iutA and papA, but not afaldraBC nor kpsMT Il 
(iii) Clones B-C-E group: isolates harboured iutA and kpsMT Il, but not afaldraBC nor 
papA. 
Such division of isolates was further enhanced based on the whole set of virulence factor genes 
screened. While afaldraBC was specific to clone A, papA and papEF were detected in clone D 
isolates only, and only representatives of clones B, C and E harboured the kpsMTIl, sfaS and K5 
genes. Minor variations were detected within these three groups (e.g. for PAl among clone A 
isolates). This probably was due to loss of DNA from the genome, as shown previously among 
fluoroquinolone-resistant E. coli isolates (Horcajada, J. P. et al., 2005; Soto, S. M. et al., 2006). 
11. Further evolution of antibiotic resistance in epidemic clone A 
Third-generation cephalosporinlclavulanate combinations retained good activity vs. most strain A 
isolates. However, some clone A isolates from around Preston have acquired a CIT -type plasmid-
mediated AmpC ~-lactamase (CMY-23), increasing their level of resistance to all ~-lactams, except 
carbapenems (Woodford, N. et al., 2007b). These isolates showed resistance to 
cephalosporinlclavulanate combinations. In November 2006, a further variant of clone A, also from 
Preston, and with ertapenem resistance (MIC = 4 mgIL) was referred to ARMRL. PFGE confirmed 
the isolate, designated A12, was a clone A variant (Figure 28). In addition to blacrx-M, a blaclT gene 
was also detected by PCR in this isolate (Figure 29). Al2 was isolated from a catheter urine 
specimen from an 86-year-old female nursing-home resident. She had had a catheter in situ for over 
four years, but had no recent hospital admissions and minimal exposure to antibiotics, with just one 
course of oral cephalexin in the preceding 12 months. No other resident had received carbapenems 
in the home, though they may have done so during periodic hospitalisations. Isolate Al2 was 
resistant to most ~-lactams, including cephalosporinlclavulanate combinations, to fluoroquinolones, 
and to aminoglycosides except gentamicin (Table 15). 
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Figure 28. Xbal-digested genomic DNA profiles of isolates AI and All 
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Figure 29. Agarose gel electrophoresis of blaclT and blaCTX-M universal peR products of clinical 
isolates AJ2 and AI3 
blaclT 
amplicon 
(462-bp) 
AI 2 A13 
<3 
..... 
i:i 
0 
u , 
d) 
.::: 
-.tij 
0 
0-
I-
0 
~ 
-Q 
,-... 
0 
N 
e; ..... d) 
"0 
<3 "0 Cl:! 
..... 
-s::l 
-< 0 
u Z 
rl> Cl 
.::: 0-
eo oD , 
01} 
...... d) N Z 
<3 
..... 
-s::l 0 
u , 
d) 
:5 
en 
0 
0-
~ 
" . ~
c 
" ::E 
6 
~ AI 2 A13 -Q 
..-.. 
0 
N 
e; 
"0 
..... 
..... 
s::l 
0 
Co) 
rl> 
.::: 
'iii 
01} 
d) 
Z 
bla X-M un iversal 
amplicon 
(544-bp) 
163 
Table 15. MICs (mg/L) for E. coli strain A variants AI, AI2 and A13 
Isolate AI Isolate AI2 Isolate A13 
CTX-M-15, CMY-
CTX-M-15,OXA-l CTX-M-15, CMY-
Features and TEM-l 
23, OXA-l and 
23, OXA-1 , TEM-l 
TEM-l 
OmpC present OmpC absent 
OmpC present 
AMP > 64 > 64 > 64 
AMX/CLA 16 32 64 
CTX 64 64 32 
CTX/CLA 0.25 > 32 16 
CAZ 8 32 16 
CAZ/CLA 0.25 16 16 
FOX 8 > 64 > 64 
PIP > 64 > 64 > 64 
PIP/TZM 16 64 > 64 
ETP ~0.125 4 ~.125 
[PM 0.125 0.25 
MEM ~0.06 0.25 ~0 .06 
CIP > 8 > 8 > 8 
AMK 16 8 16 
GEN 1 
164 
Susceptibility to imipenem and meropenem also was reduced compared with classical E. coli strain 
A isolates such as AI. and with CMY-23-positive strain A variants, such as A13 (Table 15). 
Carbapenem resistance, which may arise from the association of permeability changes with 
production of ESBLs or AmpC enzymes, is rarely observed in E. coli isolates (Lartigue, M. F. et 
al., 2007). Also, production of carbapenemase enzymes by A12 was very unlikely according to the 
MICs (imipenem and meropenem MICs not being affected). The outer membrane protein profile of 
isolate AI2 was investigated and compared with those of other clone A representatives, as well as 
with representatives of the other four epidemic clones. SDS-PAGE of bacterial cell extracts (Figure 
30) showed loss of OmpC in isolate Al2 by contrast with isolate AI, An and representatives of 
clones B-E, which all had identical outer membrane protein profiles. OmpF was not detectable on 
the SDS-P AGE since its expression was not induced under the low osmolarity cultural conditions 
used (H. Chart, Laboratory of Enteric Pathogens, Centre for Infections, personal communication). 
OmpA was present in all seven clinical isolates. Ertapenem resistance in isolates AI2 may therefore 
be explained by the change in permeability (loss of OmpC), together with the production of 
acquired AmpC and CTX-M-15 enzymes. 
12. Summary 
The multi-drug resistance phenotypes of the five major UK epidemic E. coli clones were largely 
encoded by single plasmids harbouring the blacrx-M gene. These molecules were found to be se1f-
transferable (except for that of epidemic clone A) and to share a range of additional antibiotic 
resistance genes such as blaoxA-h blaTEM-h aac3-IIa (except clones A and C) or aac(6 ,)-Ib-cr 
(except clone C). The CTX-M-encoding plasmids from all five clones belonged to incompatibility 
group IncFII, and most shared high-level homology according to cross-hybridization studies. The 
representative clone C plasmid however appeared less related to the remaining four; it also 
harboured fewer antibiotic resistance genes and carried blacrx-M-3 instead of blacrx-M-1S. It is 
nevertheless worth mentioning that some clone C representative isolates (not part of the molecular 
characterisation study, but undistinguishable by PFGE) required high ceftazidime MICs, suggesting 
they possibly encoded CTX-M-15 J3-lactamase, and not CTX-M-3. 
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Figure 30. Outer membrane protein profiles of E. coli strain A variants AI, A u, AI3 and of 
representative isolates of epidemic clones B-E 
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High-level resistance to quinolones resulted from the same mUltiple nucleotide substitutions in all 
members of the five epidemic clones. Finally, clone A-E isolates belonged to the virulent extra-
intestinal phylogenetic group B2. Although similar, three virulence factor profiles were 
distinguishable, one each for clone A, clone D and the cluster comprising clones B. C and E. 
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Chapter 11. Molecular characterisation of non-clonal Escherichia coli 
isolates with CTX-M-15-like beta-Iactamases 
1. Introduction 
Non-clonal E. coli isolates with CTX-M-15-like 13-lactamases represented the majority of 
CTX-M-positive isolates referred to ARMRL, according to PFGE data (approximately 70% of all 
referred isolates). While not of major concern at the national level, most of these isolates remained 
a challenge on a smaller scale, often associated with local outbreaks (e.g. around Truro). 
Furthermore, the fact that these diverse CTX-M-producers outnumbered clonal E. coli isolates with 
group-l CTX-M enzymes further emphasised their significant contribution to the epidemiological 
success ofCTX-M extended-spectrum 13-lactamases in the UK. 
Non-clonal E. coli isolates with CTX-M-15-like enzymes were multi-drug resistant (Table 
16) and had similar antibiograms to those of epidemic clone A-E isolates. High-level resistance to 
both cefotaxime and ceftazidime, with synergy between clavulanate and third-generation 
cephalosporins was consistent with the possible production of CTX-M-15 13-lactamase (although 
rarer group-l CTX-M variants such as CTX-M-23 and CTX-M-42 may also confer this 
phenotype). The vast majority (c. 90%) of non-clonal isolates were highly resistant to ciprofloxacin 
(MIC >8 mg/L), and c. 75% were resistant to at least one aminoglycoside antibiotic (gentamicin or 
amikacin); resistance to gentamicin (c. 75% of isolates) was more common than resistance to 
amikacin (c. 20% of isolates). However, no isolate was fully susceptible to amikacin, and nearly all 
required amikacin MIC ~ 2 mg/L. Those genetically diverse isolates were mostly resistant to 
trimethoprim too, and had reduced susceptibility to minocycline, according to CLSI guidelines (no 
BSAC breakpoint being defined). As for the clonal isolates, the diverse producers remained 
completely susceptible to carbapenem antibiotics; most were also susceptible to nitrofurantoin and 
to fosfomycin. 
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Table 16. MIC ranges and geometric mean MICs (mg/L) for non-clonal E. coli isolates with 
CTX-M-lS-like ~-Iactamases (n = 242 isolates) 
MIC range Geom. Mean MIC 
AMP 64 - >256 69 
AMX/CLA 16 32 - >64 26.5 
CTX 1 32 - >256 66.6 
CTX/CLA 1 g).06 - 4 0.1 
CAZ 2 1 - 128 57 
CAZ/CLA 2 g).06 - 2 0.3 
CPD 1 256 256 
CPD/CLA 1 1 - 2 1.9 
FOX 8 4 - 64 14.9 
PIP 16 64 - >256 69.2 
PIP ITZB 16 2 - >256 39 
ETP 2 g).125-1 0.1 
IPM 4 g).06 - 1 0.1 
MEM 4 g).06 - 0.25 0.1 
CIP 1 g).125 - >256 7 
AMK 16 1 - 64 7 
GEN 4 0.25 - 128 30 
MIN 8 0.5 - >32 6.3 
COL 4 ~. 5 - 8 0.7 
TMP 2 g).25 - >256 47 
NIT 32 4 - 256 23.5 
FOS 128 0.5 - 256 2.3 
a BSAC breakpoints defining resistance (Andrews, J. M ., 2007) 
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By interpretative reading of the antibiograms, it was inferred that the same mechanisms of 
resistance, as seen in epidemic clones A-E, were likely to be involved in the non-clonal isolates; i.e. 
aac(6')-Ib (tobramycin resistance), aac3-IIa (gentamicin resistance), multiple chromosomal 
mutations in the QRDRs of gyrA and pare (ciprofloxacin resistance), in addition to the blacrx-M-Is 
gene. 
On this basis, /3-lactamases from various randomly-selected isolates were characterised by 
IEF, and the presence and identity of bla genes were confIrmed by PCR. Transfer of cefotaxime 
resistance by electroporation from six non-clonal CTX-M-15 /3-lactamase-producers (requiring 
MICs representative of the non-clonal isolates) to E. coli DH5a was attempted to confIrm whether 
blacrx-M-Is was plasmid-mediated (at least in those isolates). Additionally, various features ofCTX-
M-encoding plasmids, such as plasmid maintenance systems and origins of replication, were sought 
by PCR among representative isolates. Finally, the phylogenetic background and the virulence 
genotypes of a representative sample were also investigated. 
2. Transfer of cefotaxime resistance 
Transfer of cefotaxime resistance via electroporation was achieved successfully from all six clinical 
isolates (designated NCt. NC\3. NC I4• NC I6, NC21 and NC34), representing the diverse E. coli 
producing CTX-M-15-like /3-lactamase. The transfer of blacrx-M was confIrmed by PCR and by 
antibiotic susceptibility testing by agar dilution. MICs for the recipient, the donor strains (NC), as 
well as the transformants (TrNC) are shown in Table 17. 
MICs for the selected donor isolates were representative of those for non-clonal isolates in 
general, and appeared very similar to those for the clonal isolates (e.g. CTX-M phenotype, multi-
drug resistance, carbapenem susceptibility, variable susceptibility to aminoglycosides). MICs for 
the cefotaxime-resistant transformants revealed that additional mechanisms of antibiotic resistance 
were transferred along with the CTX-M phenotype. These included mechanisms of resistance to 
gentamicin (except for TrNC)(,) and to tobramycin, as well as reduced susceptibility to amikacin 
and ciprofloxacin. 
170 
Table 17. MICs (mgIL) for E. coli DH5a, representative non-clonal E. coli isolates with CTX-M-I5-like ~lactamases, and their transformants 
DHSa NCt TrNCt NC13 TrNC13 NCt4 TrNCt4 NCt6 TrNC16 NC21 TrNC21 NC34 TrNC34 
AMP 8 >64 >64 >64 >64 >64 >64 >64 >64 >64 >64 >64 >64 
AMX/CLA 4 16 16 16 16 16 16 16 16 16 16 16 16 
crx ~.125 >256 >256 >256 256 >256 256 64 32 256 64 >256 >256 
CTX/CLA ~.060 ~.060 ~.060 ~.060 ~.060 ~.060 ~.060 ~.060 ~.060 0.125 ~.060 ~.060 ~.060 
CAZ ~.125 64 32 32 16 32 32 32 16 32 16 64 32 
FOX 4 8 8 8 4 16 4 8 4 8 4 8 8 
PIP S >64 >64 >64 >64 >64 >64 >64 >64 >64 >64 >64 >64 
PIP/TZB S 8 4 4 4 16 4 8 2 16 4 4 4 
ETP ~.125 ~.125 ~.125 ~.125 ~.125 ~.125 ~.125 ~.125 ~.125 ~.125 ~.125 ~.125 ~.125 
IPM 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 
MEM ~.060 ~.060 ~.060 ~.060 ~.060 ~.060 ~.060 ~.060 ~.060 ~.060 ~.060 ~.060 ~.060 
CIP 0.03 >8 0.125 >8 0.125 >8 0.25 >8 0.125 >8 0.25 >8 0.125 
TOB 0.25 >32 16 ND3 8 ND3 16 >32 8 ND3 16 ND3 16 
AMK ~.5 8 4 8 2 4 2 16 2 16 4 4 2 
GEN 0.25 >32 32 >32 16 >32 32 1 0.25 >32 32 >32 16 
MIN 1 4 4 4 2 4 4 4 2 4 4 2 4 
SFM 4 ND3 4 ND3 4 ND3 4 ND3 8 ND3 8 ND3 4 
COL ~.5 ~.5 ~.5 1 ~.5 ~.5 ~.5 ~.5 ~.5 1 ~.5 1 ~.5 
• ND = not determined 
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3. Characterisation of 8-lactamases by IEF 
The ~-lactamase enzymes from 12 randomly selected non-clonal isolates (designated NCt-NC12), 
most of which originated from different centres across the UK, were characterised by IEF. These 
isolates were known to produce CTX-M-15 ~-lactamases, as previously shown by PCR and DNA 
sequencing (N. Woodford, personal communication). IEF results are summarised in Table 18. 
As with most clonal representatives, the non-clonal isolates investigated in this study 
produced up to three ~-lactamases in various combinations; the approximate pI values for each 
enzymes were 5.4,7.4 or 8.6. PCR confirmed these enzymes to be ofTEM, OXA-l-like and CTX-
M types, respectively and DNA sequencing of a representative of each PCR product identified 
TEM-l, OXA-l and CTX-M-15. Most isolates (7/12), and also the NCt-derived transformant, 
produced TEM-l, OXA-l and CTX-M-15 enzymes. Four isolates lacked blaTEM-t and the blaoxA-t 
gene was absent from one isolate only. None of the 12 isolates produced AmpC type enzymes as no 
band was inhibited by cloxacillin on the IEF gels. 
4. Plasmid characterisation 
Since clonal and non-clonal isolates had comparable antibiograms and produced similar ~­
lactamases according to IEF, it was hypothesised that closely-related multi-resistance plasmids 
were spreading horizontally among clonal and non-clonal E. coli isolates. The features ofthe CTX-
M-encoding plasmids of clone A-E representatives were therefore sought by PCR among the non-
clonal representatives. These features included the aac(6 ,)-lb-cr gene, as well as the repF and 
repFIA replicons and the plasmid maintenance system ccdAlccdB. All these markers had been 
detected on pEK499, the blacrx_M_ts-encoding plasmid of clonal isolate At. 
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Table 18. Summary of IEF and PCR results for non-clonal representative isolates with CTX-
M-IS-like enzymes 
No. of pI values of 
Isolates Origin bla genes detected by PCR 
bands tl-Iactamases· 
NC1 Fairfield 3 5.4 7.4 8.6 blaTEM, blaoxA-I-like, blacrX-M 
NC2 Bristol 2 7.4 8.6 blaoxA-I-like, blacrx-M 
NC3 Bury 2 7.4 8.6 blaoxA-l-like, blacrx-M 
NC4 Eastbourne 2 5.4 8.6 blaTEM, blacrx-M 
NCs Belfast 3 5.4 7.4 8.6 blaTEM, blaoxA-l-like, blacrx-M 
NC6 Hull 3 5.4 7.4 8.6 blaTEM, blaoxA-I-like, blacrx-M 
NC7 Manchester 3 5.4 7.4 8.6 blaTEM, blaoxA-l-like, blacrx-M 
NCs Newcastle upon Tyne 2 7.4 8.6 blaoxA-l-like, blacrx-M 
NCq Nottingham 2 7.4 8.6 blaoxA-I-like, blacrx-M 
NC IO Shrewsbury 3 5.4 7.4 8.6 blaTEM, blaoxA-I-like, blacrx-M 
NC l1 Shrewsbury 3 5.4 7.4 8.6 blaTEM, blaoxA-I-like, blacrx-M 
NC I2 London 3 5.4 7.4 8.6 blaTEM, blaoxA-I-like, blacrx-M 
• pI ofTEM-l is 5.4; pI ofOXA-l is 7.4; pI ofCTX-M-15 is 8.6. 
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4.1. Detection of aac(6,)-Ib-cr 
MICs for the transformants derived from the non-clonal representative isolates indicated the 
potential presence of aac(6')-Ib-cr on the CTX-M-encoding plasmids as tobramycin resistance 
(~2-fold increase in MIC) and reduced susceptibility to amikacin (~4-fold increase in MIC) and 
ciprofloxacin (~-fold increase in MIC) were co-transferred. This was confirmed by PCR-RFLP 
and DNA sequencing (Figure 31). The aac(6')-Ib allele was sought by PCR using the primer pair 
aac(6')-IbF/aac(6')-IbR (Appendix 6) among a total of27 non-clonal clinical isolates with CTX-M-
15-like {3-lactamases and was detected in 24 of them. Both strands of the aac(6')-Ib amplicon from 
ten randomly-selected representatives (including NC\) were sequenced and the allele always 
corresponded to the aac(6')-Ib-cr variant. Some of these aac(6 ')-Ib-cr-positive isolates dated from 
year 2000, i. e. prior to the first report of this allele variant in E. coli isolates from China (Robicsek, 
A. et al., 2006). The wide occurrence of aac(6')-Ib-cr in clonal as well as non-clonal producers of 
CTX-M-15-like enzymes may reflect the dissemination of closely-related groups of plasmids 
among these isolates. 
4.2. Detection of repF and repFIA replicons 
Since the blacrx_M-encoding plasmids from representatives of clone A-E harboured repF, and in 
some cases repFIA as well, both these replicons were also sought by PCR with the primer pairs 
FrepB-FW IFrepB-RV (repF) and FIA-FW IFIA-RV (repFIA) among the 27 non-clonal 
representatives previously screened for aac(6 ')-Ib. Results are summarised in Table 19. Apart from 
two isolates, most of the unrelated isolates with CTX-M-15 enzymes investigated harboured the 
repF replicon and were therefore inferred to be carrying IncFII plasmids. Additionally, 17/27 
encoded repFIA. Both repF and repFIA replicons were alleged to be harboured by the blacrx-M-
encoding plasmids, as previously found in most of the UK clonal isolates, as well as by many other 
blacrx-M_\s-harbouring plasmids worldwide (Canton, R. and Coque, T. M., 2006). Six of the 
remaining ten representatives had a modified repFIA replicon according to PCR. These amplicons, 
which appeared much shorter than the usual 462-bp fragment on gel electrophoresis (Figure 32), 
suggested that the plasmids encoding CTX-M-15 enzymes from those isolates maybe belonged to a 
different sub-group of IncFII plasmids. 
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Figure 31. Partial nucleotide sequence and chromatogram of aac(6~-Ib-cr from non-clonal clinical isolate Net showing the critical double base substitution 
Classical aac(6 ')-Ib 
NC, { 
CGGA T GGTGGGAAGAAGAAACCGA T CCAGGAGTACGCGGAATAGACCAGT CACTGGCGA 
CGGA C GGTGGGAAGAAGAAACCGA T CCAGGAGTACGCGGAATAGACCAGT T ACTGGCGA 
CGGA C GGTGGGAAGAAGAAACCGA T CCAGGAGTACGCGGAATAGACCAGT T ACTGGCGA 
CGGA ~GGTGGGAAGAAGAAACCGATCCAGGAGTACGCGGAATAGACCAGT T ACTGGCGA 
Chromatogram ~ 
for NC l 
'- . - . 
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Figure 32. Agarose gel electrophoresis of repFIA PCR products from randomly-selected non-
clonal isolates with CTX-M-lS-like enzyme, showing two different types of amplicon 
Expected repFIA 
amplicon (462-bp) 
Smaller repFIA 
amplicon (c. 420-bp) 
615-bp 
492-bp 
369-bp 
246-bp 
123-bp 
176 
Among the four repFIA-negative isolates, two harboured the repF replicon and two lacked the 
repF replicon. This suggested that the CTX-M-encoding plasmids from the two latter isolates did 
not belong to plasmid incompatibility group IncFI!. Interestingly, one of these isolates was shown 
not to carry the aac(6 ')-Ib gene. This gene was detected in the second repF-negative isolate, but it 
remains unknown whether it corresponded to the aac(6,)-Ib-cr allelic variant or not (not tested by 
PCR-RFLP, nor sequenced). 
Seguencing of randomly-selected repF amplicons: 
The 50-bp portion of the repF replicon, critical for the classification of IncFII plasmids, was 
sequenced from six randomly selected diverse producers of CTX-M-15-like enzyme 
(representatives NC .. NC2, NC J3, NC I6, NC21, and NC33). The repF DNA sequence from all six 
isolates was identical to the corresponding section of repF from the CTX-M-encoding plasmids of 
epidemic clones A. B, D and E (see Figure 25). This therefore suggested that these isolates shared 
closely related IncFII plasmids (surely, harbouring the same blacrx-M genes as found in the clonal 
representatives). Interestingly, some of these plasmids additionally carried a repFIA replicon, 
belonging to either of the two different types, and consequently dividing these IncFII plasmids into 
at least two different sub-groups. 
4.3. Detection of ccdAlccdB plasmid maintenance system 
Following the complete DNA sequencing of the CTX-M-15-encoding plasmid of representative 
clone A isolate AI (PEK499), discussed in detail later in Chapter V of the results section, it was 
found that pEK499 harboured the F -plasmid-derived ccdAlB addiction system. This encodes a 
stable toxin and an unstable antitoxin, militating against plasmid loss (Dao-Thi, M. H. et al., 2002). 
This key plasmid attribute was therefore also sought by PCR, using the primer pair ccdNccdB 
(Appendix 6), among the 27 unrelated clinical isolates listed in Table 19. The ccdAlccdB plasmid 
addiction system was found constantly among all the isolates, which harboured an IncFII plasmid 
(i.e. 25/27 isolates), and was absent from the two repF-negative isolates. 
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Table 19. Summary of plasmid features detected among non-clonal representative isolates 
Isolate origin (year of isolation) aac(6')-lb reEF reEFIA ccdAlB qnrAIBIS 
NCt Farifie1d (2003) + + short + absent 
NC2 Bristol (2003) + + short + absent 
NC3 Bury (2003) + + + + absent 
NC4 Eastbourne (2003) absent absent absent absent absent 
NCs Belfast (2004) + + + + absent 
NC6 Hull (2004) + + + + absent 
NC, Manchester (2003) ND ND ND ND ND 
NC12 London (2003) ND ND ND ND ND 
NC13 Stoke (2004) + + + + absent 
NCt4 Salisbury (2004) + + + + absent 
NC)s Birmingham (2004) + + short + absent 
NC)6 Southampton (2004) + + + + absent 
NC17 Winchester (2004) absent + absent + absent 
NC)8 Southampton (2004) + absent absent absent absent 
NC)9 Reading (2004) + + short + absent 
NC20 Winchester (2004) + + + + absent 
NC2) Shrewsbury (2004) + + + + absent 
NC21 Southend (2004) + + + + absent 
NC23 South Tyneside (2004) + + + + absent 
NC24 Birmingham (2004) + + + + absent 
NC2S Swansea (2004) + + short + absent 
NC26 Huddersfield (2005) + + short + absent 
NC2' Stoke (2005) + + absent + absent 
NC28 Stafford (2005) + + + + absent 
NC29 Truro (2006) absent + + + absent 
NC30 Birmingham (2000) + + + + absent 
NC3t Birmingham (2001) + + + + absent 
NC32 Birmingham (2000) + + + + absent 
NC33 Birmingham (2000) + + + + absent 
NC34 Belfast (2004) ND + + + absent 
+ - gene detected by PCR; ND = not determined; Short = gene detected by PCR. but smaller amplicon than 
expected (c. 420-bp, instead of 462-bp as found with e.g. plasmid pEK499). 
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4.4. Detection of qnrA, qnrB and qnrS 
The 27 diverse producers with CTX-M-15-like enzyme, including NC), were also screened by PCR 
for the three plasmid-mediated qnr genes (qnrA, qnrB and qnrS), which encode decreased 
susceptibility to quinolones. None of the 27 isolates harboured such genes based on PCR assays. 
Decreased susceptibility to ciprofloxacin, as observed with the NCt-derived transformant, was 
therefore anticipated to be due to AAC(6')-Ib-cr (though other unknown genes cannot be ruled 
out). 
Overall, most of the unrelated producers ofCTX-M-15-like enzymes were shown to share 
several plasmid-mediated features. These features, which were also found among most of the CTX-
M-encoding plasmids of clonal isolates, included the repF and repFIA origins of replication, the 
aac(6')-Ib-cr gene and the F-plasmid-derived addiction system ccdAlB. This suggests that closely-
related plasmids encoding CTX-M-1S t3-lactamases, and belonging to incompatibility group IncFII, 
are spreading among unrelated E. coli isolates, regardless of their genetic background, as defined 
by PFGE profiles. 
5. Plasmid cross-hybridization 
Cefotaxime resistance was transferred from six non-clonal representative isolates (NC), NC t3, 
NCt4, NC t6, NC2t and NC34) into E. coli K-12 DH5a by electroporation. Most of these isolates are 
listed in Table 19; NC34 was a non-clonal isolate from the same centre where clonal representative 
Ct was isolated from (Belfast). Following confirmation of blacrx-M transfer by PCR, the CTX-M-
encoding plasmids were extracted from the transformants by modified alkaline lysis and were then 
digested with HpaI for cross-hybridization studies with the Dig-labelled HpaI-restricted pEK499 
probe. 
All six plasmid restriction profiles appeared different [Figure 33(A)], and that ofNC34 was 
found to be the least related. Although diverse, the restriction profiles of the CTX-M-encoding 
plasmids from isolates NC), NC\3, NC t4, NCt6 and NC21 still shared a few bands in common, 
suggesting some relatedness. 
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Figure 33. (A) Hpal restriction proftles of plasmids encoding CTX-M ESBLs in selected non-clonal representative isolates· and (B) Southern blot hybridized 
with the Dig-IabeUed Hpal-digested plasmid pEK499 from TrA, 
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By contrast, the profile of the b/acrx_wharbouring plasmid of NC34 appeared more related to that 
from clonal isolate Cl (isolated at the same centre) than to those from the remaining five non-clonal 
representatives (isolated at different centres). Cross-hybridization of plasmid digests [Figure 33(B)] 
suggested the CTX-M-encoding plasmids from non-clonal isolates NC), NCI3, NCI6 and NC21 were 
related to that of epidemic clone A. pEK499. Most of their restriction fragments hybridized to the 
probe. On the other hand, the digested plasmids from isolates NC I4 and NC34 had fewer fragments 
in common with pEK499. This was very much expected for the NC34 plasmid since its restriction 
profile was noticeably different from that of pEK499. However, the NCI4 CTX-M-encoding 
plasmid was anticipated to be much more related to pEK499, considering their similar restriction 
profiles. The poor hybridization of pEK499 to this digested plasmid may reflect technical 
imprecision and in the absence of confirmation, this result will therefore not be discussed further. 
6. Molecular characterisation of high-level resistance to quinolones 
The gyrA and parC QRDRs from five randomly-selected ciprofloxacin-resistant (MIC >8 mg/L) 
non-clonal isolates with CTX-M-15-like enzymes were sequenced. Multiple mutations among 
these gene sections were found to contribute towards resistance to quinolones in epidemic clones 
A-E. All five clinical isolates exhibited the same double amino acid substitutions in both QRDRs, 
namely Ser83Leu and Asp87Asn in gyrA, and Ser80Ile and Glu84Val in parCo These mutations 
were also found among the clonal isolates and were associated with increased MICs of 
ciprofloxacin (see results section, Chapter I, section 7). 
7. Phylogenetic typing 
Fifty-six non-clonal isolates with CTX-M-15-like /3-lactamases from different locales across the 
UK (including most of isolates NCI-NC34) were phylogenetically grouped. Half of these (n=28) 
were confirmed urine isolates; the origin of 22/56 (c. 40%) was not communicated; the remaining 
six were isolated from blood (n=4) or wound (n=2). For comparison purposes, a further 20 E. coli 
isolates with non-CTX-M type ESBLs phenotypes [requiring MICs correlating with the production 
ofTEM- or SHV-type ESBLs (ceftazidime MIC> cefotaxime MIC)] were also typed. These were 
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isolated from blood samples as part of a bacteraemia survey (R. Hope, ARMRL, Centre for 
Infections, personal communication), each from a different UK. centre. Overall, the majority of 
unrelated E. coli isolates with CTX-M-15-like 13-lactamase belonged to virulent phylogenetic 
groups, most often B2 (60%) and to a much lesser extent D (11 %). More than a quarter of this 
group of isolates (28%) belonged to the commensal phylogenetic group A. and 4% were typed as 
group B 1. Similarly, the vast majority of isolates with non-CTX-M type ESBLs belonged to a 
virulent phylogenetic group (75% of group B2 isolates and 15% of group D); none belonged to 
phylogenetic group B I and 10% were typed as commensal isolates of group A. 
8. Detection of virulence factor genes 
Subsequent to phylogenetic typing, the 56 non-clonal isolates with group-l CTX-M enzymes and 
the 20 isolates with non-CTX-M type 13-lactamases were screened for the presence of 32 virulence-
associated genes, as well as for the PAl. Twenty-four out of the 32 virulence factor genes were 
detected in at least one isolate. Table 20 summarises the prevalence of these 24 virulence genes 
detected and of the PAl. Overall, both sets of isolates exhibited similar aggregate virulence score 
(number of virulence factor genes per isolates) ranging from 2 to 12 genes per isolates for non-
clonal CTX-M-producers (average of 6.43 genes/isolate) and from 2 to 14 genes per isolates for 
non-CTX-M ESBL-producers (average of 6.32 genes/isolate). Among these, only papEF was not 
found among any of the non-clonal isolates with CTX-M-15-like 13-lactamases, while kpsMTIIl, 
rjc, nfaE,focG and afaldraBC were absent from those with TEM- or SHY-type ESBLs. The eight 
virulence factor genes absent from all 56 clinical isolates, but detected among their respective 
positive-control strains, included bmaE, Kl, hlyA, papG allele I, papG I, gajD, cvaC and cdtB. The 
proportion of ExPEC isolates among the two populations of isolates was not significantly different 
(67% ExPEC isolates among unrelated isolates with CTX-M enzymes vs. 79% among TEM- or 
SHY-type ESBL-producers; p value = 0.0792). Similarly to the group of clone B, C and E 
representatives (but not clones A and D), the vast majority of ExPEC isolates from the non-clonal 
CTX-M-producers, as well as those from the producers of non-CTX-M-type ESBLs, were defined 
as such by the presence ofthe two key virulence markers iutA and kpsMTIl. 
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Table 20. Prevalence of virulence factor genes among non-clonal isolates with CTX-M-15-like 
enzymes and among isolates with non-CTX-M-type ESBLs· 
prevalence of factor (% of total) 
Virulence gene non-clonal isolates with CTX-M- isolates with non-CTX-M-
15-like enzymes (n=56) type ESBLS (n=20) 
afaldraBC' 17 (31%) 0(0%) 
cnfl 2 (3%) 1 (5%) 
fimH 52 (92%) 19 (95%) 
(ocG 1 (2%) 0(0%) 
fyuA 40 (72%) 13 (65%) 
ibeA 1 (2%) 1 (5%) 
iutA6 48 (86%) 16 (80%) 
K5 19 (34%) 18 (90%) 
kpsMTIJ'> 20 (36%) 17 (85%) 
kpsMTIll 2(3%) 0(0%) 
nfaE 1 (2%) 0(0%) 
ompT 6 (11%) 2 (10%) 
PAl 16 (29%) 12 (60%) 
papA6 3 (5%) 2 (10%) 
pap~ 4(7%) 3 (15%) 
papEF 0(0%) 7 (35%) 
papG al/ele II 3 (5%) 2 (10%) 
papG al/ele III 1 (2%) 1 (5%) 
papG II,III 1 (2%) 2 (10%) 
rfc 1 (2%) 0(0%) 
sfa/focDg 2 (3%) 2 (10%) 
sfaS 4 (7%) 1 (5%) 
traT 48 (86%) 15 (75%) 
uidA 53 (95%) 18 (90%) 
usp 32 (57%) 14 (70%) 
• Significant differences in prevalence are highlighted in bold font. 
b Key virulence gene marker of ExPEC isolates. 
p value 
<0.0001 
0.7209 
0.5679 
0.4975 
0.5392 
0.4448 
0.4464 
<0.0001 
<0.0001 
0.2462 
0.4975 
1 
<0.0001 
0.2828 
0.2582 
<0.0001 
0.2828 
0.4448 
0.033 
0.4975 
0.0818 
0.5679 
0.1528 
0.2828 
0.0776 
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The most prevalent virulence factor genes among both populations of isolates included the 
PAl (mostly in isolates with non-CTX-M ESBLs), fimH, fyuA, iutA, kpsMTII, traT, afaldraBC 
(among non-clonal CTX-M-producers only), uidA and usp. This combination of virulence traits 
was found among approximately 30% of diverse isolates with CTX-M-15-like /3-lactamases and 
60% of isolates with non-CTX-M-type ESBLs. Overall, the diverse CTX-M-producers showed 
much more diversity in their virulence profiles. The afaldraBC virulence gene, which encodes a 
urinary tract adhesin, was found among the unrelated CTX-M-producing isolates only. 
Furthermore, this virulence gene was specifically found in isolates belonging to a virulent 
phylogenetic group (B2 or D). On the other hand, isolates with TEM- or SHY-type ESBLs showed 
less variation in their virulence profiles, often exhibiting the same repertoire of nine virulence-
associated genes (jimH,fyuA, iutA, K5, kpsMTII, PAl, traT, uidA and usp). PAl, papEF, kpsMTII 
and K5 were found to be significantly more common among these isolates than in diverse isolates 
with CTX-M-15-like /3-lactamases. 
9. Summary 
Non-clonal isolates with CTX-M-15-like /3-lactamase were multi-drug resistant, exhibiting a 
similar phenotype to that of epidemic clones A-E. The blacrx-M gene was mediated by IncFII 
plasmids among the vast majority of these non-clonal isolates, and was linked to various other 
antibiotic resistance genes such as blaTEM-h blaoxA-l and aac(6 ,)-Ib-cr. It was also shown that the 
plasmids encoding CTX-M ESBLs in the majority of non-clonal isolates shared additional features 
in common with those of the clonal isolates; e.g. the origins of replication and the plasmid 
addiction system ccdAlccdB. Cross-hybridization studies strongly suggested that closely-related 
plasmids were spreading between clonal and non-clonal isolates. Finally, most of these producers 
of CTX-M-15-like enzymes belonged to an extra-intestinal virulent phylogenetic group (mostly 
B2). They did not appear to carry more virulence factor genes than isolates producing non-CTX-M 
ESBLs, but a collection of eight virulence traits, including the urinary tract adhesin-encoding gene 
afaldraBC, was consistently exhibited by many of the non-clonal CTX-M-producers. 
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Chapter III . Molecular characterisation of Escherichia coli isolates with 
phylogenetic group-2, -8 and -9 CTX-M beta-Iactamases 
1. Introduction 
The majority of blacrx-M genes detected among clinical isolates referred to ARMRL between 
2003 and 2006 were phylogenetically typed by PCR (Woodford, N. et al., 2006). Among E. coli 
isolates, group-l CTX-M 13-lactamases (mostly CTX-M-15) were overwhelmingly the predominant 
type recorded, representing approximately 85% of all CTX-M enzymes. Most of the remaining 
blacrx-M genes detected encoded group-9 CTX-M enzymes, while only a few sporadic isolates 
harboured group-2 (n=8) or group-8 (n=2) -encoding blacrx-M genes. None of the referred E. coli 
clinical isolates was found to carry a blacrx-M-2s126-like gene. 
Table 21 summarises the geometric mean MICs for isolates with group-2, -8 or -9 CTX-M 13-
lactamases. The CTX-M phenotype was evident among the three groups of isolates, with high-level 
cefotaxime resistance and synergy between clavulanate and third-generation cephalosporins. 
Ceftazidime MICs for these isolates were low (especially when compared with those for producers 
of CTX-M-1S 13-lactamases). While approximately 85% of E. coli isolates with group-l CTX-M 
enzymes required ceftazidime MICs above the BSAC breakpoint (2 mgIL), only c. 28% of group-9 
CTX-M producers were resistant to that antibiotic. Similarly, ciprofloxacin resistance (MIC > 1 
mgIL) was not as common among isolates with CTX-M-9-like enzymes (44%) as it was among 
isolates with CTX-M-15-like enzymes (95%). Isolates with group-2 or -9 CTX-M enzymes were 
variably resistant to aminoglycosides (c. 50% and 33% were resistant to gentamicin, respectively), 
and most remained susceptible to amikacin. Both isolates with group-8 CTX-M enzymes were 
susceptible to aminoglycosides. Carbapenems alone retained their full activity against all these 
isolates. 
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Table 21. MIC ranges and geometric mean (GM) MIC (mg/L) for E. coli isolates with group-
2, -8 or -9 CTX-M enzymes 
Isolates with group-2 Isolates with group-8 Isolates with group-9 
R>a 
CTX-M enzymes CTX-M enzymes CTX-M enzymes 
(n=8) (n=2) (n=127) 
Range GM Range GM Range GM 
AMP 16 > 64 64 > 64 64 64 - >256 66.2 
AUG 16 8 - 32 19.5 8 - 16 11.3 4 - 64 14.4 
CTX 32 - >256 64 64 64 16- >256 79.6 
CTX/CLA 0.125 - 1 0.2 0.06 - 0.25 0.1 ~.06 - 4 0.2 
CTZ 2 2 - 16 4 1 - 4 2 0.5 - 64 1.9 
CTZ/CLA 2 0.25 - 2 0.6 0.25 - 0.5 0.4 ~.06 - 4 0.3 
CPM 16 - 64 22.6 16 16 1 - 64 8.6 
CPM I CLA ~.06 - 0.125 0.1 0.125 0.125 ~.06 - 0.25 0.1 
FOX 8 8 - 64 13.1 8 - 64 22.6 2 - 64 14 
PIP 16 64 64 64 64 64 - 256 64.7 
PIP/TZB 16 2 - 64 4.6 4 - 8 5.7 2 - 64 4.3 
ETP 2 0.125 0.125 0.125 0.125 ~.125 - 0.5 0.14 
IPM 4 0.125 - 0.5 0.14 0.125 0.125 ~0 .06 - 0.5 0.18 
MEM 4 0.06 0.06 0.06 0.06 0.06 0.06 
CIP ~.125- >8 1.2 8 8 ~. 125 - >8 0.9 
AMK 16 1 - 16 2.4 1-4 2 1 - >64 2.3 
GEN 4 0.5 - >32 6.6 0.5 0.5 0.5 - >32 2.7 
MIN 8 1 - 32 4 1 - 2 1.4 0.25 - 32 5.2 
COL 4 ~.5-2 0.5 ~.5 -1 0.7 ~.5-4 0.6 
a BSAC breakpoints defining resistance (Andrews, 1. M., 2007) 
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Overall, although many of the antibiotics tested against E. coli isolates with group-2, -8 or -9 CTX-
M enzymes showed reduced efficacy, these organisms did not appear as resistant as the group-l 
CTX-M-producers (e.g. lower MICs of piperacillinitazobactam, ciprofloxacin .. . etc). Moreover, 
antibiograms of isolates with CTX-M-9-like enzymes were more variable, especially regarding 
ceftazidime, ciprofloxacin and gentamicin. 
The molecular epidemiology, as well as the molecular characterisation of antibiotic 
resistance mechanisms and virulence genes among representative isolates with group-2, -8 or -9 
CTX-M 13-lactamases was investigated in detail. Transfer of cefotaxime resistance by conjugation 
and electroporation was attempted, in addition to plasmid profiling, and to localization of the 
blacrx-M genes. Randomly selected blacrx-M genes were cloned and fully sequenced; their genetic 
environment is discussed in the next chapter (Chapter N). 
2. E. coli isolates with CTX-M-9-like 8-lactamases 
2.1. Molecular epidemiology 
Group-9 CTX-M enzymes were the second most common CTX-M types detected among E. coli 
isolates in the UK. Although not as prevalent as those with group-l CTX-M, their host organisms 
were still widely referred to ARMRL from across the UK and therefore, it became important to 
understand their epidemiology. A representative sample of twenty clinical isolates, with each one 
being selected from a different UK centre, was subjected to PFGE in order to identify potential 
national epidemic clones; the digestion profiles for 19 isolates were analysed with the BioNumerics 
software as shown in Figure 34 (digestion of genomic DNA for one isolate was not successful). All 
19 genomic XbaI-digestion profiles shared less than 85% similarity, indicating that none of the 
investigated isolates were clonally related. Most isolates shared between 50 and 70% similarity in 
their genomic digestion profiles. Although these isolates might have been involved in local 
outbreaks, it seemed unlikely there was a major national epidemic clone with CTX-M-9-like 
enzyme in the UK. 
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Figure 34. Cluster analysis of PFGE fingerprints of representative E. coli isolates with CTX-
M-9-like enzymes 
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2.2. DNA sequencing of selected blacTX-M-9-like genes 
The complete blacrx-M open reading frame from the 20 representative isolates with CTX-M-9-like 
enzymes was amplified, and four of these were cloned into pCR2.1 and sequenced fully. Two 
corresponded to blacrx-M-9 (representative isolates 11 and 19) and the remaining two encoded CTX-
M-14 (representatives 2 and 16). The blacrx-M-14 gene differs from blacrx-M-9 by four nuc1eotides 
(g372a, a570g, c701t and c702g), but the resulting proteins differ by one amino acid only, namely 
an Ala234Val substitution (see Figure 35). 
2.3. Localisation of the blacTX-M-9-like genes 
Plasmids from ten of the 20 representative isolates with blacrx-M-9-like genes were extracted by 
alkaline lysis for hybridization with a Dig-labelled blacrx-M probe, and also for transfer of 
cefotaxime resistance by electroporation. 
2.3.1. Plasmid extraction and hybridization studies 
The majority of isolates with CTX-M-9-like 13-lactamases investigated here harboured very few 
plasmids [Figure 36(A)]; most only had one or two. A similarly-sized plasmid of approximately 
150-kb was present in all ten representatives. However, hybridization of the blacrx-M probe to the 
plasmid extracts was inconclusive with regards to the localisation of the blacrx-M-9-like genes. The 
probe did not recognise any of the plasmids [Figure 36(B)], nor did it hybridize with the 
chromosomal DNA. Hybridization of the plasmids extracts from group-9 CTX-M-producers with 
the blacrx-M probe was repeated twice more, but no positive results were obtained, except with the 
Dig-labelled A.-HindlIl DNA (positive-control), which was successfully detected in each case_ 
Since no blacrx-M gene was detected by hybridization, it was inferred that these genes were 
possibly harboured by very large plasmids (>200-kb), which are generally not efficiently extracted 
by conventional alkaline lysis, a problem exacerbated by the often low copy-number of such 
plasmids. In support of this, the blacrx-M probe hybridized to the DNA left in some loading wells 
[Figure 36(B)]. 
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Figure 35. Amino acid sequence alignment of CTX-M-9 and CTX-M-14 enzymes 
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Figure 36. (A) Plasmid extracts of representative clinical isolates with CTX-M-9-like enzymes and (B) Southern blot of plasmid extracts hybridized with the 
Dig-labelled blacTX_M probe 
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2.3.2. Cefotaxime resistance transfer 
Since hybridization studies did not successfully localise the blacrx-M-9Iike genes, conjugative transfer 
of cefotaxime resistance from one CTX-M-9-producer (isolate 19) and one CTX-M-14-producer 
(isolate 16) was attempted_ 
The transfer was successful in both cases, and was confIrmed both by PCR and by 
antibiotic susceptibility testing of the resulting transconjugants. The conjugative transfer 
frequencies were low however; 3.5 x 10-5 and 6 x 10-8 for isolates 19 and 16, respectively. Both 
blacrx-M-9 and blacrx-M-14 genes were therefore plasmid-mediated. Furthermore, as the transfer rates 
of these vectors were low and since the blacrx-M-9-like genes were not detected by hybridization of 
plasmids extracted by alkaline lysis, those blacrx-M genes were likely to be encoded by very large 
low-copy number plasmids. 
2.4. Antibiotic susceptibility testing of transconjugants 
MICs for the transconjugants derived from representative clinical isolates 16 and 19 (respectively 
named TCl6 and TC19) are summarised in Table 22. 
The CTX-M phenotype was evident among both the plasmid donors and their derived 
transconjugants. Clinical isolate 16 was resistant to ciprofloxacin and to minocycline, but these 
were not co-transferred into E. coli J53-2 along with the CTX-M phenotype. Except for drugs 
affected by the CTX-M-9 enzyme itself, isolate 19 remained susceptible to most of the antibiotics 
tested. Moreover, MICs of ceftazidime were relatively low reflecting the fact that CTX-M-9-like 
enzyme variants are poorly effective against ceftazidime, though still responsible for reducing 
susceptibility to this antibiotic. 
Overall, the plasmids encoding CTX-M enzymes from both isolates 16 and 19 did not 
appear to encode resistance to classes of antibiotics other than those affected by the CTX-M-9 or -
14 f3-lactamases. Also, susceptibility to piperacillinltazobactam indicated no OXA-type enzyme 
was likely to be co-encoded with the blacrx-M-9-like gene (by contrast with most isolates producing 
CTX-M-15 f3-lactamases). 
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Table 22. MICs (mgIL) for E. coli strain J53-2, representative clinical isolates 16 and 19 and 
their derived cefotaxime-resistant transconjugants 
Clinical isolates Recipient Transconjugants 
16 19 J53-2 TC16 TC19 
(CTX-M-14) (CTX-M-9) (CTX-M-14) (CTX-M-9) 
AMP >64 >64 4 >64 > 64 
AUG 8 16 4 8 8 
CTX 256 64 ~.125 > 64 32 
CTX I CLA 0.25 0.125 ~.060 ~.060 0.125 
CAZ 1 2 ~.125 2 1 
CAZ/CLA 0.25 0.25 ~.060 0.125 0.25 
FOX 32 8 4 4 8 
PIP 64 >64 ::S;;1.0 >64 >64 
PIP/TZB 4 2 ::s;;1.0 ::s;;1.0 2 
ETP ~.125 ~.125 ~.125 ~.125 ~.125 
IPM 0.125 0.125 0.125 0.125 0.25 
MEM ~.06 ~.06 ~.060 ~.060 ~.060 
CIP >8 ~.125 ~.125 ~.125 ~.125 
AMK 1 1 1 2 1 
GEN 2 0.5 0.5 1 1 
TOB ND8 ND8 0.5 2 1 
MIN 32 1 2 1 0.5 
COL ~.5 ~.5 ~.5 ~.5 ~.5 
8 ND = not detennined 
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2.5. Additional antibiotic resistance mechanisms 
2.5.1. fj-Lactamase production 
The production of additional 13-lactamases by the 20 representative isolates with CTX-M-9-like 
enzymes was sought by IEF and conflrmed by PCR. Results are summarised in Table 23. 
IEF identifled two types of 13-lactamase with approximate pI values of 5.4 and 8.0 among 
the 20 representative isolates. All 20 isolates had a band at c. pI = 8.0, which surely corresponded 
to the CTX-M-9-like enzyme; CTX-M-9 and CTX-M-14 13-lactamases have very close pI values 
(they differ by one un-ionised amino acid only, http://www.lahey.org/studies/other.htm): 8.0 and 
8.1, respectively, and such small variation might not be distinguishable by IEF. Half the 
investigated isolates produced an additional enzyme with a pI value of 5.4, probably TEM-l. 
All 20 isolates were screened in parallel by PCR for the presence of blaoxA-I-like, blaSHV (all 
ORFs) and blaTEM (all ORFs) genes. While none of the isolates had blaoXA-I-like or blasHV, blaTEM 
was detected in the ten isolates with the pI 5.4 band, thus correlating with the IEF results. 
2.5.2. Resistance to aminoglycosides 
According to antibiotic susceptibility testing, gentamicin was variably active against isolates with 
CTX-M-9-like enzymes, and amikacin remained active against 19/20 (amikacin MIC ~8 mg!L). 
Both aac(6 J-Ib and aac3-IIa genes were sought by PCR among all 20 representatives and 
results are summarised in Table 23, along with amikacin and gentamicin MICs. One isolate only 
(4) had reduced susceptibility to amikacin (MIC = 16 mg!L), and PCR conflrmed this 
representative to harbour the aac(6 J-Ib gene. The remaining 19 isolates remained fully susceptible 
to amikacin, and tested negative for aac(6 J-Ib. Furthermore, it is worth mentioning that 
representative isolate 4 was likely to harbour the classical aac(6J-Ib gene, as indicated by PCR-
RFLP, and not the aac(6J-Ib-cr variant, which encodes the aminoglycoside acetyltransferase 
cross-reacting with ciprofloxacin. 
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Table 23. Summary oflEF and PCR results, and of aminoglycosides MICs for representative 
E. coli isolates with CTX-M-9-like I3-lactamases 
IEF results PCR results 
Isolate no. of pI values· blaTEM aac(6')-ID bands Ib 
1 1 8.0 
21i 1 8.0 
3 2 5.4 8.0 + 
4 1 8.0 + 
5 2 5.4 8.0 + 
6 1 8.0 
7 2 5.4 8.0 + 
8 1 8.0 
9 2 5.4 8.0 + 
10 1 8.0 
H C 2 5.4 8.0 + 
12 1 8.0 
13 1 8.0 
14 2 5.4 8.0 + 
15 2 5.4 8.0 + 
166 1 8.0 
17 2 5.4 8.0 + 
18 2 5.4 8.0 + 
19c 1 8.0 
20 2 5.4 8.0 + 
a pI ofTEM-1 is 5.4; pI ofCTX-M-9 and ofCTX-M-14 is c. 8.0 
b Isolates with CTX-M-14 enzyme 
C Isolates with CTX-M-9 enzyme 
aac3-IIa 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
MICs (mg/L) 
AMK GEN 
2 1 
2 >32 
2 1 
16 8 
2 >32 
8 4 
1 >32 
2 0.5 
2 >32 
2 2 
4 4 
2 >32 
2 4 
1 0.5 
4 32 
1 0.5 
2 >32 
1 >32 
1 2 
2 >32 
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Gentamicin resistance was more common than amikacin resistance among these isolates; 9/20 had 
the gentamicin resistance-encoding gene aac3-IIa based on PCR, and these results correlated with 
their high gentamicin MICs (> 32 mg/L). Most of the remaining 11 isolates, which tested negative 
for aac3-IIa, required gentamicin MICs :Q mg/L only. 
2.6. Phylogenetic typing and screening for virulence factor genes 
Twenty-four randomly-selected clinical E. coli isolates with CTX-M-9-like 13-lactamases from 
across the UK were phylogenetically typed, and their virulence factor profiles were examined. Nine 
of these (isolates 2, 4, 5, 10, 14-17 and 19) had been investigated previously for antibiotic 
resistance mechanisms. 
The majority of isolates (17/24, 71 %) belonged to a virulent extra-intestinal phylogenetic 
group (B2 or D); 12 (50%) belonged to phylogenetic group D and five (21 %) to phylogenetic group 
B2. Six (25%) were typed as commensal group A isolates and one (4%) belonged to the non-
virulent phylogenetic group B 1. 
On average, E. coli producing CTX-M-9-like 13-lactamases harboured seven virulence 
factor genes per isolate. Phylogenetic group B2 and D isolates harboured more virulence-associated 
genes than their commensal counterparts (from groups A and Bl). Isolates from phylogenetic 
groups B2 and D had on average 10 and 7 virulence genes per isolate, respectively, compared with 
four and three for phylogenetic groups A and Bl isolates. Thirteen of the 24 isolates (54%) were 
defined as ExPEC; predictably this trait was significantly less common among commensal isolates 
with CTX-M-9 enzymes (2/7, 29%) than among their virulent counterparts [11117, 65% (p value < 
0.0001)]. Most ExPEC isolates (10/13, 77%) were defined as such by the presence of iutA and 
kpsMTII (Table 24); afaldraBC (also a marker of ExPEC isolates) was detected in six isolates 
producing CTX-M-913-lactamases (25%). 
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Table 24. Prevalence of virulence factor genes among E. coli isolates (n=24) with CTX-M-9-
like enzymes 
Virulence gene Prevalence of gene (% of total) 
aJa/draBC 6 (25%) 
bmaE 1 (4%) 
cnfl 2 (8%) 
fimH 22 (92%) 
JocG 1 (4%) 
fyuA 19 (79%) 
gajD 1 (4%) 
ibeA 1 (4%) 
iutA3 13 (54%) 
Kl 1 (4%) 
K5 12 (50%) 
kpsMTIl' 13 (54%) 
kpsMTllI 0(0%) 
nJaE 0(0%) 
ompT 3 (13%) 
PAl 4 (17%) 
papA3 1 (4%) 
papC 6 (25%) 
papEF 2(8%) 
papG allele II 2 (8%) 
papG allele III 2 (8%) 
papGI 1 (4%) 
papG If, III 4 (17%) 
rJc 0(0%) 
sJalfocD£I 2 (8%) 
sJaS 2 (8%) 
traT 18 (75%) 
uidA 21 (88%) 
usp 5 (21%) 
a Key virulence gene marker of ExPEC isolates 
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Seven of the thirty-three virulence factor genes sought by PCR were not detected among 
any of the 24 E. coli producing group-9 CTX-M enzymes (Table 24). These were: cdtB, cvaC, 
hlyA, kpsMTIII, papG allele I, nfaE and rfc. Overall, isolates belonging to phylogenetic groups B2 
or D showed very similar virulence profiles. The most prevalent virulence genes (~50% 
prevalence) includedfimH,JYuA, iutA, K5, kpsMTII, traTand uidA. All these were found together, 
sometimes along with additional virulence genes, in six isolates (25%), always from a virulent 
phylogenetic background (B2 or D). 
3. E. coli isolates with group-2 CTX-M tJ-lactamases 
At the time of this investigation, ARMRL had been referred only three E. coli isolates with group-2 
CTX-M 13-lactamases, each from a different centre (Milton Keynes, Manchester and Welwyn 
Garden City). Five more isolates (from four new centres: Jersey, Hereford, Birmingham and 
Sutton-in-Ashfield) have since been referred, but these were not included in the molecular and 
biochemical investigations. 
All eight isolates with group-2 CTX-M enzymes had antibiograms consistent with the 
production of CTX-M ESBLs, and all remained susceptible to carbapenems (Table 21). The three 
representative isolates investigated here were also resistant to gentamicin (MIC ~16 mg/L). One 
isolate only remained fully susceptible to ciprofloxacin (MIC = 0.25 mgIL), while one was resistant 
(MIC> 8 mgIL), and the last showed reduced susceptibility (MIC = 1 mglL) to this antibiotic. 
3.1. PFGE of XbaI-digested genomic DNA 
XbaI-digested genomic DNA profiles of the three E. coli representatives with CTX-M-2-like 
ESBLs (Figure 37) shared less than 85% similarity according to a BioNumerics analysis, indicating 
that they were not clonally related. 
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Figure 37. PFGE of XbaI-digested genomic DNA of clinical E. coli isolates with CTX-M-2-like 
enzymes 
B 
u 
-
= 
'" 
~ 
~ "Cl 
= 
- -
» 
-
= ~ ~ C,!) ~ .... 
'" ~ ~ = .Cl C (j .... 
= ~ = ~ 6 6 ~ 
...-I N ~ 
~ ~ ~ 
.... .... .... 
= = = 
"0 "0 "0 
'" '" '" ..... ..... ..... 
294-kbp 
242.5-kbp 
194-kbp 
145.5-kbp 
97-kbp 
48.5-kbp 
199 
3.2. DNA sequencing of hlacTX-M-l-like genes 
The entire blacrx-M genes from the three isolates were amplified, cloned into the pCR2.1 vector and 
sequenced. All three DNA sequences were 100% identical and corresponded to the classical blacrx-
M-2 allele. 
3.3. Localisation of the hlacTX-M-2 genes 
Plasmids were extracted by alkaline lysis for hybridization and for cefotaxime resistance transfer 
studies. 
3.3.1. Plasmid extraction profiles and hybridization studies 
The three CTX-M-2-producing isolates had different plasmid profiles. None of the plasmids 
hybridized with the dig-labelled blacrx-M probe [Figure 38 (A and B)]. This suggested the blacrx-M-
2 genes were harboured either by very large plasmids (>200-kb) or by the bacterial chromosome. 
However, the probe did not hybridize strongly enough to the chromosomal DNA to unequivocally 
support chromosomal carriage of the genes. Therefore, it remained most likely that the blaCTx-M-2 
genes were carried by very large plasmids, which are prone to shearing during the alkaline lysis 
procedure (the sheared fragments then migrate with the sheared chromosomal DNA, causing the 
weak hybridization). 
Since hybridization of plasmid extracts was not convincing, the total genomic DNA 
(including both chromosome and plasmids) from the three isolates was also extracted. It was then 
digested with BamHI (there is no BamHI restriction site within the blacrx-M-2 gene) for 
hybridization purposes [Figure 38 (C and D)]. This experiment confirmed the presence of the 
blacrx-M genes in the genome of the three isolates, as the probe strongly hybridized to restriction 
fragments at approximately 2.I-kb in each case. Additional and very weak hybridization signals 
detected were likely to be associated with partially digested DNA fragments containing the 
blacrx-M gene. 
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Figure 38. (A) Plasmid extracts of representative E. coli isolates with CTX-M-2 ESBLs and (B) Southern blot of plasmid extracts hybridized with Dig-labelled 
blacrx_M; (C) BamID-digested total genomic DNA of representative E. coli isolates with CTX-M-2 ESBLs and (0) Southern blot hybridised with Dig-labelled 
blaCTX_M probe 
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3.3.2. Cefotaxime resistance transfer 
Transfer of cefotaxime resistance by conjugation was not achieved in three separate attempts, nor 
was transfer by electroporation of plasmids extracted by alkaline lysis. This might been explained 
by (i) the plasmids being non-conjugative and/or (ii) plasmids shearing during the extraction 
procedure (due to their size), leaving no viable material to be transferred even by electroporation. 
3.4. Additional antibiotic resistance mechanisms 
3.4.1. Additional {3-lactamase production 
Production of additional {3-lactamases among the three CTX-M-2-producing isolates was sought by 
IEF. All three bacterial cell extracts showed a similar band at c. pI = 7.9, which according to the 
literature (http://www.lahey.org/studies/other.htm) was consistent with CTX-M-2 ESBL. In 
addition, isolate 1 had a second {3-lactamase with a pI of 5.4, which was anticipated to be TEM-l. 
None of the three isolates harboured blasHV or blaoXA-l-like genes based on PCR assays. Isolate I 
was positive for blaTEM, and this gene was absent from the remaining two isolates, correlating with 
IEF results. 
3.4.2. Resistance to aminoglycosides 
All three isolates were resistant to gentamicin (MIC ~16 mg/L), but remained fully or moderately 
susceptible to amikacin (MICs comprised between 1 and 4 mg/L). Gentamicin resistance was 
associated with aac3-IIa in all three cases as shown by PCR. The aae(6')-Ib gene was also detected 
by PCR, but in isolate 1 only (amikacin MIC for isolates 1 =4 mg/L, vs. 1 mg/L for isolates 2 and 
3). The amplicon was subjected to RFLP with NdeI and FokI, and only the latter enzyme digested 
the PCR product, indicating that the allele was not the er variant, but rather a classical aae(6 ')-Ib 
variant. 
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3.5. Phylogenetic typing and screening for virulence factor genes 
The three CTX-M-2-producing isolates investigated appeared completely unrelated, each belonging 
to a distinct phylogenetic group: Bl (isolate 1), A (isolate 2) and D (isolate 3). 
Both the isolates typed as belonging to commensal groups (isolates 1 and 2) harboured 
only two of the 33 virulence factor genes sought by PCR; specifically fimH and traT. The virulent 
isolate 3 had nine virulence genes: cvaC, fimH, fyuA, ibeA, iutA, KJ, kpsMTII, traT and the 
pathogenicity-associated island. This isolate met the criteria for an extra-intestinal pathogenic E. 
coli, since it harboured both the ExPEC markers iutA and kpsMTII. 
4. E. coli isolates with unusual CTX-M enzymes 
Two very unusual E. coli isolates with CTX-M enzymes were referred to ARMRL during this 
investigation. One had a group-8 CTX-M /3-lactamase and the other had both a group-! and a 
group-9 CTX-M enzymes. These were investigated in detail, and compared with more typical 
CTX-M-producers from the UK. 
4.1. E. coli isolate with group-8 CTX-M p-Iactamase 
The isolate with a group-8 CTX-M enzyme had a typical CTX-M phenotype, i.e. high-level 
resistance to cefotaxime and synergy of clavulanate with oxyimino-cephalosporins. It was also 
resistant to ceftazidime, but only at a low level (MIC =4 mg/L). This isolate remained susceptible 
to carbapenems and to aminoglycosides, but was highly resistant to ciprofloxacin (MIC> 8 mg/L). 
PFGE showed this isolate was unrelated «85% homology) to any of the five major 
epidemic E. coli strains producing C.TX-M-IS ESBLs, as expected. 
4.1.1. Antibiotic resistance mechanisms 
DNA sequencing revealed the isolate harboured blacrx-M4o, a variant described only once before in 
an E. coli isolate dating from 1999, also from a UK patient (Hopkins, K. L. et al., 2006b). IEF and 
PCR assays showed the isolate did not produce additional /3-lactamase enzymes, such as TEM, 
203 
SHY or OXA-l-like enzymes. The aac(6 ')-Ib and aac3-IIa genes, which are respectively 
responsible for resistance to tobramycin and gentamicin, were absent from this isolate based on 
PCR assays. This finding correlated with the antibiotic susceptibility testing results, which 
indicated susceptibility to all aminoglycosides. 
4.1.2. Localisation of blacrx-M-4o 
Plasmid extraction by alkaline lysis revealed that this isolate harboured at least eight plasmids 
ranging in size from approximately l-kb to 150-kb. Transfer of cefotaxime resistance by 
conjugation or by electroporation was unsuccessful despite three separate attempts at each method. 
Moreover, none of the eight plasmids, nor the chromosomal DNA hybridized with the blacrx-M 
probe. Nevertheless, the presence of the blacrx-M gene in the genome of this isolate was confirmed 
by PCR, and by hybridization of its BamHI-digested total genomic DNA, in which the gene was 
harboured by a digested DNA fragment of approximately 2.1-kb. All this suggested blacrx-M4o was 
possibly mediated by a very large plasmid (>200-kb). 
4.1.3. Phylogenetic typing and screening for virulence genes 
The CTX-M-40-producing E. coli isolate belonged to the virulent phylogenetic group D and was 
defined as an ExPEC. It harboured seven of the 33 virulence factor genes investigated, namely 
ajaldraBC,jimH,fyuA, iutA, traT, uidA and usp. 
4.2. E. coli isolate with two CTX-M ~-lactamases 
This unusual E. coli isolate, which harboured two blacrx-M genes (encoding group-l and group-9 
CTX-M enzymes) according to PCR, was a multi-drug resistant organism with a typical CTX-M 
phenotype. It required a cefotaxime MIC above 256 mg/L, which was decreased to 0.5 mg/L in 
presence of c1avulanate at 4 mglL. The isolate was also highly resistant to ceftazidime (MIC =64 
mg/L), a feature associated with a few CTX-M variants such as CTX-M-15. Other antibiotics to 
which the isolate was resistant included ciprofloxacin (MIC >8 mg/L), gentamicin (MIC >32 
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mgIL) and minocycline (MIC =32 mgIL). It had reduced susceptibility to amikacin (MIC =4 
mgIL), and remained susceptible to carbapenems, as did most E. coli isolates with CTX-M ESBLs. 
The XbaI-digested genomic DNA profile of this isolate was less than 85% similar to those 
of the five major VI( epidemic strains with CTX-M-15 ESBLs, indicating that it did not belong to 
any ofthe major clones. 
4.2.1. Antibiotic resistance mechanisms 
Both blacrx-M genes were amplified and cloned into the pCR2.1 vector. DNA sequencing indicated 
this isolate was producing simultaneously the group-9 enzyme CTX-M-14 and the group-l enzyme 
CTX-M-15. IEF indicated the isolate had four f3-lactamases in total, with approximate pI values of 
5.4, 7.4, 8.1 and 8.6. The latter two corresponded to CTX-M-14 and CTX-M-15 enzymes, 
respectively. PCR assays confirmed this isolate also harboured the blaTEM and blaoXA-l-like genes, 
but not bias IN, correlating with IEF results. Synergy between tazobactam and piperacillin was poor 
(MIC = 16 mgIL), correlating with the presence of an OXA-type enzyme. 
Gentamicin resistance was associated with the presence of an AAC3-IIa enzyme, as PCR 
detected the presence of the aac3-IIa gene. Also, PCR-RFLP and DNA sequencing showed this 
isolate harboured the aac(6')-Ib-cr variant, which encodes the ciprofloxacin-modifying 
aminoglycosides acetyltransferase variant. 
4.2.2. Localisation of blacrx-M-14 and blacrx-M-Is 
Plasmid extraction by alkaline lysis indicated the isolate harboured at least two plasmids of c. 70-
and 150-kb. Only the latter hybridized with the Dig-labelled blacrx-M probe [Figure 39(A and B)]. 
Conjugative transfer of cefotaxime resistance was not attempted with this isolate. The blacrx-M-ls 
gene only was successfully transferred to E. coli DHSa by electroporation, as confirmed by PCR. 
Transfer of blacrx-M-14 by electroporation was not achieved after three separate attempts. Based on 
hybridization of the plasmid extract of the cefotaxime-resistant transformant, blacrx-M-ls was 
mediated by the c. lS0-kb plasmid, and was not linked to blacrx-M-14. 
205 
N 
o 
0\ 
Figure 39. (A) Plasmid extracts of the E. coli isolate with two CTX-M ESBLs and (B) Southern blot of its plasmid extract hybridized with the Dig-labelled blac-rx_M probe; (C) 
BamHI-digested total genomic DNA of the E. coli isolate with two CTX-M ESBLs and (D) Southern blot hybridised with the Dig-labelled blac-rx_~1 probe 
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The presence of two blacrx-M genes among the genome of this isolate was confIrmed by 
hybridizing its BamHI-digested total genomic DNA with the Dig-labelled blacrx-M probe [Figure 
39(C and D)]. Two strong signals at c. 2.1- and 6.5-kb indicated this isolate clearly harboured two 
blacrx-M genes. Although blacrx-M-14 was not successfully localised, it appeared that this gene was 
possibly mediated by a very large plasmid (>200-kb), prone to shearing under the alkaline 
conditions during plasmid extraction. 
4.2.3. Phylogenetic typing and screening for virulence genes 
The E. coli clinical isolate harbouring both blacrx-M-14 and blacrx-M-15 genes belonged to the virulent 
phylogenetic group D. It harboured eight virulence factor genes (aJa/draBC, fimH, fyuA, iutA, 
KpsMTlI, traT, uidA and usp) and was defIned as an ExPEC. 
5. Summary 
On a national scale, E. coli with CTX-M enzymes other than the CTX-M-15 variant account for 
about 15% only of referrals of CTX-M-positive isolates. Nevertheless, at a local level, these 
organisms may be more prevalent than E. coli isolates with CTX-M-15-like enzymes in some 
centres. 
Although many of these isolates were resistant to l3-lactams, aminoglycosides and 
fluoroquinolones, they did not appear as resistant as the producers of CTX-M-15-like enzymes in 
general. Also, the antibiotic resistance profIles were very diverse among isolates with CTX-M-9-
like enzymes by comparison with CTX-M-15-producers, but both these groups of isolates still 
shared similar mechanisms of antibiotic resistance. The blacrx-M-9-like genes were found to be 
plasmid-mediated among the representative isolates with CTX-M-9-like l3-lactamase investigated, 
and it seemed likely to be the case also for blacrx-M-2 and blacrx-M-4o. Finally, most of the isolates 
with non-group-l CTX-M enzymes investigated in this study belonged to virulent phylogenetic 
groups, and most shared similar virulence profIles. 
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Chapter IV . Genetic environment of blacTx-M genes 
CTX-M ESBLs are divided into five phylogenetic groups (group-I, -2, -8, -9 and -25/26). 
Enzyme variants from each of these five groups have been reported in the UK (see below), 
indicating different and independent introductory events took place: 
Group-l CTX-M enzymes: e.g. CTX-M-15, first reported in 2001 in E. coli isolates 
from London, Newcastle-upon-Tyne and Belfast (Mushtaq, S. et al., 2003) 
Group-2 CTX-M enzymes: e.g. CTX-M-2, first reported in 2006 in E. coli strains 
isolated in 2004/2005 from Milton Keynes and Manchester (Karisik, E. et al., 2006b) 
Group-8 CTX-M enzymes: e.g. CTX-M-40, first described from an E. coli strain 
isolated in 1999 (Hopkins, K. L. et al., 2006b) 
Group-9 CTX-M enzymes: e.g. CTX-M-9, first reported in a K. oxytoca isolate from 
2000 in Leeds (Alobwede, I. et al., 2003) 
Group-25/26 CTX-M enzymes: e.g. CTX-M-25, first described in a K. pneumoniae 
isolate involved in a hospital outbreak in Birmingham in 2001 (Brenwald, N. P. et al., 
2003) 
In this study, only CTX-M enzymes from the E. coli clinical isolates referred to ARMRL 
were investigated. These included the CTX-M-2, -3, -9, -14, -15 and -40 variants, representing the 
phylogenetic group-I, -2, -8 and -9. Until now, no isolates with phylogenetic group-25/26 CTX-M 
enzymes had been referred to ARMRL and thus, none was investigated; indeed enzymes from this 
phylogenetic group are extremely rare, having been reported twice only, in Canada and in the UK 
(Brenwald, N. P. et al., 2003; Munday, C. J. et al., 2004a). 
It has now been established that blacrx-M genes have escaped from the chromosome of 
various Kluyvera species; e.g. the plasmid-mediated blacrx-M-2 gene shares >95% sequence 
homology with the chromosomally-encoded blaKLuA of K. ascorbata (Humeniuk, C. et al., 2002) 
and the KLUY-l{3-lactamase of K. georgiana exhibits complete amino acid identity with the CTX-
M-I4 variant (Olson, A. B. et al., 2005). 
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Exploring the genetic surroundings of blacrx-M genes has played a major role in the discovery of 
their origin, as well as in the understanding of the mobilization mechanisms involved in their 
escape. Such investigation may also play a significant role for epidemiological purposes. The 
genetic environments of blacrx-M-2, blacrx-M-3, blacrx-M-9, blacrx-M-14, blacrx-M-15 and blacrx-M4o in 
various representative UK isolates were therefore examined. 
1. Genes encoding group-1 CTX-M enzymes 
The genetic surroundings of the group-l CTX-M-encoding genes blacrx-M-3 and blacrx-M-15 were 
investigated. These genes have previously been shown to be linked to ISEcpJ-like insertion 
sequence elements (Karim, A. et al., 2001; Lartigue, M. F. et al., 2004; Woodford, N. et al., 2004), 
which, as well as being involved in the initial mobilization, also provides a strong promoter, 
allowing their expression (Karim, A. et al., 2001). The spacer region between ISEcpJ and the 
blacrx-M-3/-1S genes was therefore examined among representatives E. coli isolates. It should be 
added that E. coli epidemic clone A had previously been shown to harbour an IS26 element, 
located between the blacrx-M-15 gene and the promoter provided by ISEcpJ [see Figure 40, 
(Woodford, N. et al., 2004)] and so its impact on the level of expression of blacrx-M-15 was also 
explored. Whilst this insertion was always present in epidemic clone A isolates typed by PFGE, it 
was not specific to that clone. Rather, this element had also been detected at that same position 
among a few clonally related E. coli isolates from a single centre (Hope, R., personal 
communication). 
1.1. ISEcpl-blacTX-M-3/-1S spacer region 
While investigating 13-lactamase production by IEF, and more especially, when confirming the 
presence of blacrx-M genes by PCR among various clonal and non-clonal E. coli isolates using the 
primer pair CTX-Morf F (prom+)/CTX-Morf R (preCTX-M-3B), three different types of PCR 
product with sizes of c. 1.1, 1.2 and 2-kb were obtained (Figure 41). This led to further 
investigation. 
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Figure 40. Schematic representation of the genetic environment of blocrx-M- Is in UK E. coli 
epidemic clone Aa 
r 'o,m, , ."mo'" 
[826 blacrX-M-15 
a (Woodford, N. et al., 2004). 
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Figure 41. Agarose gel electrophoresis showing the different types of blac rx_M ORF PCR 
products obtained with various clonal and non-clonal E. coli isolates producing CTX-M-lS-
like f3-lactamases 
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The primer pair prom+/preCTX-M-3B was designed to anneal to the 3'-end of insertion sequence 
ISEcpl (located upstream of blacrx-M-3/-ls) and immediately downstream of blacrx-M-3/-ls, 
respectively. The expected PCR product of 1,106-bp included the entire blacrx-M ORF (poirel, L. et 
al., 2002a). This specific amplicon size was obtained with the vast majority of E. coli isolates with 
group-l CTX-M enzymes investigated here. However, epidemic clone A isolates yielded a much 
longer PCR product, of approximately 2,000-bp, owing to the insertion of IS26 between blacrx-M-Is 
and its normal promoter provided by ISEcpl (see Figure 40), as also previously shown by DNA 
sequencing (Woodford, N. et al., 2004). Finally, a third type of PCR product of approximately 
1,200-bp was obtained in a small number of cases; this was detected in a few E. coli isolates (either 
clone C or non-clonal isolates), all having been referred from Belfast City Hospital only. 
Nevertheless, it should be stressed that most clone C isolates and the majority of non-clonal isolates 
referred from Belfast City Hospital still yielded the expected I, 106-bp PCR product. 
DNA sequencing (using the primer pair prom+/preCTX-M-3B) of a representative c. 
1, lOO-bp amplicon (obtained with clonal isolate D I) revealed that blacrx-M-ls was located 48-bp 
downstream of the right-inverted repeat of ISEcpl. This 48-bp sequence (highlighted in red in 
Figure 42) was also detected upstream of the blacrx-M gene in a representative amplicon of c. 
1,200-bp (e.g. obtained with clonal isolate Cl), along with an additional 80 nucleotides (highlighted 
in light blue in Figure 42) located immediately downstream of ISEcpl and upstream the 48-bp 
sequence; the spacer region between the 3' -end of ISEcpl and the blacrx-M gene therefore measured 
128-bp in the 1,200-bp amplicon. Finally, the c. 2,000-bp amplicon from clone A isolates (e.g. AI) 
also harboured the same 48-bp link upstream of blacrx-M-Is (highlighted in red in Figure 43), with; 
the IS26 element (c. 800-bp) located immediately upstream of this link, moving blacrx-M-Is further 
away from its normal promoter, located at the 3'-end oflSEcpl. 
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Figure 42. Partial DNA sequence alignment of the 3'-end of the ISEcpl-h/acrx_M spacer 
regions from representative clonal isolates Cl and DI a 
3'-end ofISEcpl 
~-----------~-----------, 
· ... I •... I .... I ... • I •..• I .... I •..• I ••.• I •.•. I .•.• I 
160 170 180 190 200 
· . .. I •..• I ..•. I ..•. I .. • . I ...• I .... I • . •• I ... • I •.•. I 
210 220 230 240 250 
· ... I . •.. I ..•• I • .. • I ..•• I .•.• I . .•. I •• •. I .• . • I ..•. I 
260 270 280 290 300 
· ... I .... I .... I .... I ..•. I . . .. I .•.. I .•.. I •.• . I .... I 
310 320 330 340 350 
IATGGTTAAA AAATCACTGC GCCAGTTCAC GCTGATGGCG ACGGCAACCG 
IATGGTTAAA AAATCACTGC GCCAGTTCAC GCTGATGGCG ACGGCAACCG 
'-- .-/ 
5'-end ~TX-M 
a The 48-bp Link is highlighted in red; the additional 80-bp found in the J,200-bp amplicon are highlighted in 
light blue; ISEcpl is highlighted in green. 
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Figure 43. Partial alignment of the DNA sequences upstream of blacrx._M in representative 
clonal isolates AI and 01 
3'-end of insertion element IS26 
r------------------~-----------------~ 
.... I . . .. I .... I . ... I ... . I . ... I • .. . I . • .. I .... I ... . I 
210 220 230 240 250 
TTTGCAACAG TGCCTAAAAA ACACACGTGG AATTT 
.... I .... I . . .. I .... I .•.. I . ... I .... I ... . I • .. . I .•.. I 
260 270 280 290 300 
TTAAAAAATC 
TTAAAAAATC 
5'-end of blaCfX-M.15 
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The 48-bp sequence spacer region between ISEcpl and the blacrx-M-Is gene was the most common 
among the investigated E. coli isolates with group-l CTX-M enzymes in the UK. This link had 
been widely reported upstream of blacrx-M-Is worldwide [e.g. among producers isolated in 
Cameroon, Canada or India (Boyd, D. A. et al., 2004; Gangoue-Pieboji, J. et al., 2005; Karim, A. 
et al., 2001)]. By contrast the 128-bp link, which has been described previously in association with 
either blacrx-M-3 or blacrx-M-Is (Baraniak, A. et al., 2002a) has until now, only been reported among 
isolates from Poland (e.g. plasmid pCTX-M-3, GenBank accession number: NC_004464). This 
link has now also been found among CTX-M-positive UK isolates, but remains rare and seems to 
be confined to clinical isolates from Belfast. These two ISEcpl-blacrx-M spacer regions certainly 
illustrate two independent (initial) mobilization events of their respective blacrx-M gene. 
The 128-bp link was always associated with isolates showing a /3-lactamase band at pI = 
8.4 according to IEF (e.g. isolate Cl), i.e. encoding CTX-M-3 rather than CTX-M-lS. Nevertheless, 
one non-clonal isolate, also from Belfast, had a /3-lactamase band at pI = 8.6 corresponding to 
CTX-M-1S, together with the 128-bp link. Otherwise, all the investigated clone C representatives 
with /3-lactamases at pI = 8.6 harboured the widespread 48-bp link. Therefore, it seems that 
representatives of UK epidemic clone C had independently gained either of two distinct genetic 
supports (i.e. plasmids) harbouring blacrx-M genes, one maybe related to plasmid pCTX-M-3 from 
Poland, the other to the widespread UK plasmids with the 48-bp link. This conclusion was 
supported by the fact that the CTX-M-encoding plasmid from isolate Cl differed slightly from the 
plasmids from the other four clonal representatives (see section 8.3.1 and Figure 24), which 
harboured the classical 48-bp spacer link. 
Finally, the third type of am pi icon (c. 2,000-bp) was found among all PFGE-defined clone 
A isolates investigated in this study, but was not specific to these. A few clonally related isolates, 
as shown by PFGE Cn = 26), from a centre that had also referred members of the epidemic clone A, 
have been shown by PCR to harbour the IS26 element 48-bp upstream of blacrx-M (Woodford, N. 
and Hope, R., personal communications). The repercussions of IS26 in clone A isolates are 
discussed in the next section of this chapter. 
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1.2. Impact of 1826 in E. coli epidemic clone A isolates 
As previously mentioned, strain A has an IS26 element between blacrX-M-IS and its normal 
promoter, which is provided by ISEcpJ. Most other producers of CTX-M-lS enzyme, such as 
strain 0 isolates have no such interruption. It was also noted that third-generation cephalosporin 
MICs and especially those of ceftazidime for the majority of strain A isolates were lower compared 
with those for other more conventional producers of CTX-M-lS enzymes, including members of 
epidemic clone 0 (see geometric mean MICs in Table 9). The bases for these associations were 
therefore investigated, with attempts to measure the level of CTX-M-lS expression, which was 
anticipated to be decreased contingent on the IS26 insertion. In this part of the study, epidemic 
clone 0 representative isolates 0 1-03 were used as controls (representing classical producers of 
CTX-M-lS enzyme), for comparison purposes with clone A representative isolates AI-A3. The 
CTX-M expression level in these isolates was quantified by RT-PCR and visually assessed on 
agarose gels. In addition, the specific activity of CTX-M-lS enzyme in the representatives AI-A3 
and 0 1 was biochemically measured by spectrophotometric assays. Selection pressure with high-
level ceftazidime was also used in an attempt to remove the IS26 element from the promoter-
blacrx-M link in transformant TrAI. Finally, the DNA section immediately upstream of blacrx-M-Is 
in representative isolates AI-A3, which includes IS26, was sequenced. 
Representatives AI and A3 were typical strain A isolates, requiring low cefotaxime, 
ceftazidime and cefepime MICs (Table 2S) compared with the three strain 0 representatives (DI-
0 3); the third strain A representative (A2) was atypical, requiring cephalosporin MICs similar to 
those for 0 1-03 and having a strong pI 8.6 band on IEF (see Figure 44). Transfonnants of all three 
strain A representatives, including that derived from A2, required low cephalosporin MICs 
compared with those derived from the three strain 0 representatives. 
Following these patterns, cefotaximase specific activity was 6- to IS-fold lower in clinical 
isolates AI and A3 than in 0 1-03, but only about two-fold lower in case of A2 (Table 2S). 
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Table 25. Cefotaximase specific activity ("moles CTX hydrolysed/min/mg protein) and MICs (mgIL) for clinical isolates and their transformants 
Cefotaximase MICs 
Isolate CTX+ CAZ+ CPM+ PIP + specific Activity AMP AUG CTX CAZ CPM IPM MEM PIP CLA CLA CLA TZM 
Recipient strain: 
DH5a NDa 8 4 ~.125 ~.060 ~.250 0.125 ~.125 ~.060 0.125 ~.060 2 2 
Clinical isolates: 
A, 1.65 >64 32 32 ~.060 4 0.25 4 ~.060 0.125 ~.060 >64 16 
A2 4.58 >64 16 >64 0.125 32 0.25 32 ~.060 0.25 ~.060 >64 32 
A3 1.18 >64 16 16 ~.060 2 0.25 1 ~.060 0.125 ~.060 >64 16 
D, 11.16 >64 32 >64 0.25 32 1 64 1 0.25 ~.060 >64 32 
D2 9.17 >64 16 >64 0.125 64 0.25 64 ~.060 0.125 ~.060 >64 32 
D3 11.94 >64 16 >64 0.125 64 0.5 >64 ~.060 0.125 ~.060 >64 32 
Transformants: 
TrA, 1.08 >64 16 4 ~.060 1 0.125 0.25 ~.060 0.125 ~.060 >64 4 
TrA2 1.83 >64 16 8 ~.060 1 ~.060 0.5 ~.060 0.125 ~.060 >64 8 
TrA3 1.19 >64 16 4 ~.060 1 0.125 0.5 ~.060 0.125 ~.060 >64 8 
TrD, 24.87 >64 16 >64 ~.060 32 0.25 16 0.125 0.125 ~.060 >64 8 
TrD2 17.37 >64 16 >64 ~.060 32 0.25 16 ~.060 0.125 ~.060 >64 4 
TrD3 16.09 >64 16 >64 ~.060 16 0.25 16 ~.060 0.125 ~.060 >64 8 
aND = not detennined 
N 
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Figure 44. Isoelectric focusing of JS-Iactamases from strain A (A) and strain D (B) 
representative isolatesa 
(B) 
+ Dl TEM-l (pI = 5.4) 
OXA-l (PI = 7.4) 
CTX-M-15 (PI = 8.6) 
a The arrow incticated the direction of protein migration. 
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Transformants derived from all three strain A isolates, including that of A2, had 9- to -23-fold 
lower cefotaximase specific activity compared with transformants of isolates 0 1-03. 
Additionally and as previously mentioned (see results - Chapter I, section 4), the CTX-M-
15 /3-lactamase was hardly detectable by IEF in isolates AI and A3 but was obvious in A2 and in 0 1-
0 3 (Figure 44). The OXA-l /3-lactamase band was equally intense in all six isolates. Correlating 
with these IEF results, RT -PCR indicated a decrease in the level of CTX-M expression in isolates 
Al and A3. The blacrx-M-Is band reflecting mRNA presence was of lower intensity for isolates Al 
and A3 compared with that for isolates A2 or 0 1-03, whereas the blaoXA-1 band, which was used as 
control, was equally intense for all six isolates (Figure 45). Finally, all three strain A representative 
isolates AI-A3 had the IS26 element between blacrx-M-Is and its normal promoter. DNA sequencing 
indicated no differences immediately upstream of blacrx-M-Is among these three strain A isolates. 
Attempts to remove the insertion sequence by selective pressure using high-level 
ceftazidime alone or in presence of ciprofloxacin (an inducer of the SOS response) at ~ x MIC 
were unsuccessful. High-level ceftazidime-resistant mutants of TrAI were obtained, but all those 
examined still harboured IS26 between blacrx-M-Is and its promoter (as detected by PCR using the 
primer pair IS26-CTX-M forIIS26-CTX-M rev). The mechanisms of high-level ceftazidime 
resistance in those mutants was not investigated further, but may have involved changes in 
membrane permeability. 
Overall, antibiotic susceptibilities, CTX-M specific activities, IEF and RT-PCR results, all 
correlated and indicated that expression of CTX-M-15 13-lactamase in two of the three strain A 
isolates tested was lower than in the strain D isolates used as controls. This probably explained the 
lower resistance to third-generation cephalosporins of most strain A isolates, and IS26, located 
between blacrx-M-ls and its normal promoter, may be responsible for this decrease in enzyme 
expression. However, CTX-M-15 expression was sometimes up-regulated (such as in isolate A2) 
for reasons that remain yet unclear, raising MICs of third-generation cephalosporins. Trans-acting 
factors are thought to intervene in this phenomenon. 
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Figure 45. (A) RT-PCR agarose gel electrophoresis picture evaluating OXA-l and CTX-M-15 
mRNA levels and (8) three-dimensional representation of mRNA levels' 
(A) 
(B) 
Normal expression 
Low expression 
a Peak heights are related to mRNA quantity. 
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2. Genes encoding group-2 CTX-M enzymes 
Genes encoding group-2 CTX-M enzymes comprise at least eight different variants 
(http://www.lahey.org/studies/other.htm). blacrx-M-2 is the most common allele of this phylogenetic 
group and has long been the predominant blacrx-M variant detected among CTX-M-positive 
Enterobacteriaceae in Argentina (Bonnet, R., 2004). A number of studies looking at the genetic 
environment of blacrx-M.2-like genes have shown they were most likely to have originated from the 
chromosome of K. aseorbata (Humeniuk, C. et al., 2002). Most blacrx-M-2-like genes, including 
blacrx-M-2 itself, have been described in unusual class I integrons and were located upstream of 
orfJ, a gene also present downstream of the chromosomal blaKLUA-l gene of K. aseorbata. By 
contrast, a few other members of this phylogenetic group of blacrx-M genes, such as blacrx-M-s, 
have been shown to be associated with an ISEepl-like element; even here though the immediate 
genetic surroundings of both blacrx-M-s and blaKLUA-1 were found to share a very high level of 
homology (Humeniuk, C. et al., 2002). 
For this study, the genetic surroundings of blacrx-M-2 in the three unrelated clinical isolates 
referred to as isolate 1, isolate 2 and isolate 3 in Chapter Ill, section 3 were investigated. This was 
achieved by conventional PCR in the fIrst instance, and then by long-range PCR assays using 
various sets of primers (in accordance with previously published data on the genetic environments 
of blacrx-M-2), and fInally by DNA sequencing. 
No PCR product was obtained following amplifIcation using primers specifIcally binding 
to the 3' end of ISEepl (forward primer) and to blagroup-2 crX-M genes (reverse primer). The three 
clinical isolates were shown on the other hand to carry class I integrons (Figure 46), whereas 
neither class II nor class III integrons were detected by PCR. The DNA sequences located between 
the S' and 3' conserved sequences of these class I integrons were then amplifIed using the primer 
pair intS'-CS/int-3'CS, and PCR products were subsequently sequenced. 
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Figure 46. Agarose gel electrophoresis of Class I-Ill integron PCR products of E. coli isolates 
1-3 harbouring the blacTX_M_2 gene 
Type I integrase 
amplicon (484-bp) 
Class I Class IT 
integron PCR integron PCR 
Class III 
integron PCR 
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Similar c. l-kb amplicons were obtained for isolates 2 and 3 using primers int5'-CS and int3'-CS, 
while isolate 1 showed a c. 1.8-kb peR product. DNA sequencing showed none of these amplicons 
to contain the blacrx-M-2 gene. Rather, the integrons from all three isolates were found to carry the 
gene cassette aadAl; that from isolate 1 additionally had aac(6J-Ib at its 5'-end. 
It was then postulated that the CTX-M-2-encoding gene was mediated by large and 
complex class I integrons, as often found in the past (Arduino, S. M. et al., 2002; Power, P. et al., 
2005; Valverde, A. et al., 2006), and in which the 3' conserved sequence has been duplicated. The 
resulting integron then becomes too long to be amplified successfully by conventional PCR. In 
order to overcome this, various pairings of primers (selected according to the published literature) 
were used to create a map of the whole integrons; the primer pairs used were as following (primer 
binding sites are indicated in Figure 47): 
- SullAllATGR (shown in orange in Figure 47) to amplify from sull to orf513 
- 34ISTOP/MP-CTX-Mgroup2r (shown in blue in Figure 47) to amplify from orf513 to 
blacrx-M-2 
- MP-CTX-Mgroup2f1qacEl-B (shown in green in Figure 47) to amplify from blacrx-M-2 to 
qacEAl 
The PCR reactions using the primer pairs listed above were positive with all three isolates 
suggesting that the blacrx-M-2 gene was mediated by complex class I integrons indeed. These 
integrons shared a common 3'CS(I)-3'CS(2) region, which harboured the gene cassettes orf513 
and blacrx-M-2 (Figure 47). These complex integrons also encoded either aadAl only (isolates 2 and 
3) or aac(6J-Ib and aadAl (isolate 1) in their variable region (5'-3'CS). Both these types of 
integron have been described previously, among various Gram-negative clinical strains isolated in 
Argentina (Arduino, S. M. et al., 2003). 
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Figure 47. Schematic representation ofthe blacTX.M.2-harbouring class I integrons in isolates 2 and 3 (A), and in isolate 1 (B) 
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3. Genes encoding group-8 CTX-M enzymes 
During this study, a single E. coli clinical isolate with a group-8 CTX-M enzyme (CTX-M-40) was 
referred to ARMRL [in 2004, (see Chapter Ill, section 4.1 )]. This allele, found once previously in 
an E. coli isolate from 1999 (E134200), was then found to be associated to an ISEcpl-like element 
(Hopkins, K. L. et al., 2006b). 
A PCR assay using the primers prom+ (specific to the 3'-end ofISEcpl) and CTX-Mgp8-
R (specific to 3' end of blagroup_8 crX-M) yielded a c. 1,1 OO-bp amplicon (Figure 48), similar to that 
obtained with the positive control (isolate E134200). This suggested blacrx-M4o was also associated 
with ISEcpl in the isolate referred to ARMRL. This view was confirmed by DNA sequencing, 
which showed that blacrx-M-40 was located 66-bp downstream of the 3'-end oflSEcpl, and that its 
genetic environment shared a high-level of homology to that of blaKLuG-h the chromosomal {3-
lactamase-encoding gene of K. georgiana (Hopkins, K. L. et al., 2006b). As previously observed 
with other blacrx-M genes such as blacrx-M-Is (Karim, A. et al., 2001), the ISEcpl element was 
thought to be responsible for the initial mobilization and the expression of blacrx-M-4o. 
4. Genes encoding group-9 CTX-M enzymes 
CTX-M-9-like {3-lactamases were the second most widespread CTX-M variants found in E. coli 
isolates in the UK, accounting for c. 15% of all CTX-M enzymes (N. Woodford, personal 
communication). Two blacrx-M-9-like allele variants were investigated during this study, namely 
blacrx-M-9 and blacrx-M-14. These two genes shared 99.5% DNA sequence homology, differing by 
four nucleotides only, but have been shown to be associated with two distinct genetic structures 
facilitating their spread and expression. The blacrx-M-9 gene has repeatedly been reported within 
complex class I integrons (Garcia, A. et al., 2005; Novais, A. et al., 2006), while blacrx-M-14 has 
usually been linked with the ISEcpi element (Lartigue, M. F. et al., 2004). 
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Figure 48. Agarose gel electrophoresis ofISEcpl-blagroup_8CTX_M peR product 
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In view of these previous data, class I integrons and the association of ISEcpl with blacrx-M-9-like 
were sought by PCR among the 20 representative isolates with CTX-M-9-like {j-Iactamases 
previously mentioned in Chapter III of results, section 2. Class I integrons were sought with the 
intl-f and intl-r primers, while the ISEcpl-blacrx-M-9-like link was searched using the primer pair 
prom+/CTX-M M9L. Results are summarised in Table 26. 
Half the screened isolates (10/20) harboured a class I integron. These included both 
representatives 11 and 19, which have been shown to encode blacrx-M-9 genes but not the two with 
CTX-M-14 enzymes (see Chapter Ill, section 2.2). Also, the association ISEcpl-blacrx-M-9-like was 
detected among most of the screened isolates (75%, 15/20), including representatives 2 and 16, 
shown previously to encode blacrx-M-14 (see Chapter Ill, section 2.2), though not in the two 
confIrmed by sequencing to produce the CTX-M-9 enzyme. These fmding agree with previous 
fIndings reporting blacrx-M-9 to be integron-mediated and, blacrx-M-14 to be associated with the 
ISEcpl element. Class I integrons nevertheless were detected in a few isolates harbouring the 
association ISEcpl-blacrx_M (representatives 7, 8, 13, 17 and 18). Although these integrons were 
not characterised, they were not expected to mediate the blacrx-M -9-like gene. 
4.1. Genetic environment of hlacTX-M-9 
The genetic environment of the blacrx-M-9 gene in representative isolates 11 and 19 was 
investigated. This was done with three separate long PCR assays, in accordance with a previously 
described method (Sabate, M. et al., 2002), using the following primers pairs: 
Reaction 1: 341stop1lATGR, amplifying from orf513 to blacrx-M-9 
Reaction 2: I stopPRl03000SR, amplifying from blacrx-M-9 to orfl 005 
Reaction 3: CTX-M M9U/int3'-CS, amplifying from blacrx-M-9 to the 3'-conserved 
sequence of class I integron 
Reaction 1 yielded the expected c. 900-bp DNA fragment with both isolates 11 and 19 agreeing 
with data from the literature, which report blacrx-M-9 as being located downstream of orf513. 
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Table 26. Results summary for class I integron and ISEcpl-blacTX_M_9_like PCR assays· 
Isolate CTX-M class I 
ID variantb integron 
1 NDc + 
2 CTX-M-14 
3 NDc 
4 NDc + 
5 NDc 
6 NDc 
7 NDc + 
8 NDc + 
9 NDc 
10 NDc 
11 CTX-M-9 + 
12 NDc 
13 NDc + 
14 NDc 
15 NDc 
16 CTX-M-14 
17 NDc + 
18 NDc + 
19 CTX-M-9 + 
20 NDc + 
a + indicates a positive PCR result. 
b All 20 CTX-M variants belonged to phylogenetic group-9. 
C ND = not detennined. 
ISEcpl-
blaCTX-M-9-lIke 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
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No amplification product was obtained in reaction 2 suggesting there was no orfl 005 located 
downstream of blacrx-M-9; this was in contrast to various reports in the literature (Nova is, A. et al., 
2006; Sabate, M. et al., 2002). Finally, a I.5-kb PCR product was obtained with both isolates 11 
and 19 in reaction 3, confirming blacrx-M-9 was integron-mediated. In summary, these data 
suggested that the blacrx-M-9 gene in representative isolates 11 and 19 was linked to orf513, also 
known as CRI (Common Region 1), within class I integrons. The CRI element has been shown 
previously to mobilise and promote the expression of various antibiotic resistance genes, including 
blacrx-M genes such as blacrx-M-9 and blacrx-M-2 (Rodriguez-Martinez, J. M. et al., 2006). 
4.2. Genetic environment of blaCTX-M-14 
With preliminary PCR data showing the presence of an ISEcpl-blacrx-M association in both the 
representative isolates 2 and 16 (confIrmed to produce CTX-M-I4/3-lactamase), it was inferred that 
blacrx-M-14 was linked to ISEcpl, which correlated with previous reports from the literature 
(Lartigue, M. F. et al., 2004). As seen with blacrx-M-Is, the ISEcpl element was thought to be 
responsible for the initial mobilisation and the expression of blacrx-M-14. Also, this association was 
detected by PCR among the majority of representative isolates with group-9 CTX-M enzymes 
investigated in this study (15/20); this may possibly reflect a dominance of the CTX-M-14-type 
enzyme vs. the CTX-M-9-type among UK E. coli isolates with phylogenetic group-9 CTX-M /3-
lactamases, though this was not investigated further. 
5. Summary 
The blacrx-M genes of UK E. coli clinical isolates were found to be linked either to ISEcpl (e.g. 
blacrx-M-3, blacrx-M-14, blacrx-M_ls and blacrx-M-4o). or to CRI (also known as orf513) within 
complex class I integrons (blacrx-M-2 and blacrx-M-9). Both these elements have been shown 
previously to promote the mobilisation and the expression of blacrx-M genes. 
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Chapter V • Complete nucleotide sequence of pEK499, the multi-drug 
resistance plasmid of UK Escherichia coli epidemic clone A with CTX-M-
15 beta-Iactamase 
1. Introduction 
In the past decade, CTX-M type enzymes have rapidly become the most common plasmid-
mediated ESBLs around the globe, reported among a number of various genera of 
Enterobacteriaceae, but predominantly in E. coli. CTX-M-15 iJ-Iactamase, the most common 
variant across Europe (except probably in Iberia) and the Far East, is often encoded by self-
transferable plasmids belonging to incompatibility group FII (Canton, R. and Coque, T. M., 2006; 
Lavollay, M. et al., 2006). Very few blacrx_M-harbouring plasmids have been completely 
sequenced so far and data for only two are available publicly (accession numbers NC _005327 and 
NC_004464, http://www.ncbi.nlm.nih.gov). Consequently, very little is known about the degree of 
relatedness of these blacrx_M-encoding plasmids, although most have been shown in this work and 
in the literature, to share a number of characteristics such as the antibiotic resistance determinants 
blaTEM-I. blaoxA-1 and aac(6 ')-Ib. 
As this study showed, blacrx-M-Is is also often mediated by IncFII plasmids in the UK, 
including in the national E. coli epidemic clones (see Chapter I), and it is often linked to blaTEM-I. 
blaoxA-1 and aac(6,)-Ib-cr. Most of these plasmids were found to be self-transferable, except for 
that of E. coli epidemic clone A. the most widespread lineage in the UK, having been referred to 
ARMRL from over 50 different centres. This study firstly focused on the molecular 
characterisation of the resistance mechanisms of clone A to the major classes of antibiotics (see 
Chapter I), finding that most of these were co-encoded on a single plasmid of c. 120-kb. Therefore, 
it was decided to characterise this plasmid further, aiming at better understanding its role in the 
epidemiological success of clone A. The CTX-M-15-encoding plasmid of representative isolate AI 
(plasmid pEK499) was therefore sequenced fully, by MWG Biotech AG (Ebersberg, Germany) and 
was annotated in collaboration with Dr Anthony Underwood (HP A-Centre for Infections, 
Bioinforrnatics Unit, Colindale). 
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2. General molecular characteristics of plasmid pEK499 
Plasmid pEK499 was a double-stranded circular DNA molecule of 117,536 nucleotides precisely. 
It encoded 185 predicted genes based on analysis using the BASys web-server. As previously 
determined by PCR, plasmid pEK499 belonged to incompatibility group IncFII; it harboured genes 
encoding for the repAlBIE initiation replication protein system, specific to plasmids of the IncFII 
group. Overall, 140 of the 185 predicted genes encoded proteins with known functions, and 
involved in a wide range of biological processes (Figure 49), including: 
- DNA replication, recombination and repair mechanisms 
- Transcription and translation regulation 
- Post-translational modifications (chaperones) 
- Carbohydrate transport and metabolism 
- Amino acid transport and metabolism 
- Inorganic ion transport and metabolism 
- Cell cycle control and chromosome partitioning 
- Energy production and conversion 
- Co-enzyme metabolism 
- Cell envelope and outer membrane biogenesis 
None of the remaining 45 predicted genes, encoding proteins with unknown functions, displayed 
conserved domains according to the Conserved Domain Database search tool (version 2.11, 
http://www.ncbi.nlm.nih.gov/Structure/cddlwrpsb.cgi). 
3. Antibiotic resistance determinants 
As previously demonstrated (see MICs for TrA\o Table 10), plasmid pEK499 encoded multi-drug 
resistance. It affected the activity of most (3-lactam antibiotics, except cephamycins and 
carbapenems, aminoglycosides (except gentamicin), ciprofloxacin, tetracycline, trimethoprim and 
sulphamethoxazole. 
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Figure 49. Genetic map of plasmid pEK499 (117,536-bp) from clonal representative isolate AI 
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DNA sequencing of the entire plasmid revealed that it carried eleven known antibiotic resistance 
genes, affecting the activity of eight major classes of antibiotics (Table 27). Nine of these genes 
were clustered in a c. 25-kb "Multi-Drug Resistance" (MDR) region as shown in Figure 50, and 
included the blacrx-M-Is gene (resistance to third-generation cephalosporins) as well as blaoxA-1 
(resistance to penicillins and /3-lactaml/3-lactamase inhibitor combinations). aac(6')-Ib-cr 
(resistance to tobramycin and reduced susceptibility to ciprofloxacin), catB4 (chloramphenicol 
resistance), mphA (macrolide resistance) and tet(A) (tetracycline resistance). It was also confIrmed 
that the association of blacrx-M-Is with ISEcpl was interrupted by the introduction of the insertion 
sequence IS26. The 1.8-kb class I integron, initially detected by PCR (see Chapter J) and shown to 
carry djrl7 (trimethoprim resistance), aadA5 (streptomycin resistance) and sun (sulphonamide 
resistance), was also part of the MDR cluster. This MDR region also incorporated TnJ- and 
Tn1721-like transposons, as well as four copies of the insertion element IS26 (including that 
adjacent to blacrx-M-Is). Transposons and insertion elements are involved in DNA rearrangements, 
and may therefore have played a major role in the mobilisation of the antibiotic resistance genes 
mentioned above. The remaining two antibiotic resistance genes encoded by plasmid pEK499, 
namely macAB (macrolide resistance) and blaTEM-1 (ampicillin resistance), were located 
approximately 12-kb downstream and 10-kb upstream ofthe 25-kb MDR region, respectively. 
4. Other selected genetic determinants 
Several genes (30/185) carried by pEK499 encoded recombinase or transposase enzymes, which 
are involved in DNA reshuffling. Most of these were assembled around the different antibiotic 
resistance genes in the MDR region as just mentioned, suggesting this cluster may be prone to 
genetic changes. The two genes chrA (chromate transport) and pecM (membrane protein involved 
in carbohydrate transport) completed the MDR region (Figure 50). The sequence outside the MDR 
region, referred to as the backbone or the skeleton of the plasmid, principally comprised genes 
involved in plasmid replication and maintenance, as well as those encoding proteins with 
unrecognised functions. 
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Table 27. Selected genes encoded by plasmid pEK499 and their function3 
Gene Function 
aac(6')-Ib-cr Aminoglycoside and ciprofloxacin resistance 
aadA5 Streptomycin and spectinomycin resistance 
blacrx-M-15 {3-Lactam resistance = 0 ... 
blaoxA-1 {3-Lactam resistance ~ ~ 
... 
catB4 Chloramphenico I resistance ~ ~ 
mphA Macrolide resistance ~ 
.Q 
~ 
sulI Sulphonamide resistance th 
M 
djrt? Trirnethoprim resistance .s 
-= 
-let (2 genes) Tetracycline resistance ... ~ 
chrA Chromate transport 
pecM Carbohydrate transport and metabolism 
macAB (3 genes) Macrolide resistance 
blaTEM-1 {3-Lactam resistance 
traT Serum survival gene (anti-phagocytosis) 
vagC/vagD Virulence associated genes 
ccdA/ccdB F-plasmid-derived addiction system 
pemK/pemI RIOO-plasmid-derived addiction system 
= 
Inorganic ion (Fe2+/Pb2+) transport and metabolism 
0 
FTRl ... ~ ~ 
... 
ice Phosphorus metabo lism ~ 
resA Cytochrome c maturation ~ 
~ 
sopA/sopB Plasmid partitioning 't:l ... 
", 
-kleA Post-conjugation anti-restriction protein = 0 
rep (3 genes) IncFII plasmid replication initiation system 
tra (14 genes) Genes invo Ived in conjugative transfer 
ugp (4 genes) Carbohydrate transport and metabolism 
araQ L-arabinose transport system pennease protein 
yjgB Zinc-dependent alcohol debydrogenase 
a Antibiotic resistance genes are highlighted in grey. 
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Figure 50. Schematic representation of the c. 25-kb multi-drug resistance region of pEK499 
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The backbone of plasmid pEK499 shared a number of genes with plasmid RI 00, including many 
genes with undefined functions, as well as the pemKlpemI system (RI00-plasmid-derived addiction 
system) and part of the tra operon (plasmid conjugative transfer). The backbone of plasmid 
pEK499 also carried the F-plasmid-derived addiction system ccdAlccdB. Both plasmid addiction 
systems encode a stable toxin and an unstable antitoxin, which militate against plasmid loss, and 
therefore ensure the maintenance of the plasmid, even in the absence of antibiotic pressure. 
Besides antibiotic resistance genes and transposons, plasmid pEK499 also harboured 
virulence-associated sequences. These included the traT gene, also known as the serum survival 
gene, which encodes on outer membrane protein enhancing resistance to phagocytosis (Aguero, M. 
E. et al., 1984), and the pathogenicity-associated genes vagClvagD (pullinger, G. D. and Lax, A. J., 
1992). Finally, an assortment of genes encoding proteins with various biological functions, a 
sample of which is summarized in Table 27, completed the skeleton ofpEK499. 
5. Comparison of pEK499, pCl5-la and pCTX-M-3 nucleotide 
sequences 
As previously mentioned, the DNA sequences of two additional CTX-M-encoding plasmids are 
publicly available via the GenBank database. These are plasmids pel5-la (accession number: 
NC_005327) and pCTX-M-3 (accession number: NC_004464). Plasmid pCl5-la was from a 
CTX-M-15-positive E. coli clinical isolate collected in Canada in 1999 (Boyd, D. A. et al., 2004), 
and plasmid pCTX-M-3 is a widely disseminated CTX-M-3-encoding plasmid widespread across 
Poland (Gniadkowski, M. et al., 1998). 
The nucleotide sequences of these plasmids were compared with that of pEK499 with the 
Artemis Comparison Tool (http://www.webact.org) using an 825-bp threshold, as representative of 
the average open reading frame length, allowing comparison at the gene level (Figure 51). 
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Figure 51. Schematic representation of nucleotide sequence homoJogies' between pJasmids 
pEK499, pC15-1a and pCTX-M-3 
11 7000 tII@ ... _ ... 
pC15- la 
(92,353-bp) 
pEK499 
Cl 17,536-bp) 
pCTX-M-3 
C89,468-bp) 
a Using a 825-bp threshold; homologous sequences are shown in red (same orientation) and blue 
(opposite orientation). 
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On the whole, plasmid pEK499 appeared to have more genes in common with pCl5-la than with 
pCTX-M-3. The vast majority of these corresponded to antibiotic resistance genes, including 
blacrx-M-15, blaoxA-J. blaTEM-I, aac(6J-Ib-cr and tet(A), but also to transposase-encoding genes 
(tnpA), and to insertion sequence elements such as IS26. More generally, most of the similarities 
between pEK499 and pCl5-la were clustered in a c. 50-kb region, which included the MDR region 
as well as a part of the pEK499 skeleton found to share some level of homology with plasmid 
RIOO. However, the genes within this 50-kb region, most of which were located within 
transposons, were arranged differently in the two plasmids. Like pEK499, plasmid pCl5-la 
belonged to incompatibility group IncFII, thus suggesting that both plasmids descended from a 
common ancestor. Finally, both plasmids were found to carry remnant sequences from plasmid 
RIOO, most of which encoded proteins with uncharacterised functions. 
About half the genes present on plasmid pEK499 were not found on plasmid pCI5-la; 
these included the virulence-associated genes vagClvagD, several genes involved in carbohydrate 
transport and metabolism such as kdgt (2-keto-3-deoxygluconate permease) and the ugp operon 
(glycerol-3-phosphate transport), also the macAB operon (macrolide resistance) and various genes 
encoding proteins with undefined functions. Also and in contrast to pEK499, plasmid pCl5-la did 
not encode a toxin-antitoxin system, and nor did plasmid pCTX-M-3. 
Homology between plasmids pEK499 and pCTX-M-3 was limited on the whole, and their 
similarities mainly consisted of transposase-encoding genes as well as the blacrx-M gene, though 
plasmid pCTX-M-3 carried blacrx_M -3 and not blacrx-M-15. The known antibiotic resistance genes 
mediated by plasmids pEK499, pCTX-M-3 and pCl5-la are summarised in Table 28. 
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Table 28. Summary of known antibiotic resistance genes carried by pEK499, pCTX-M-3 and 
pC1S-la 
Antibiotic resistance genes pEK499 pCTX-M-3 pC1S-la 
aac3-Ila + + 
aac(6')-Ih-cr + + 
aadAl'" + 
aadA58 + 
blacrx_M_3 + 
blaCTX-M-15 + + 
blaoXA_l + + 
blaTEM_1 + + + 
catB3 + 
catB4 + 
dfr12 a + 
dfr17 a + 
macAB + 
mphA + + 
suUa + + 
tet(A) and tet(R) + + 
a Class I integron-mediated genes. 
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6. Summary 
Overall, it appeared that plasmid pEK499 was much more related to pC15-1a than to pCTX-M-3, 
correlating with data reported earlier in Chapter I and Chapter IV. Firstly, plasmid cross-
hybridization studies showed that the CTX-M-encoding plasmids from E. coli epidemic clones A, 
B, D and E were highly similar, but were less so to that of epidemic clone C (or representative 
isolate Cl at least). Secondly, the CTX-M-encoding plasmid from isolate Cl was shown to carry the 
exact same ISEcpJ-blacrx_M link as that previously found on plasmid pCTX-M-3 only. As a result, 
the plasmid of isolate C t and pCTX-M-3 are likely to be more related to each other, than to those of 
the remaining four epidemic clones, which in contrast were more close to plasmid pC 15-1 a. 
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Chapter VI . In-vitro evolution of ceftazidime resistance in hypermutable 
Escherichia coli with CTX-M-3 beta-Iactamase 
1. Introduction 
In contrast to TEM- and SHV-type ESBLs, most CTX-M enzyme variants have weak catalytic 
activity against ceftazidime, but changes to amino acids 167 and 240 are associated with increased 
ceftazidimase activity (Bonnet, R., 2004; Sturenburg, E. et al., 2004). At least eight variants from 
three of the five phylogenetic groups of CTX-M enzymes have been shown to confer increased 
resistance to ceftazidime. These are the group-l enzymes CTX-M-15, -23, -42 and -54; the group-9 
enzymes, CTX-M-16, -19, and -27; and finally, CTX-M-25 (Bae, I. K. et al., 2006; Bonnet, R. et 
al., 2003; Munday, C. J. et al., 2004a; Poirel, L. et al., 2001; Poirel, L. et al., 2002a; Stepanova, M. 
et al., 2005; Sturenburg, E. et al., 2004). 
CTX-M-15, the commonest CTX-M variant worldwide (Canton, R. and Coque, T. M., 
2006), including in the UK (Woodford, N. et al., 2004), is a ceftazidime-hydrolysing variant of 
CTX-M-3 enzyme, differing from its "parent" only by an aspartate to glycine substitution at 
position 240 (poirel, L. et al., 2002a). One factor that may potentially accelerate the evolution of 
CTX-M /3-lactamases such as CTX-M-3 with ceftazidimase activity, is hypermutability, which 
arises via defects in the methyl-directed, post-replication DNA mismatch repair system, notably in 
the MutS protein (Chopra, I. et al., 2003; LeClerc, J. E. et al., 1996; Miller, K. et al., 2002). 
The in-vitro evolution of the ceftazidimase activity ofCTX-M-3/3-lactamase was therefore 
investigated in a hypermutable MutS-negative E. coli strain. Also, the rate of emergence of high-
level ceftazidime resistance in the hypermutable background was compared with that in an isogenic 
CTX-M-3-producing wild-type E. coli strain, which has a normal mutation frequency. 
2. Cloning of blacTX-M-3 into pBBRIMCS-2 
The blacrx-M-3 gene was amplified from E. coli clinical representative isolate Cl (Chapter I) using 
the primer pair prom+/preCTX-M3B, and was cloned into pBBRIMCS-2; the resulting 
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recombinant vector was designated pCTX-M-3. The successful insertion of blacrx.M.3 into the 
vector was conflrmed by PCR with the primer pair T3ff7 [Figure 52(A)], which bind on either side 
of the multiple cloning site (MCS), and also by enzymatic restriction as shown in Figure 52 (B and 
C). The recombinant pCTX-M-3 element was then transfonned into isogenic E. coli wild-type 
1411 (WT) and hypermutable MutS-negative 1413 (ll.mutS) strains. 
3. Mutation frequencies 
Both the WT and ll.mutS transformants harbouring pCTX-M-3 had the classical phenotype of CTX-
M-3-producers; i.e. higher MICS of cefotaxime than ceftazidime (Table 30), with clavulanate 
restoring full susceptibility to both cephalosporins. As ceftazidime MICs were only 1 and 1.5 mg/L 
for the pCTX-M-3-harbouring WT and ll.mutS strains, respectively, resistant mutants were selected 
using this third-generation cephalosporin at 4 and 6 mg/L. 
The mutation frequencies to ceftazidime resistance for WT and ll.mutS E. coli in four 
independent experiments are summarised in Table 29. Predictably, ceftazidime resistance emerged 
more readily in the hypermutable background than in the wild-type, with an average mutation 
frequency approximately 60-fold higher with the ll.mutS strain (average mutation frequency of 1.29 
x 10.5, SE 4.9 x 10-6) than with the WT strain (average mutation frequency of2 x 10.7, SE 4.3xlO·8). 
4. DNA sequences of blaCTX-M mutants 
Both strands of the blacrx.M gene from the parental WT and ll.mutS recombinant strains, and from 
three WT (WTl-3) and flve ll.mutS (mutSl-S) randomly selected ceftazidime-resistant mutants 
were sequenced. 
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Figure 52. Agarose gel electrophoresis to confirm cloning of blacTx-M-3 into pBBRIMCS-2: 
T3ff7 PCR product (A) and restriction analysis of pBBRIMCS-2 and pCTX-M-3 using ApaI 
only (B) or using SmaI and ApaI (C) 
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Table 29. Mutation frequencies to ceftazidime resistance for E. coli strains 1411 WT and 1413 
AmutS harbouring pCTX-M-3 
1411 WT 141311mutS 
Experiment 1 2.88 x 10-7 1.80 x 10-5 
Experiment 2 8.60 x 10-8 2.40 X 10-5 
Experiment 3 2.37 x 10-' 3.90 X 10-6 
Experiment 4 2.00 x 10-' 5.60 X 10-6 
Mean 2.03 x 10-7 1.29 x 10-5 
Standard Error 4.3 x 10-8 4.9 x 1006 
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All eight randomly selected mutants (WT and t1mutS) had single base substitutions at nucleotide 
508 or 509 (Figure 53), resulting in amino-acid changes at position 167 (Figure 54). 
All five mutants derived in the t1mutS background had the same amino acid substitution: 
Pro167Ser. This change had been associated with increased ceftazidimase activity in the group-9 
enzyme, CTX-M-19 (poirel, L. et al., 2001), and in laboratory-generated mutants of CTX-M-2 
[group-2 CTX-M, (Welsh, K. J. et al., 2005)], though not previously in group-l enzymes such as 
CTX-M-3. 
Two mutants, both derived in the WT background (WTl-2), had a Pro167Thr substitution 
corresponding to CTX-M-42 (Stepanova, M. et al., 2005); this substitution is also present in the 
ceftazidime-hydrolysing group-l enzyme, CTX-M-23 (Sturenburg, E. et al., 2004). The remaining 
ceftazidime-resistant WT mutant (WT3) had a Pro167Gln substitution. This change had not been 
reported at the time of this study in any wild-type CTX-M variant, but was described soon 
afterwards in a clinical K. pneumoniae isolate from Korea (Bae, I. K. et al., 2006) as variant CTX-
M-54. 
None of the selected blacrx-M mutants was found to encode CTX-M-15, which is believed 
to be the commonest ceftazidimase variant ofCTX-M-3. 
5. Evolution of antibiotic susceptibilities 
All of the randomly-selected mutants (WTl-3 and t1mutSI-5) were clearly resistant to ceftazidime, 
with MICs increased 32-fold at least (Table 30) by comparison with their respective parent strain. 
Extraction of the recombinant vectors from ceftazidime-resistant mutants and re-transformation 
into new cultures of their respective WT or t1mutS host strains was performed to ensure that 
changes in antibiotic susceptibilities were solely due to the altered blacrx-M genes. MICs for the re-
transformants, which remained very similar to those for their respective mutant hosts, confirmed 
that ceftazidime resistance was conferred by the altered ,s-lactamases encoded by pCTX-M-3. 
However, variations in MICs between mutants and re-transformants with the same enzyme mutant 
(e.g. cefotaxime MICs for mutSI-5 mutants ranged from 8 to 128 mg/L) suggested that other 
factors, such as levels of enzyme expression levels might also play a role. 
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Figure 53. Chromatograms of partial blacrx_M sequences from ceftazidime-resistant mutants 
blaCTX-M-3 
WTl 
(cSOSa) 
WT2 
(cSOSa) 
WT3 
(c509a) 
611lutSl 
(cSOSt) 
611lutS2 
(cSOSt) 
611lutS3 
(cS08t) 
611lutS4 
(cSOSt) 
611lutS2 
(cS08t) 
ACCGTACCGAGCCGACGT T AA 
ACCG T ACCGAG ACGACG TTA A 
&~J\.J\f'i\e 
ACCGTACCGAGC AGACGT TAft 
~~ 
ACCGTACCGAG CGACGTTAA 
~
ACCGTACCGAG T CGACG TTAA 
fi-&c[\dxil.dVwv 
ACCGTACCGAG CGACGT TAA 
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Figure 54. Partial amino acid sequence alignment (residues 148 to 197) of CTX-M-3, -19, -23, 
-54, and of CTX-M enzymes from ceftazidime-resistant WT and AmutS mutants showing the 
different substitutions at position 1673 
Residue 167 
! 
CTX - M- 3 VTA FARQLGDETF RLDRTEPTLN TAIPGDPRDT TSPRAMAQTL RNLTLGK 
WTl-2 VTA FARQLGDETF RLDRTEt LN TAIPGDPRDT TSPRAMAQTL RNLTLGK 
CTX- M- 23 VTA FARQLGDETF RLDRTE LN TAIPGDPRDT TSPRAMAQTL RNLTLGK 
WT3 VTA FARQLGDETF RLDRTEt LN TAIPGDPRDT TSPRAMAQTL RNLTLGK 
CTX- M- 54 VTA FARQLGDETF RLDRTE LN TAIPGDPRDT TSPRAMAQTL RNLTLGK 
mutsl-S VTA FARQLGDETF RLDRTEt LN TAIPGDPRDT TSPRAMAQTL RNLTLGK 
CTX - M- 19 VTA FA DETF RLDRTE LN TAIPGDPRDT T PRAMAQTL ;LTLG 
a The amino acid changes highlighted in grey correspond to the differences in phy10geny between 
the group-l enzyme CTX-M-3 and the group-9 variant CTX-M-19. 
247 
N 
~ 
00 
Table 30. MIC ranges (mgIL) for host strains, wild-type (1411) and AmutS (1413) E. coli with CTX-M-3 enzyme, and for mutants selected for enhanced 
ceftazidimase activity and for their derived re-transformants 
1411 1411 1411 1411 re- 1411 1411 re- 1413 1413 1413 mutant 1413 re-Organism pCTX-M-3 mutant transformant mutant transformant pCTX-M-3 transformant (n=l) (n=l) (n=2) (n=2) (n=l) (n=l) (n=l) (n=l) (n=5) (n=5) 
Mutation nlaa Absent Pro167Thr Pro167Thr Pro167Gln Pro167Gln nlaa Absent Pro167Ser Pro167Ser 
AMP 2 >64 >64 >64 >64 >64 4 >64 >64 >64 
AMX + CLA 2 8 8 4 8 8 4 8 8 4-8 
CTX ~.125 128 16 - 32 8 - 64 32 8 ~.125 256 8 -128 4 -128 
CTX+CLA ~.060 ~.060 ~.060 ~.060 ~.060 ~.060 ~.060 ~.060 ~.060 - 0.125 ~.060 
CAZ ~.250 1 32 - 64 32 32 32 ~.250 1.5 64 -128 16 - 64 
CAZ + CLA 0.125 0.125 1-2 1 1 0.5 0.125 0.25 1-2 0.5 -2 
CPM ~.125 8 4 4-8 4 2 ~.125 16 2-8 2 -16 
CPM+ CLA ~.060 ~.060 ~.060 ~.060 ~.060 ~.060 ~.060 ~.060 ~.060 ~.060 
FOX 4 4 4-8 4 4 4 8 8 4-8 8 -16 
PIP :S;;1.0 >64 >64 64 >64 32 :S;;1.0 >64 ~4 64 
PIP+TZB :s;;1.0 :s;;1.0 :S;;1.0 ~1.0 ~1.0 ~1.0 ~1.0 ~1.0 ~1.0 ~1.0 
ETP ~.125 ~.125 ~.125 ~.125 ~.125 ~.125 ~.125 ~.125 ~.125 ~.125 
IPM 0.25 0.5 0.25 0.25 0.25 0.25 0.5 0.5 0.25 - 0.5 0.5 -1 
MEM ~.060 ~.060 ~.060 ~.060 ~.060 ~.060 ~.060 ~.060 ~.060 ~.060 
a n/a = not applicable. 
Most mutants required higher MICs for ceftazidime than for cefotaxime. This was also observed 
with other CTX-M variants harbouring changes at position 167, such as CTX-M-19, -23 and -42 
(Poirel, L. et al., 2001; Stepanova, M. et al., 2005; Sturenburg, E. et al., 2004). In contrast, 
cefepime MICs were decreased up to eight-fold compared with strains harbouring the unchanged 
blacrx-M-J. Such an exchange in catalytic activity between ceftazidime and cefepime was previously 
reported between CTX-M-19 and its progenitor CTX-M-18 (Poirel, L. et al., 2001), and between 
CTX-M-2 and its in-vitro ceftazidimase mutants (Welsh, K. 1. et al., 2005). Notably, and perhaps 
explaining its clinical success, the CTX-M-15 enzyme confers high-level resistance to both 
cefepime and cefotaxime, as well as ceftazidime. 
All of the studied ceftazidime-resistant mutants remained susceptible to carbapenems, and 
to the combinations of cephalosporin with clavulanate and of piperacillin with tazobactam (the 
OXA-l enzyme was not present in these organisms). 
6. Summary 
Mutations in blacrx-M-3 conferring high-level resistance to ceftazidime emerged more readily in a 
hypermutable background, but also occurred in the wild-type host. All the selected ceftazidime-
resistant mutants had changes at residue 167, a site shown previously to affect ceftazidimase 
activity in various CTX-M enzyme variants. At the time of this study, the Pro I 67Gln substitution 
was novel, and has since been found in a clinical K. pneumoniae isolate where it was named CTX-
M-54 (Bae, I. K. et al., 2006). The presence of this substitution suggests that mutations could play 
a role in the expansion of substrate ranges for CTX-M enzymes and ESBLs more generally, as 
others have shown for e.g. TEM enzymes (Ellington, M. J. et al., 2006). 
More generally, since mutator E. coli strains with lesions in mutS are known to be present 
among natural bacterial populations (LeClerc, J. E. et al., 1996), hypermutable E. coli may have 
played and may still play a role in the evolutionary diversification ofCTX-M enzymes. 
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DISCUSSION 
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Escherichia coli is an ambiguous micro-organism. Some would regard it as "foe", being a major 
cause of blood-poisoning, gastro-intestinal diseases and of extra-intestinal infections such as those 
of the urinary tract. Others however would consider E. coli mostly as a harmless inhabitant (or 
"friend") of the human gut, contributing to essential biochemical processes (e.g. synthesis of 
vitamin K). E. coli is seen also by many as a reliable laboratory companion, being an exceptionally 
versatile tool in molecular research. A recent and critical shift is that E. coli causing extra-intestinal 
infections, once considered as among the most susceptible members of the Enterobacteriaceae 
family, are now becoming among the more antibiotic-resistant. A key element here is the 
emergence of the CTX-M extended-spectrum ~-lactamase family. In the past few years, these 
ESBLs and their producer strains have rapidly disseminated, not only in the UK, but across the 
globe. 
The emergence and swift diffusion of CTX-M ESBLs has completely altered the landscape 
of antibiotic resistance in E. coli, forcing clinicians to adopt new approaches in terms of antibiotic 
therapy, and pharmaceutical companies to seek and develop new drugs. It is still not clear when 
organisms producing CTX-M enzymes ftrst appeared in the UK (producers certainly date back to 
1999), but the situation worsened dramatically around year 2003. Since then, reported cases of 
infection caused by E. coli producing CTX-M enzymes, mostly of the urinary tract and many in 
community patients, have risen exponentiaUy. E. coli with CTX-M enzymes are now the most 
prevalent cephalosporin-resistant Enterobacteriaceae in the UK. and represent a major cause for 
concern in terms of public health (potz, N. A. et al., 2006). 
The epidemiology of E. coli with CTX-M enzymes in the UK is complex, as was shown 
previously by DNA fingerprinting (Woodford, N. et al., 2004). It includes ftve major epidemic 
clones (A-E) producing CTX-M-15 enzyme (or CTX-M-3, a close relative, in a few clone C 
isolates), along with many genetically-diverse producers of CTX-M-15-like enzymes (mostly 
CTX-M-15 ~-lactamase itself), and also a few isolates producing other CTX-M variants (mostly 
CTX-M-9 and -14). This study sought to characterise current E. coli isolates producing CTX-M ~­
lactamases at the molecular level, so as to identify and better understand the reasons behind their 
epidemiological success. 
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1. Multi-drug resistance of clonal and non-clonal E. coli with CTX-M-lS tJ-
lactamases 
Whether they belonged to one of the five major epidemic clones or not, UK E. coli isolates with 
CTX-M-15-like enzymes exhibited similar multi-drug resistance phenotypes. Major classes of 
antibiotics, widely utilised for therapy, such as extended-spectrum cephalosporins, 
aminoglycosides, quinolones, tetracyclines and trimethoprim, were all inactive against those 
organisms, or had their activity reduced significantly. 
Resistance to t3-lactams was due to enzymatic inactivation. Most clonal and non-clonal 
isolates with CTX-M-15 enzymes investigated produced multiple t3-lactamases in various 
combinations, also including TEM-l and/or OXA-l t3-lactamase(s). CTX-M-15 is one of a few 
CTX-M variants capable of hydrolysing ceftazidime efficiently (poirel, L. et al., 2002a); it is 
believed to be a descendant of CTX-M-3, which differs only by a single amino acid (Asp240Gly). 
This latter variant, which is poorly effective vs. ceftazidime, was detected in four of nine epidemic 
clone C representatives investigated, all from Belfast. Clone C isolates from other UK centres 
always had CTX-M-15 enzyme. Other differences between the Belfast isolates with CTX-M-3 
enzyme and those with CTX-M-15 are discussed elsewhere. 
Resistance to extended-spectrum t3-lactams, including third- and fourth-generation 
cephalosporins (e.g. cefotaxime, ceftazidime, cefepime), doubtless resulted from hydrolysis by the 
CTX-M ESBLs. Of the other t3-lactamases found, TEM-l t3-lactamase has been a common cause of 
resistance to penicillins in E. coli isolates since the 1970s (Livermore, D. M., 1995), and a recent 
pan-European study showed that it remains widespread among E. coli isolates responsible for 
uncomplicated UTIs in the community (Kahlmeter, G. and Menday, P., 2003). The class D OXA-l 
/3-lactamase preferentially hydrolyses oxacillin and, more importantly, is poorly inactivated by 13-
lactamase inhibitors. This was illustrated in this study by the MICs of the piperacillinitazobactam 
combination, which were three-fold higher at least for clonal isolates harbouring blaoxA-1 (geom. 
mean MIC = 20 mg/L, i.e. above the BSACIEUCAST breakpoint defining resistance) than for 
those few clonal mutants lacking the gene (geom. mean MIC = 6 mg/L, below the BSAC/EUCAST 
breakpoint). 
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Unlike penicillins, oxyimino-cephalosporins, which are poor substrates for OXA-l, remained 
active in the presence of clavulanate vs. isolates producing the CTX-M-15, OXA-l and/or TEM-I 
combination of enzymes. Some E. coli epidemic clone A isolates, all referred from Preston, also 
had a plasmid-mediated AmpC-type /3-lactamase, CMY-23, able to withstand inhibition by 
clavulanic acid and to hydrolyse cephamycins effectively. The accumulation of multiple (3-
lactamases in E. coli is very worrying since /3-lactams represent approximately two-thirds of all 
prescribed antibiotics, and also since cephalosporins [27% of the market shares (by sales) of the 
leading antibacterial drug classes (Kresse, H et al., 2007)] have long been considered as the drugs 
of choice for the treatment of many severe infection types. 
Among the (3-lactams tested here, only carbapenems consistently retained activity vs. E. 
coli isolates with CTX-M-15-like enzymes, whether clonal or diverse and whether or not these also 
had CMY-23. It is worth adding that previous studies reported that the prevalence of resistance to 
mecillinam among E. coli isolates with CTX-M ESBLs also was relatively low [7.5%, (potz, N. A. 
et al., 2006)], and that temocillin, a derivative of ticarcillin highly stable to most (3-lactamases 
(Denton, M, 2007), also retains good in-vitro activity against E. coli with ESBLs (including CTX-
M types), with an 8% resistance rate (Rodriguez-Villalobos, H. et al., 2006). Mecillinam however 
is only suitable in general for the treatment of lower urinary tract infections, and both it and 
temocillin have yet to be proved clinically active in infections due to ESBL producers. 
Most isolates in this study were resistant, or had reduced susceptibility, to 
aminoglycosides. In isolates with CTX-M-15 enzymes, this was attributable to the aminoglycoside-
modifying enzymes AAC(6')-Ih and AAC(3)-IIa. The latter enzyme was present among the 
majority of clonal and non-clonal isolates, but not in epidemic clone A, which remained 
consistently susceptible to gentamicin. The AAC(6')-Ih enzyme, with substrates including 
tobramycin, kanamycin and amikacin in descending order of preference, was produced by clone A 
isolates, as well as by most other clonal and non-clonal with CTX-M-15-like enzymes. The 
exception was that aac(6 ')-Ib was not detected in the clone C representatives from Belfast 
producing the CTX-M-3 enzyme variant. DNA sequencing of the allele aac(6')-Ib from randomly-
selected clonal and non clonal producers with CTX-M-15 enzyme revealed it corresponded to the 
aac(6')-Ib-cr variant, recently shown to encode an enzyme also capable of acetylating those 
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fluoroquinolones that have an unsubstituted amino nitrogen on the piperazinyl group, such as 
ciprofloxacin and norfloxacin (Robicsek, A. et al., 2006). 
UK. microbiologists, like those elsewhere, have witnessed also a dramatic increase in the 
number of quinolone-resistant E. coli isolates in recent years. Around 80% of E. coli isolates with 
CTX-M enzymes referred to ARMRL are cross-resistant to these drugs, maybe because successful 
fluoroquinolone-resistant clones had subsequently acquired CTX-M enzymes. Overall, most clonal 
and non-clonal isolates with CTX-M-15 enzymes required ciprofloxacin MICs above 8 mgIL and 
such high-level resistance was due to multiple chromosomal mutations in the Quinolone-
Resistance-Determining-Regions of the gyrA and pare genes, in addition to production of the 
AAC(6')-Ib-cr enzyme. The plasmid-mediated qnr genes, which encode peptides responsible for 
reduced susceptibility to quinolones (Tran, J. H. et al., 2005), were absent from all the investigated 
isolates. 
Resistance to tetracycline and to trimethoprim in UK. E. coli isolates with CTX-M-15 
enzyme was attributable to efflux [tet(A)] and to metabolic bypass (dfrl7) mechanisms, 
respectively. 
2. Relatedness of the five major UK E. coli epidemic clones with CTX-M-
15 B-Iactamases 
Although PFGE distinguished five major national E. coli epidemic clones with CTX-M-15 enzyme 
in the UK., other typing methods suggest these to be very closely related to one another. All five 
groups of isolates shared the same serotype [025, (Woodford, N. et al., 2004)], and also belonged 
to the same multi-locus sequence type [ST131, (Fox, A.. personal communication)]. These data 
suggest that the five UK. epidemic clones share a common ancestor strain. 
This present study further supports this view of relatedness: epidemic clones A-E were 
shown to belong to the same virulence-associated phylogenetic group (B2) and also, to exhibit the 
same mUltiple chromosomal mutations conferring high-level resistance to quinolones. Additionally 
and most importantly, the virulence factor gene pools of those five clones appeared very similar, 
both quantitatively and qualitatively. However, it should be added that most extra-intestinal 
pathogenic E. coli (ExPEC) isolates belonging to phylogenetic group B2, including 100% of the 
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clonal isolates and 57% of the non-clonal, generally had similar virulence profiles. The slight 
variations in the virulence gene patterns of the five epidemic clones suggested evolution in three 
distinct directions, leading to the emergence of epidemic clone A, clone D and to the B-C-E group 
of clones, with each lineage acquiring or losing a few virulence genes along their evolutionary 
route (e.g. afaldraBC was specific to clone A among the epidemic lineages). More generally, 
phylogenetic group B2 ExPEC isolates, defined as diverse by PFGE, but exhibiting similar 
virulence profiles, may be distant evolutionary mutants of the three early ancestor clones (i.e. 
diverse B2 isolates harbouring afaldraBC might come from the same evolutionary route as 
epidemic clone A). 
The five epidemic clones with CTX-M-15 enzyme did not appear to have more potent 
virulence factors than the diverse producers of CTX-M-15 enzyme belonging to phylogenetic 
group B2, or than B2 isolates producing other ESBL types. It follows that the reasons behind the 
epidemiological success of ST131 isolates in the UK remain questionable since none of the 
virulence factors sought in this study was specific to these isolates. Differential expression of the 
virulence factor genes sought in this study however cannot be ruled out, and remains a plausible 
explanation for their success. Carriage of isolates with CTX-M enzymes, including epidemic clone 
A in the UK, by healthy individuals in the community and in hospitals has been reported in the 
literature (Loughrey, A. et al., 2007; Munday, C. J. et al., 2004b); this suggests that these 
organisms (harmless in the gut), might be able to "switch on" their pathogenic potential following 
transfer to the urinary tract. Other factors besides resistance seem especially likely to underpin the 
success of UK epidemic clone A, which has unusual susceptibility to gentamicin and lower 
resistance to cephalosporins. 
Another possible reason, which might explain the general success of epidemic clones A-E 
with CTX-M-15 in the UK, may lie in their chromosome. Their close relationship was 
demonstrated in this study, and maybe they harbour specifically other factors, either not sought in 
this study or possibly still unidentified. Those chromosomal traits may be revealed by high-
throughput genome sequencing, which is now achievable rapidly and is becoming more affordable. 
This method may become a very valuable tool in the near future for the rapid comparison of entire 
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genomes, allowing the identification of new determinants, which may prove to serve those E. coli 
isolates with CTX-M enzymes, and particularly the successful epidemic clones. 
3. Plasmids encoding multi-drug resistance in UK E. coli isolates with 
CTX-M-15-like B-lactamases 
It is well known that most plasmids are not essential for bacterial growth, but many provide 
significant selective benefits for their hosts. This study revealed that the blacrx-M-IS-Jike genes were 
plasmid-mediated in both clonal and diverse E. coli isolates. These plasmids co-encoded all the 
mechanisms of antibiotic resistance discussed above [TEM-l, OXA-l, AAC(3)-IIa, AAC(6')-Ih-cr, 
Tet(A) and Dfr17]. Complete DNA sequencing of the plasmid encoding CTX-M-15 enzyme of a 
representative of epidemic clone A (PEK499) revealed that it encoded twelve antibiotic resistance 
genes, affecting eight classes of antimicrobials. Such multi-drug resistance plasmids render their 
host strains easily selectable, particUlarly in antibiotic-rich environments such as in hospitals, and 
are likely therefore to play a major role in their epidemiological success. The presence of addiction 
systems on those multi-drug resistance plasmids furthermore ensures their maintenance, even in the 
absence of antibiotic pressure (e.g. when carried in the guts of healthy people in the community). 
Although the plasmids encoding CTX-M-15-like enzymes from clonal isolates varied in 
size (c. 70 to 150-kb), all belonged to incompatibility group IncFII. IncFII plasmids are narrow-
host range elements, mostly found among E. coli and Salmonella spp., but which may cross further 
genus boundaries following the acquisition of additional replicon(s) (Carattoli, A. et al., 2006). 
This might possibly explain the common association of CTX-M -15 enzyme with E. coli. 
The plasmids encoding CTX-M enzymes in epidemic clones a, C, D and E, but not that 
from clone A, were self-transferable by conjugation in-vitro. This may have contributed towards 
the spread of CTX-M ESBLs among unrelated E. coli isolates across the UK, and such a view is 
supported by several lines of evidence. 
(i) Firstly, the plasmids encoding CTX-M-15 enzyme in genetically-diverse isolates from different 
centres across the UK. were also self-transferable. 
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(ii) Secondly, these plasmids (whether from clonal or non-clonal isolates) had multiple features in 
common, including several antibiotic resistance genes [blacrx-M-Is, blaTEM-J. blaoxA-I, aac(6')-
Ib-cr], the origin of replication repF, and also the plasmid addiction system ccdAlccdB. 
(iii) Finally and most importantly, the plasmids encoding CTX-M-15 enzyme in clonal and non-
clonal isolates shared a high degree of homology (see plasmid cross-hybridization with 
pEK499), even when the host strains belonged to different phylogenetic groups. 
It was known, prior to this study, that the spread of CTX-M ESBLs in the UK, particularly of CTX-
M-15 enzyme, was due in some part to clonal expansion, as illustrated by the nationwide spread of 
epidemic clone A. This present study has provided further insights in the dominance of these 
enzymes in the UK. The similar multi-drug resistance phenotype of clonal and non-clonal E. coli 
isolates with CTX-M-15-like ESBLs and, more importantly, the spread ofCTX-M enzymes across 
the UK, appear also to be due to the horizontal spread of closely-related plasmids harbouring the 
blacrx-M-Is gene. Faecal carriage of isolates producing CTX-M enzymes in hospitalised and healthy 
individuals has been well documented (Miro, E. et al., 2005; Munday, C. 1. et al., 2004b; Pallecchi, 
L. et al., 2004; Valverde, A. et al., 2004), including in the UK (Lougbrey, A. et al., 2007). This 
suggests that the conjugative transfer of plasmids harbouring the blacrx-M genes may take place 
between the different E. coli populations inhabiting the human gut. 
It remains surprising that plasmid pEK499, which carries blacrx-M-Is in the most clinically 
successful E. coli lineage with CTX-M enzyme in the UK (clone A), was non-conjugative in vitro, 
even though this plasmid shared a high degree of homology with self-transferable plasmids from 
the other epidemic clones. As with the non-conjugative IncFII plasmid pRSB 1 07 (multi-drug 
resistance plasmid isolated in Germany - accession number: AJ851089), pEK499 harboured the 
remnants of a conjugative transfer module (Szczepanowski, R. et al., 2005). It remains unknown 
whether the truncated form of this tra operon prevents conjugative transfer of pEK499. Such a 
condition was found previously among non-conjugative plasmids, such as in the virulence plasmid 
pWR101 (accession number:AF294823) from a Shigella flexneri strain; though this plasmid 
nevertheless remained mobilisable, i.e. able to "parasitize" the conjugative transfer functions of 
another plasmid (Sansonetti, P. J. et al., 1982), a situation that may apply also for pEK499. 
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4. Epidemic clone C has aCquired independently two distinct pJasmids 
encoding different CTX-M enzymes 
UK E. coli epidemic clone C, as defmed by PFGE (Woodford, N. et al., 2004), was exceptional in 
that some of its members had CTX-M-15 enzyme, while others produced CTX-M-3. Among the 
clone C and non-clonal representative isolates investigated, the majority (but not all) of those 
referred from Belfast had CTX-M-3 enzyme, while CTX-M-15 was expressed by clone C and non-
clonal isolates referred from all other participating centres. 
Although they appeared almost indistinguishable by PFGE, clone C isolates sometimes 
exhibited a few phenotypic variations between them. For instance, ceftazidime MICs were 
predictably dependent upon the CTX-M variant produced being lower for those with CTX-M-3. 
Also, clone C isolates that produced the CTX-M-3 enzyme were shown consistently to lack the 
blaoxA-l gene, thereby explaining lower piperacillinltazobactam MICs than for most of those with 
CTX-M-15 enzyme, which generally co-produced the OXA-I {3-lactamase. Clone C isolates 
additionally exhibited variation at the molecular level. Investigation of the genetic surroundings of 
their blacrx-M genes identified two distinct ISEcpl-blacrx_M links. A 48-bp link was associated with 
the blacrx-M-15 gene, while blacrx-M-3 was consistently located further downstream from the ISEcpl 
element, 128-bp apart. The 48-bp link, which was characteristic of all the investigated plasmids 
encoding blacrx-M-ls in UK isolates and not just those from clone C, was identical to that found on 
plasmid pCI5-la, isolated from an epidemic E. coli strain in Canada (Boyd, D. A. et al., 2004), as 
well as to the link found in isolates from India (Ensor, V. M. et al., 2006). On the other hand, the 
128-bp link has only been reported on plasmid pCTX-M-3, a broad-host range plasmid encoding 
CTX-M-3 and prevalent among different species of Enterobacteriaceae in Poland since 1998 
(Baraniak, A. et al., 2002b). Plasmid pCTX-M-3 also lacks the blaoxA_1 and aac(6,)-Ib-cr genes, as 
did clone C isolates producing CTX-M-3 enzyme in Belfast. 
Consequently, representatives of UK epidemic clone C isolates appeared to have acquired 
independently two distinct plasmids encoding different CTX-M enzymes. The plasmids themselves 
carry different genes, but share the same incompatibility group, suggesting a common ancestor. 
One of these plasmids was related to the plasmids encoding CTX-M-15 enzyme prevalent among 
other clonal and non-clonal isolates in the UK, as well as to plasmid pC 15-1 a from Canada, to 
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which they may also be related, though comparison of DNA sequences revealed low sequence 
identity. The second plasmid on the other hand, which harboured blacrx-M-3, showed less homology 
to the plasmid encoding CTX-M-15 enzyme from the remaining four epidemic clones as shown by 
cross-hybridization, but appeared to be possibly related to pCTX-M-3. Since Poland joined the 
European Union in 2004, there has been an influx of Polish migrants to the United Kingdom, with 
the Polish community becoming the "dominant" ethnic minority in certain areas (though not in 
Belfast). Consequently, the plasmid encoding CTX-M-3 enzyme found in epidemic clone C 
isolates from Belfast may have been "imported" from Poland. Furthermore, the fact that E. coli 
epidemic clone C had acquired two distinct plasmids encoding CTX-M enzymes independently 
suggests that the host strain was likely to have been established in the UK before the introduction 
and spread of CTX-M l3-lactamases. Acquisition of different CTX-M enzymes is likely to have 
followed the emergence of quinolone resistance in the ancestral ST131 strain (see Figure 55), since 
the identical multiple chromosomal mutations in the QRDRs are unlikely to have developed in 
parallel. 
blacrx-M-Is differs from blacrx-M-3 only by an adenine-to-guanine substitution at position 
725. The resulting Asp240Gly change in the CTX-M-15 protein extends the spectrum of good 
substrates to include ceftazidime (poirel, L. et al., 2002a). Both enzyme variants have most often 
been reported from the same geographical areas (Canton, R. and Coque, T. M., 2006), including in 
the UK, leading to suggestion that blacrx-M-3 might have mutated into blacrx-M-Is. This seems to be 
the case in Poland, where CTX-M-15 enzyme was coded by minor variants of the widespread 
pCTX-M-3 plasmid (Baraniak, A. et al., 2002a). Such a close relationship between CTX-M-3 and 
CTX-M-lS can be discounted for UK strains, allowing the different ISEcpllinkages, as well as the 
different genes carried and the limited cross-hybridization. It follows that CTX-M-3 and CTX-M-
15 were "introduced" or evolved independently in the UK. Similarly and more broadly, even 
though blacrx-M-3 has been detected in isolates from many countries worldwide (Canton, R. and 
Coque, T. M., 2006), there has been no report in the published literature to my knowledge of this 
gene being connected to ISEcpl (which is believed to have had a direct role in the initial 
mobilization process) with the 48-bp link, as is standard for blacrx-M-Is. 
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Figure 55. Proposed sequence of events leading to the dissemination of E. coli epidemic clones A-E with CTX-M enzymes in the UK. 
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This suggests that the widespread blacrx-M-15 allele is likely to have escaped, and migrated on to a 
mobile genetic element independently from blacrx-M-3. 
Nonetheless, CTX-M-3 is able to evolve into an efficient ceftazidime-hydrolysing mutant 
as inferred by the encoding of both CTX-M-3 and CTX-M-15 by pCTX-M-3-like plasmids in 
Poland, and as shown here by in vitro selection (Karisik, E. et al., 2006a). However, none of the in-
vitro selected enzyme mutants was found to correspond to CTX-M-15. Rather, the majority of 
high-level ceftazidime-resistant mutants raised in this study had CTX-M enzymes harbouring a 
Pro167Ser substitution, a mutation not reported in any wild-type group-l CTX-M variant so far. 
Pro167Ser resulted from a cytosine-to-thymine change, which has been shown previously to be the 
most likely nucleotide substitution to occur in general (Hastad, O. and Bjorklund, M., 1998). 
Overall, I propose that the blacrx-M-15 gene (associated with the 48-bp link), which 
predominates among blacrx-M genes worldwide, escaped directly from Kluyvera spp., and has been 
selected independently from blacrx-M-3 associated with the 128-bp link. Following its initial escape, 
the wide occurrence of blacrx-M-15 around the globe is largely due to the spread of closely-related 
plasmids, sometimes acquired by clones with epidemic potential. This dissemination is independent 
of the escape, spread and subsequent mutation of blacrx-M-3. 
5. Comparison of antibiotic resistance in E. coli with CTX-M-t5 enzyme to 
that in E. coli with other CTX-M types 
Variants from all five CTX-M phylogenetic groups have been found among UK E. coli clinical 
isolates, illustrating independent introductory and/or evolutionary events. CTX-M-15 has become 
grossly the most prevalent variant (Woodford, N. et al., 2006), not only in the UK, but also in much 
of continental Europe, North and Central Africa and India. Based on referrals to ARMRL, CTX-M-
9-like enzymes (e.g. CTX-M-9 and -14) were the second commonest CTX-M types in the UK (c. 
10-15%), while other variants, such as CTX-M-2 and CTX-M-40, have been seen only 
sporadically. The greater ability of CTX-M-15 to hydrolyse ceftazidime efficiently may have 
contributed to its success, but it is not the only variant with ceftazidimase activity, and other 
parameters should therefore be considered. 
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Isolates producing non-CTX-M-15-like variants generally were resistant to fewer 
antibiotics. In particular, isolates with group-2, -8 or -9 CTX-M enzymes were more susceptible to 
J3-lactaml/3-lactamase inhibitor combinations than those with CTX-M-15 (probably because no 
OXA-type enzyme was present in those isolates), also to ciprofloxacin and to the aminoglycosides 
amikacin and gentamicin (though epidemic clone A with CTX-M-15 enzyme was also susceptible 
to this last antibiotic). The multi-drug resistance phenotype of isolates producing CTX-M-15 
enzyme may render them more easily selectable (and thus more successful) than those producing 
other CTX-M variants, thus explaining maybe their dominance in the UK. On a larger scale, the 
linkage of blacrx-M-Is with resistances to multiple other classes of antibiotics on self-transferable 
plasmids may also explain its wide occurrence worldwide. Besides the UK, blacrx-M-Is has been 
found also on multi-drug resistance IncFII plasrnids in France, Canada, India, North and Central 
Africa (Canton, R. and Coque, T. M., 2006). It may be that the features of these plasrnids, 
including their fitness cost and addiction systems underpin their success and so that ofCTX-M-15. 
CTX-M-15 is not predominant or has only recently become the dominant variant in some 
other countries. In Spain for instance, the group-9 CTX-M-9 and -14 enzymes have long been the 
most common CTX-M variants, while CTX-M-2 is the most prevalent variant in Israel (Canton, R. 
and Coque, T. M., 2006; Chmelnitsky, I. et al., 2005), and has also long been the most common 
type in Argentina (Quinteros, M. et al., 2003). The genes encoding these enzymes have been shown 
to be mediated by highly transmissible plasmids in Spain and in Israel (Chmelnitsky, I. et al., 2005; 
Novais, A et al., 2006) while, in the UK, conjugative transfer of the plasrnids encoding these genes 
was either unsuccessful or much harder to achieve in vitro, perhaps explaining the geographic 
variability in their success. Moreover the isolates with CTX-M-2, -9 or -14 enzymes in Spain or 
Israel appear resistant to more antibiotics than those in the UK, again suggesting that different 
plasmids are responsible in locales where these are successful. For example, the majority of isolates 
producing CTX-M-2 enzymes from Israel and from Argentina co-produce OXA-2 (Chmelnitsky,I. 
et al., 2005; Power, P. et al., 2005), conferring resistance to /3-lactaml/3-lactamase inhibitor 
combinations, as with OXA-l. OXA-2 enzyme was not found in the few isolates with CTX-M-2 
enzyme in the UK. 
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6. Phylogeny and virulence of UK E. coli isolates with CTX-M-lS or CTX-
M-9-like enzymes 
Whether or not the general success of CTX-M-15 enzyme reflects its own activity and that of 
linked resistances, or the other traits of the host plasmids, it cannot by itself explain the high 
prevalence of particular producer clones. Their success implies additional parameters, specific to 
these host strains themselves, such as virulence factors. 
Half the isolates with CTX-M-9-like enzymes studied here belonged to phylogenetic group 
D. This was in contrast with isolates producing CTX-M-15 enzyme; where all of the clonal and c. 
70% of non-clonal isolates belonged to phylogenetic group B2. Since intestinal E. coli pathotypes 
belong mostly to phylogenetic group D and extra-intestinal pathotypes mainly belong to group B2 
(Donnenberg, M. S., 2002), it appears that isolates with CTX-M-15-like enzymes were more likely 
to cause extra-intestinal infections such as those of the urinary tract than those with CTX-M-9-like 
enzymes. This inference was further supported by considering only those phylogenetic group B2 
isolates that met the definition of ExPEC. These comprised all members of all five epidemic clones 
A-E with CTX-M-15 enzyme, 57% of non-clonal isolates with CTX-M-15-like enzymes, and 75% 
of isolates with non-CTX-M ESBLs, but only 21% of those with group-9 CTX-M enzymes. 
Adding to the fact that producers of CTX-M-9-like enzymes were generally resistant to fewer 
antibiotics than isolates with CTX-M-15 enzyme, this may also explain the dominance of isolates 
producing CTX-M-15 enzymes vs. producers of group-9 CTX-M enzymes in the UK. Additional 
factors (not considered in this study) that might "weaken" isolates with CTX-M-9-like enzymes in 
the UK (vs. those with CTX-M-15) cannot be ruled out however. The possible absence of addiction 
systems on plasmids encoding blacrx-M-9-like genes may be responsible for the lower success of their 
host strains. Also, a low transfer rate or a higher fitness cost associated with the carriage of 
plasmids encoding blacrx-M-9-like genes may be responsible for their low prevalence in this country. 
The plasmids encoding blacrx-M-9-like genes were generally much larger and harder to transfer by 
conjugation in vitro (owing perhaps to a lower copy-number) than those harbouring blacrx-M-Is. 
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7. Dissemination of CTX-M extended-spectrum B-Iactamases in the UK 
and elsewhere 
The emergence and worldwide dissemination of CTX-M ESBLs at the beginning of this century 
has opened a new era in clinical microbiology and infectious disease; E. coli producing CTX-M 
enzymes represent a major challenge for many microbiologists around the world. 
As mentioned earlier, E. coli with CTX-M-IS enzyme are widely distributed in many 
countries besides the UK, including in much of continental Europe (except Iberia, where they 
nevertheless are spreading), also in North Africa, India and Canada. Here, in the UK, these 
organisms and their epidemiology have been the subjects of extensive investigations. The situation 
in France is comparable to that in the UK, i.e. the high prevalence of the CTX-M-15 enzyme 
appears to be the result of clonal expansion of epidemic E. coli strains, as well as of the spread of 
plasmids (Eckert, C. et al., 2004; Lavollay, M. et aI., 2006; Leflon-Guibout, V. et al., 2004). More 
generally, it appears that wherever it is the most common enzyme variant (e.g. Canada, France, 
India, Italy or the UK), CTX-M-15 tends to use more or less the same means for dissemination, 
combining clonal expansion of successful producer strains [e.g. an outbreak caused by an E. coli 
strain harbouring plasmid pCl5-la in Toronto and the surrounding regions, (Boyd, D. A. et al., 
2004)] as well as conjugative transfer of multi-drug-resistance plasmids [e.g. spread of plasmid 
pCl5-la among several E. coli strains isolated in Western Canada, (Boyd, D. A. et al., 2004)]. In 
each of these countries, CTX-M-15 was encoded by large self-transferable multi-drug resistance 
plasmids belonging to incompatibility group IncFII. These plasmids have several features in 
common, including an RIOO backbone as well as a number of antibiotic resistance genes, including 
blacrx-M-Is (associated with ISEcpJ by a 48-bp link), hlaTEM-h blaoxA-h aac(6')-Ih-cr and tet(A). 
This suggests that the major factor behind the worldwide rise ofCTX-M-15 ESBL is the spread of 
related multi-drug resistance plasmids. These plasmids may contribute reciprocally towards the 
epidemiological success of their host strains. 
Epidemiological patterns are different in those countries -Argentina, Israel, Poland and 
Spain- where CTX-M-IS enzyme is not endemic. In Poland for example, CTX-M-3 has been the 
dominant CTX-M variant since the late 1990s. Its wide dissemination is mainly associated with the 
horizontal transfer of a broad-host range plasmid (pCTX-M-3), spreading not only among E. coli 
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isolates, but among various other species of Enterobacteriaceae. Variants of this plasmid coding 
CTX-M-15 have been documented (Baraniak, A. et al., 2002a), but remain rare, suggesting that the 
increased ceftazidimase activity of CTX-M-15 (compared with that of e.g. CTX-M-3) is not a 
major selective trait. This suggests, in turn, that the dominance of CTX-M-15 in other countries 
such as in the UK might not depend on its wider spectrum of activity, but mostly on the features of 
the multi-drug resistance plasmids by which it is encoded. There have been no reports yet from 
Poland, to my knowledge, of CTX-M-15 enzyme being encoded by an IncFII plasmid similar to 
that spreading e.g. in the UK (i.e. with a 48-bp link); this might explain therefore why CTX-M-15 
is not the most common variant in Poland. 
The epidemiological scenario in Spain resembled that of Poland in the sense that, until 
recently, there were no reports of isolates harbouring IncFII plasrnids encoding CTX-M-15 
enzyme. This might explain why different CTX-M variants have become endemic; specifically 
CTX-M-9 and CTX-M-14 have long been the most common types observed [as early as 1996, 
(Canton, R. and Coque, T. M., 2006)], with their wide dissemination principaUy associated with the 
spread of multiple epidemic plasmids among unrelated isolates, mostly E. coli. Both CTX-M-9 and 
-14 variants were encoded by highly transmissible multi-drug-resistance plasrnids in the Spanish 
isolates (see section 5). Nevertheless, the epidemiology of CTX-M ESBLs in Spain may be 
changing, with the rapid spread of CTX-M-15 /3-lactamase encoded by an IncFII plasmid reported 
recently around Madrid (Nova is, A. et al., 2007). In Israel, the spread of the locally dominant CTX-
M-2 enzyme is the result of both clonal spread and horizontal transfer ofplasmids (Chmelnitsky, I. 
et al., 2005); the precise epidemiology in Argentina, where CTX-M-2 enzyme is also dominant 
(Quinteros, M. et al., 2003), remains uncertain. 
It is worth adding that some blacrx-M genes potentially may spread via transposase-
mediated lateral transfer (though has not been documented in the UK, or elsewhere), since they are 
usuaUy located within mobilisable elements such as transposons (e.g. blacrx-M-Is is located within a 
Tn2J-like transposon on pEK499). Such mechanisms of dissemination, whilst not proven, are 
suggested (but not proven) by recent studies in France and in Spain, showing that multiple 
recombinatorial events involving blacrx-M-Is and blacrx-M-9 were possible within the same plasmid 
or among different plasmids (Canton, R. and Coque, T. M., 2006). 
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8. Multi-drug resistance IncFII plasmids 
Although many IncFII plasmids encoding CTX-M-15 enzyme have been identified around the 
world (e.g. in Cameroon, Canada, France, India, Italy, North Africa, Portugal) and have been 
characterised to various levels, very few only have been completely sequenced. Besides pEK499, 
pC15-la (the plasmid widespread in Western Canada) is the only other IncFII plasmid encoding 
CTX-M-15 enzyme whose entire DNA sequence map is available publicly. Like pEK499 (117,536-
bp), pC15-la (circular molecule of c. 92-kb) harboured an R100 backbone and has its antibiotic 
resistance genes [blacrx-M-15, blaoxA-h blaTEM-h aac(6')-Ib-cr, aac3-IIa and tet(A)] clustered in a 
28.4-kb multi-drug resistance region (MDR) (Boyd, D_ A. et al., 2004). Although aac3-IIa was 
absent from pEK499, this gentamicin resistance-encoding gene was widespread in the other 
epidemic clones (B-E) and non-clonal isolates from the UK. The MDR of pEK499 was 
approximately 25-kb long, with the antibiotic resistance genes arranged differently to those in the 
MDR of pC15-la, though most were located between insertion sequences and transposon-like 
elements suggestive of mUltiple recombinatorial re-arrangements. Besides a number of genes 
encoding proteins with unknown functions, pEK499 additionally carried a class I integron 
(containing the antibiotic resistance gene cassettes aadA5, dfr17 and sull, and located within its 
MDR), the plasmid addiction system ccdAlccdB and the virulence-associated genes vagClvagD, all 
of which were absent from pC 15-1 a. 
Overall, pEK499 appeared to be a mosaic molecule (see Figure 56), sharing some sequence 
homologies with pRSB107 [a plasmid isolated from activated-sludge bacteria of a wastewater-
treatment plant in Germany (Szczepanowski, R. et al., 2005)] as well as pC15-la. All these three 
IncFII plasmids harboured the repF origin of replication (specific to plasmid RlOO and its 
derivatives). Plasmids pEK499 and pRSB107 also had repFIA (found on the F-plasmid), which 
indicated that both these plasmids were the fusion product of two ancestor plasmids, one of which 
was related to RlOO (and to pC15-la) and the other to the F-plasmid. Like pEK499, pRSBI07 
harboured only remnants ofthe F-homologous DNA-transfer (tra) module, which may explain why 
in vitro conjugative transfer of both these plasmids was not successful (see section 3). A possible 
evolution pathway is shown in Figure 56, but more complex routes cannot be excluded. 
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Figure 56. Potential sequence of events leading to the formation of pEK499 and other plasmids 
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The full DNA sequence of pCTX-M-3, the CTX-M-3-encoding plasmid widespread among 
Enterobacteriaceae across Poland, is also available publicly. Although this plasmid encoded a 
different CTX-M enzyme and exhibited significantly less sequence identity than pCl5-la with 
pEK499, it also belonged to incompatibility group IncFII, though to a different subtype than that of 
pEK499. As with pEK499 (and pRSBI07), pCTX-M-3 harboured the two origins of replication 
repF and repFIA. The latter might be responsible for extending the range of hosts compared with 
typical IncFII plasmids, which are generally narrow-host range, preferring E. coli. Plasmid pCTX-
M-3 and its derivatives have been found among seven different Enterobacteriaceae species, 
including E. coli, C. freundii, K pneumoniae, K oxytoca, E. c/oacae, S. marcescens and M 
morganii (Livermore, D. M. et al., 2007). The spread ofpEK499 derivatives among enterobacterial 
species other than E. coli in the UK. has not been investigated, though it should be noted that CTX-
M-15 is now also the dominant ESBL in K pneumoniae [BSAC survey, Hope, R., personal 
communication, (potz, N. A. et al., 2006)]; moreover, Klebsiella spp. and Enterobacter spp. 
isolates producing CTX-M-15 enzyme are referred to ARMRL on a regular basis (though most 
Enterobacter spp. isolates usually have CTX-M-9-like enzymes rather than CTX-M-15), along 
with sporadic Proteus spp., C. freundii and M morganii isolates, also with CTX-M-15 enzyme. 
Such data indicate that at least some blacrx_M_wencoding plasmids circulating in the UK. have the 
ability to transfer into Klebsiella and other species. 
9. Virulence of E. coli isolates with CTX-M enzymes from the UK and 
abroad 
Virulence factors seem likely to contribute to the success of epidemic clones with CTX-M-15 or 
other ESBLs, enabling these strains to cause disease. Thirty-three known virulence factors of extra-
intestinal E. coli were sought in clonal and non-clonal isolates with CTX-M enzymes in this study, 
as well as in CTX-M-negative isolates. However, none was found associated specifically with the 
five major national epidemic E. coli clones producing CTX-M-15 enzyme. 
Elsewhere, data regarding the phylogenetic background and virulence of isolates with 
CTX-M enzymes are still limited and ambiguous. Most studies, including this one, have suggested 
that isolates producing CTX-M enzymes are not more virulent than many other CTX-M-negative 
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isolates of the same virulence-associated phylogenetic groups (B2 or D). Separate studies from the 
Calgary region in Canada (pitout, J. D. et al., 2005) and from the Languedoc region in France 
(Lavigne, J. P. et al., 2007) nevertheless have shown that isolates producing CTX-M-15 enzyme 
mostly belonged to phylogenetic group B2, whilst those producing CTX-M-9 enzyme generally 
belonged to group D. Those findings agreed with data from this present study, but were in contrast 
with figures from another study in France [around Paris, (Branger, C. et al., 2005)] and from a 
more recent study in Spain (Canton, R. and Coque, T. M., 2006), where isolates producing CTX-
M-15 enzyme mostly belonged to phylogenetic group D, whereas isolates with CTX-M-9 generally 
belonged to the commensal group A, and to a lesser extent to group D. Also, isolates with CTX-M-
15 enzymes isolated around Calgary generally had different virulence genotypes compared with 
UK clonal and non-clonal producers of CTX-M-15 enzyme. In both countries, however, most 
producers had the same ExPEC markers (iutA and kpsMTII). 
There has been no report, as yet, of particular virulence factors being associated 
exclusively with isolates producing CTX-M ESBLs. But, it seems plausible that these have 
additional, unrecognised factors. It is noteworthy too that the urinary tract adhesin AfaIDraBC was 
associated significantly with production of CTX-M 13-lactamase in UK isolates, though it was not 
present in all producers, but rather in epidemic clone A and in a quarter of diverse producers (with 
CTX-M-9 or CTX-M-15 enzymes) only. This virulence factor was not found in isolates with CTX-
M-9-like or CTX-M-15 enzymes in the study from Canada (pitout, J. D. et al., 2005). While not 
more virulent, neither were UK isolates with CTX-M enzymes less virulent than the susceptible 
controls. Similar findings were also reported from the study in the Calgary region (pitout, J. D. et 
al., 2005) .. 
A recent study using the nematode Caenorhabditis elegans as infection model revealed that 
the virulence potential of UTI-causing ExPEC E. coli isolates with CTX-M enzymes belonging to 
phylogenetic groups B2 or D was relatively low (Lavigne, J. P. et al., 2006). This finding 
correlated with earlier studies (Johnson, J. R. et al., 2005), which showed (i) that UTI-causing 
antibiotic-resistant strains (typically quinolone-resistant, as with the majority of isolates producing 
CTX-M enzymes found in the UK) generally had low virulence in the model (pitout, J. D. et al., 
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2005), and (ii) that there was a decrease in the presence or the expression of some virulence factors, 
as well as a decreased invasive capacity (Velasco, M. et al., 2001; Vila, J. et al., 2002). 
Overall, the virulence potential of E. coli isolates producing CTX-M ESBLs remains a 
complex issue, which requires further investigations. Findings in this study, as well as those from 
Canada, suggest that the current multi-drug-resistant E. coli isolates with CTX-M enzymes may 
have become more virulent in comparison to early multi-drug-resistant E. coli isolates, which 
lacked CTX-M {l-lactamase. This could explain, in some part, the emergence and worldwide 
success of isolates producing CTX-M enzymes. However, the findings in this study cannot rule out 
the possibility that the successful epidemic clones producing CTX-M enzymes in the UK might 
possess additional and specific unidentified factors, or, might up-regulate the expression of 
particular virulence genes. 
10. Routes of spread of E. coli isolates producing CTX-M enzymes 
Another important question is to identify the sources and routes of propagation of E. coli with 
CTX-M-15 enzyme. Current data, from the UK and abroad, suggest three major possible routes of 
spread: (i) human migration, (ii) food and water contamination, and (iii) oro-faecal spread between 
humans. 
10.1. Human migration 
This study has shown the close similarity of the genetic surroundings of (i) blacrx-M-3 (1 28-bp link), 
(ii) blacrx-M-9 (complex class I integron structure), and (iii) blacrx-M-Is (48-bp link) found in UK E. 
coli isolates to those found in E. coli strains isolated in Poland, Spain and India, respectively. The 
migratory flux of people between these countries and the UK is well known, and might partly 
explain the dissemination of isolates producing CTX-M enzymes. Data from this study thus support 
(but do not prove) the idea that human migration contributes to the worldwide dissemination of 
CTX-M enzymes. Whilst it was argued earlier that the five major E. coli epidemic clones were 
likely to have been established in the UK before the emergence and spread of CTX-M enzymes, it 
seems likely that the plasmids encoding CTX-M-3 and CTX-M-15 enzymes, with resembling 
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plasmids found elsewhere, reached them from overseas. The source of the plasmid encoding CTX-
M-3 enzyme in isolates from Belfast may be pCTX-M-3, or a derivative plasmid from Poland (see 
section 4), but the source of those encoding CTX-M-15 remains unknown. 
10.2. Food chain contamination 
A recent investigation of the virulence gene repertoire of E. coli isolates from food-producing 
animals in the USA (Johnson, 1. R. et al., 2007) suggested that antibiotic-resistant E. coli isolates 
(particularly those resistant to quinolones, co-trimoxazole and extended-spectrum cephalosporins 
such as ceftazidime, though not producing CTX-M ESBLs) probably developed in these animals 
and was subsequently transmitted to humans. The food chain therefore may also play a role in the 
spread of producers of CTX-M enzymes. There have been a number of reports of E. coli isolates 
with CTX-M enzymes detected in food-producing animals (Duan, R. S. et al., 2006; Meunier, D. et 
al., 2006), but no epidemiological links have yet been found between those isolates and those found 
in human clinical specimens. In the UK, isolates with CTX-M enzymes have been recovered from 
raw food products [mostly raw chicken breasts, (Ensor, V. M. et al., 2007)], though none had the 
widespread CTX-M-15 variant. Interestingly, most of the food products contaminated with CTX-
M-producing E. coli were imported from Brazil, Spain, or the Netherlands and the isolates had 
either CTX-M-2 enzyme (highly prevalent in South America) or CTX-M-9 (very common in 
Spain). It is worth adding that there have been reports also (from the UK and abroad) of faecal 
carriage by live animals of E. coli isolates producing CTX-M enzymes, further supporting the 
potential role played by animals and the food chain in the spread of CTX-M enzymes. In a study 
from Portugal, wild birds were shown to carry E. coli isolates with ESBLs, including CTX-M-l or 
CTX-14 enzymes (Costa, D. et al., 2006). In an earlier study from Wales, E. coli with CTX-M-9-
like enzymes have been recovered from calves (Teale, C. J. et al., 2005). In both cases however, no 
link with the local human epidemiology was evident. Water contamination may constitute another 
route of dissemination of isolates producing CTX-M enzymes. This was suggested in a recent study 
by Galvin et al., where they identified three E. coli isolates producing CTX-M-3 enzyme (and an 
unidentified TEM-type 13-lactamase) from a wastewater treatment plant in Galway, Republic of 
Ireland (Galvin, S. et al., 2007). 
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Food and water contamination by E. coli isolates with CTX-M enzymes is now well 
documented, but it has not yet been shown to have any link to current clinical problems. 
Consequently, the role of the food chain in the emergence and spread of E. coli with CTX-M-15 in 
the UK still remain to be proven. 
10.3. Oro-faecal transmission 
Johnson et ai, demonstrated extensive sharing of a uropathogenic E. coli clone among five 
household members, including the husband, the three children and the pet dog, of a woman with 
acute cystitis (Johnson, J. R. and Clabots, C., 2006). Following ciprofloxacin therapy, this clone 
disappeared from the mother's urine and faecal samples, but persisted in the faecal samples of the 
other family members, who became in turn the reservoir of the virulent E. coli, prone for further 
spread e.g. via the oro-faecal route. It is well established that for E. coli, gut colonisation precedes 
infection, and therefore that E. coli with CTX-M enzymes may spread via the oro-faecal route. An 
exceptional characteristic of E. coli strains producing CTX-M enzymes is their great penetration in 
the community, as well as their high prevalence among hospital patients. It becomes therefore 
important to establish whether initial gut colonisation occurs in healthcare settings or in the 
community, and more generally, whether isolates producing CTX-M enzymes originated in 
hospital settings and subsequently escaped in the community, or vice versa. Very few studies have 
been undertaken with regards to this matter. Ben-Ami et al. recently demonstrated that isolates 
producing CTX-M enzymes were not the result of nosocomial emergence at a Tel Aviv hospital 
(Israel), but rather originated in the community and were subsequently introduced in the hospital 
settings (Ben Ami, R. et al., 2006). No such work has yet been carried in the UK, but a recent study 
in Belfast showed gut colonisation in 40% of nursing home residents by E. coli epidemic clone A 
and other strains with CTX-M-15 enzyme (Loughrey, A. et al., 2007). Although it is unclear where 
the residents acquired such isolates, the high prevalence suggested spread within the nursing 
homes, presumably via the oro-faecal route. 
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11. The CTX-M extended-spectrum fl-Iactamases pandemic 
The epidemiological picture of E. coli with CTX-M enzymes in the UK resembles that seen in 
many other countries, but yet it remains unclear how these organisms became a pandemic. Isolates 
producing CTX-M enzymes have been the subject of many detailed investigations at the local and 
national levels, but very rarely at the international level. There has been no major study comparing 
isolates with CTX-M enzymes from different countries, so as to identify e.g. how E. coli with 
CTX-M-15 enzymes have disseminated so quickly worldwide, though as discussed earlier, 
horizontal transfer of closely-related IncFII plasmids appears critical, with these sometimes 
establishing in strains with local or national epidemic potential. Similarly, blacrx-M-2 and blacrx-M-9 
have regularly been found in very similar and complex integron structures in isolates from different 
countries (Canton, R. and Coque, T. M., 2006; Novais, A. et al., 2006). International dissemination 
of major epidemic clones or independent selection events in different countries are possible, but 
remain unproven. An international collaboration investigating the relatedness of different national 
epidemic strains producing CTX-M enzymes and also comparing their plasmids that encode those 
ESBLs is therefore becoming more and more of a necessity. 
12. What does the future hold? 
In the past decade, E. coli isolates have accumulated multiple resistance mechanisms including 
CTX-M /3-lactamases, AAC6'-Ib-cr and Qnr protection. Aminoglycosides, /3-lactams and 
quinolones are all affected and, with the exception of carbapenems, the vast majority of antibiotics 
may no longer be universally relied upon for treating severe infections caused by E. coli strains 
producing CTX-M enzymes. First-line treatment options are having to be re-considered for high 
risk patients, and those isolates will force the clinical microbiologist to rely more and more on 
accurate antibiotic susceptibility testing. The emergence and swift dissemination of oxyimino-
cephalosporin resistance in E. coli worldwide is very worrying and many fear that CTX-M ESBLs 
might one day become a standard feature of most E. coli isolates, just as TEM-l enzyme did in the 
1960s and 1970s. 
273 
This may be facilitated, since CTX-M-15 enzyme in UK isolates is generally co-encoded with 
plasmid addiction systems, ensuring its maintenance and that of co-linked multi-drug resistance, 
even in the absence of antibiotic pressure. 
The accumulation of antibiotic resistance in E. coli isolates with CTX-M enzymes seems 
likely to evolve even further. The accumulation of multiple l3-lactamases (CTX-M-15, TEM-l, 
OXA-l and CMY-23) as well as the loss of OmpC, responsible for resistance to ertapenem (and 
reduced susceptibility to other carbapenems) was illustrated in this study in an E. coli epidemic 
clone A isolate. This represents a very worrying prospect for the future as it happened in the most 
successful UK epidemic clone, and is even more worrying since it happened in absence of 
antibiotic pressure (the patient had received only one course of cephalexin in the preceding year). 
Development of resistance to carbapenems may become more frequent as their use increases, 
driven by them being the only treatment options available for severe infections caused by multi-
drug resistant isolates with CTX-M enzymes. 
Pharmaceutical companies will have to respond quickly therefore to this shift in E. coli by 
seeking new treatment alternatives, ideally with novel modes of action, and suitable for use in 
community patients. Oral therapy options for community-acquired infections caused by E. coli with 
CTX-M enzymes are presently very limited. Potential new alternatives include the carbapenems 
sulopenem and tebipenem, as well maybe as third-generation cephalosporinll3-lactamase inhibitor 
combinations (Ranbaxy is currently developing cefpodoxime/sulbactam and cefiximelclavulanate, 
but these will only be available for the Indian market). Even among intra-venous antibiotics there 
are few options available to treat infections caused by E. coli with CTX-M enzymes, potentially 
including, asides from carbapenems, also temocillin and tigecycline. But how long before E. coli 
develops or acquires new antibiotic resistance mechanisms to these agents? 
Finally, seeking novel agents to treat infections due to multi-drug resistant organisms such 
as those E. coli with CTX-M enzymes, or trying to make better use of antibiotics (e.g. by rotation, 
though the options are very limited) might not be the only solutions to the problem. Discovering 
new antibiotics may just lead to discovering new resistance mechanisms (ideally a mid- to long-
term problem though), and rather than looking for solutions (and creating new problems), it would 
be more useful to look for ways of preventing these problems happening in the first place ("better 
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preventing a disease than treating it!"). Vaccination (e.g. against virulent phylogenetic group B2 E. 
coli isolates specifically) and improved infection control measures (to prevent the transmission of 
potential pathogens to vulnerable individuals) might be more useful (and more economical) in our 
battle against the dissemination of organisms producing CTX-M ESBLs. 
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CONCLUSIONS 
276 
E. coli has always been a major cause of extra-intestinal infections, principally of the urinary tract 
but sometimes leading to septicaemia. It is also a major component of the mixed flora of intra-
abdominal sepsis. Until recently, the species was one of the more susceptible Enterobacteriaceae 
generally leaving many treatment options. In the past decade however, the resistance of E. coli 
isolates towards antibiotic therapy has increased worryingly, particularly with respect to third-
generation cephalosporins and to quinolones. The emergence and wide dissemination of CTX-M 
ESBLs worldwide accounts for most of the resistance to third-generation cephalosporins. 
The present study followed from earlier work by Woodford et al., that reported community 
and hospital spread of E. coli isolates with CTX-M ESBLs (principally CTX-M-lS) in the UK 
(Woodford, N. et al., 2004). Five major national epidemic clones (A-E, with A being the most 
widespread across the country) were identified by DNA fingerprinting, along with many 
genetically-diverse producers of CTX-M-lS enzymes. This study aimed to characterise multi-drug 
resistant E. coli isolates with CTX-M enzymes at a molecular level, and to investigate the reasons 
behind their swift clinical success in the UK. 
1. Summary of key findings 
• Regardless of the type, CTX-M ESBLs in UK isolates of E. coli were encoded by large and, 
generally, self-transferable plasmids (non-self-transmissible in epidemic clone A). These 
plasmids largely determined the overall multi-drug resistance phenotypes of their host strains, 
except to quinolones, where resistance was due mostly to multiple chromosomal mutations in 
the QRDR of the genes encoding the DNA gyrase and topoisomerase IV enzymes. These 
QRDR mutations were conserved among the five major clones with CTX-M-lS enzyme, 
suggesting that they ante-dated the divergence of these strains from a potential common 
ancestor. 
• Regardless of the clonality of their host strains, the plasmids encoding blacrx-M-Is were highly 
homologous and belonged to the IncFII incompatibility group. They usually also carried 
blaTEM-h blaoxA-h aac(6 J-Ib-cr, aac3-IIa, tet(A), as well as the plasmid addiction system 
ccdAlccdB. The relatedness of these plasmids indicated that the wide dissemination of the 
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CTX-M-15 enzyme in the UK was fundamentally associated with horizontal spread, with these 
plasmids reaching the epidemic clones A-E along with many other, more diverse, lineages. 
• I propose the existence of a successful ST131 quinolone-resistant epidemic E. coli strain in the 
UK prior to the local emergence of CTX-M-15 enzyme. The evolution and diversification of 
this ancestor strain into the five major epidemic clones A-E was then followed by the 
acquisition of the plasmids encoding CTX-M enzymes. Evidence for this sequence of events is 
that the plasmids encoding CTX-M-lS enzyme in clone A varied from those found in members 
of the other four clones, also in that two different types ofplasmids encoding CTX-M enzymes 
were found independently in clone C isolates, but virulence genotypes of all five epidemic 
clones were related and the chromosomal mutations for quinolone resistance were consistent 
among all their members. 
• The potentially major role played by the plasmids encoding CTX-M-lS enzyme in the 
epidemiological success of their hosts was illustrated by the complete DNA sequence map of 
pEK499, which encoded twelve antibiotic resistance genes affecting eight classes of 
antimicrobials, along with virulence genes (vagC/vagD and traT). This plasmid shared many 
features with other IncFII plasmids encoding CTX-M-15 enzyme characterised from around 
the world, notably in Canada, India, France, Spain, and North and Central Africa. I propose 
that the widespread blacrx-M-Is gene, which is associated with a 48-bp link to ISEcpJ, escaped 
directly from its source (i.e. Kluyvera spp.) prior to its mobilization on to the IncFII plasmid, 
and was not a mutational product of blacrx-M-3, which is also associated with ISEcpJ, but 
generally with a 128-bp link. This view was supported by the observation that CTX-M-3 did 
not readily yield CTX-M-15 mutants during selection studies, though the fact it can do so is 
illustrated by the work of Baraniak et al. (2002), in Poland. 
• Different representatives of E. coli epidemic clone C were shown to have acquired 
independently two different IncFII plasmids, encoding either CTX-M-3 or CTX-M-15 
enzymes. Plasmid cross-hybridization studies indicated a low degree of homology between the 
plasmid encoding CTX-M-3 enzyme and pEK499. The former plasmid had several features in 
common with an epidemic broad-host range plasmid widespread among enterobacterial species 
across Poland: pCTX-M-3 (same incompatibility sub-type, self-transferability, 128-bp link 
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between blacrx-M-3 and ISEcpl, blaTEM-1o lack of blaoxA-1 and lack of aac(6 J-Ib-cr}. It is 
proposed that both pCTX-M-3 (or a derivative) and an ancestral blacrx_M_ls-encoding plasmid 
were imported into the UK from abroad, and were subsequently acquired by the pre-existing 
successful E. coli clones. 
• Finally, investigation of the virulence genotypes of the multi-drug resistant E. coli with CTX-
M enzymes suggested that they may be more virulent than previous multi-drug resistant E. coli 
without CTX-M enzymes, investigated in past studies prior to the appearance of these ESBLs. 
This might explain the emergence and clinical success of E coli isolates producing CTX-M 
enzymes worldwide. The dominance of isolates with CTX-M-15 enzyme vs. those with CTX-
M-9-like enzymes appeared to be attributable to their broader spectrum of antibiotic resistance, 
as well as being better adapted to cause extra-intestinal infections (higher proportions of 
ExPEC phylogenetic group B2 isolates). Other factors cannot, however, be excluded. 
2. Prospects for further studies 
This study focused on the molecular epidemiology and characterisation of E. coli isolates with 
CTX-M {3-lactamases in the UK, and enlightened many aspects with regards to their emergence, 
spread and success. However, the findings also raise new questions, which might be subjects for 
future research in order to comprehend fully, and eventually, counter the global threat posed by 
CTX-M ESBLs. 
First, we deduced that epidemic clones A-E with CTX-M-15 enzyme shared a common 
ST131 ancestor, present in the UK prior to the large scale dissemination ofCTX-M enzymes. Little 
is known about this strain. It was not detected in a survey of fluoroquinolone resistance by 
mutations among E. coli isolates collected in 2001 in the British Isles (Mushtaq, S. et al., 2006), 
and it is unclear whether it was imported in the UK. The dissemination of epidemic clones with 
CTX-M-1S enzyme has been documented in many other countries and it would be interesting to 
explore their relatedness to the ST131 types widespread in the UK, explaining whether the 
pandemic ofCTX-M-15 enzyme involves international dissemination of successful E. coli clones. 
The spread of closely-related multi-drug resistance plasmids among clonal and non-clonal 
isolates with CTX-M-15 enzyme in the UK was illustrated in this study. Although these plasmids 
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have undeniably contributed to the epidemiological success of their host strains (e.g. by rendering 
them easily selectable), other factors are surely involved, particularly for the most successful UK 
epidemic clone (A), which was remarkably susceptible to gentamicin and also required lower third-
generation cephalosporin MICs compared with other producers of CTX-M-15 enzyme. High-
throughput genome sequencing, which is now fast and affordable, will help identify those factors 
that promote the dissemination and/or pathogenicity of the major epidemic clones. This study also 
suggested that certain virulence factor genes might be "turned on" or expressed only under certain 
conditions; this hypothesis deserves to be pursued further. 
Thirdly, an important area that still remains unclear is the mode of transmission of isolates 
with CTX-M enzymes. Three potential routes of dissemination were suggested in this study, but 
none has yet been proven to be responsible for the spread of e.g. E. coli epidemic clone A, which 
has been found in well over 50 different centres across the UK (including in Northern Ireland). 
Screening more animal food products and more human consumables in general for the presence of 
isolates with CTX-M enzymes may prove to be very revealing. Assessing faecal carriage in 
patients admitted to hospitals, prior and following their stay, might be helpful too, as might 
sampling the general population or sewage. Such strategies might clarify also whether isolates with 
CTX-M enzymes are brought into hospitals from the community, or vice versa. 
Finally, the penetration of E. coli isolates with CTX-M enzymes in the community is well 
documented. This study indicated that their stability in antibiotic-free environments (e.g. healthy 
household members) may result from the linkage of the blacrx-M genes to addiction systems, such 
as ccdA/ccdB, on single plasmids. In order to verify this theory, it would be interesting to estimate 
the exact prevalence of such association, particularly among isolates recovered from healthy 
individuals in the community. 
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